0001689548-22-000125.txt : 20221109 0001689548-22-000125.hdr.sgml : 20221109 20221109160651 ACCESSION NUMBER: 0001689548-22-000125 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praxis Precision Medicines, Inc. CENTRAL INDEX KEY: 0001689548 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39620 FILM NUMBER: 221372557 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-300-8460 MAIL ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 10-Q 1 prax-20220930.htm 10-Q prax-20220930
false2022Q30001689548December 3100016895482022-01-012022-09-3000016895482022-11-04xbrli:shares00016895482022-09-30iso4217:USD00016895482021-12-31iso4217:USDxbrli:shares00016895482022-07-012022-09-3000016895482021-07-012021-09-3000016895482021-01-012021-09-300001689548us-gaap:CommonStockMember2021-12-310001689548us-gaap:AdditionalPaidInCapitalMember2021-12-310001689548us-gaap:RetainedEarningsMember2021-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001689548us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016895482022-01-012022-03-310001689548us-gaap:CommonStockMember2022-01-012022-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001689548us-gaap:RetainedEarningsMember2022-01-012022-03-310001689548us-gaap:CommonStockMember2022-03-310001689548us-gaap:AdditionalPaidInCapitalMember2022-03-310001689548us-gaap:RetainedEarningsMember2022-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100016895482022-03-310001689548us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000016895482022-04-012022-06-300001689548us-gaap:CommonStockMember2022-04-012022-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001689548us-gaap:RetainedEarningsMember2022-04-012022-06-300001689548us-gaap:CommonStockMember2022-06-300001689548us-gaap:AdditionalPaidInCapitalMember2022-06-300001689548us-gaap:RetainedEarningsMember2022-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000016895482022-06-300001689548us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001689548us-gaap:CommonStockMember2022-07-012022-09-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001689548us-gaap:RetainedEarningsMember2022-07-012022-09-300001689548us-gaap:CommonStockMember2022-09-300001689548us-gaap:AdditionalPaidInCapitalMember2022-09-300001689548us-gaap:RetainedEarningsMember2022-09-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001689548us-gaap:CommonStockMember2020-12-310001689548us-gaap:AdditionalPaidInCapitalMember2020-12-310001689548us-gaap:RetainedEarningsMember2020-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100016895482020-12-310001689548us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016895482021-01-012021-03-310001689548us-gaap:CommonStockMember2021-01-012021-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001689548us-gaap:RetainedEarningsMember2021-01-012021-03-310001689548us-gaap:CommonStockMember2021-03-310001689548us-gaap:AdditionalPaidInCapitalMember2021-03-310001689548us-gaap:RetainedEarningsMember2021-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100016895482021-03-310001689548us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016895482021-04-012021-06-300001689548us-gaap:CommonStockMember2021-04-012021-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001689548us-gaap:RetainedEarningsMember2021-04-012021-06-300001689548us-gaap:CommonStockMember2021-06-300001689548us-gaap:AdditionalPaidInCapitalMember2021-06-300001689548us-gaap:RetainedEarningsMember2021-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000016895482021-06-300001689548us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001689548us-gaap:CommonStockMember2021-07-012021-09-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001689548us-gaap:RetainedEarningsMember2021-07-012021-09-300001689548us-gaap:CommonStockMember2021-09-300001689548us-gaap:AdditionalPaidInCapitalMember2021-09-300001689548us-gaap:RetainedEarningsMember2021-09-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000016895482021-09-300001689548prax:FollowOnPublicOfferingMember2022-01-012022-09-300001689548prax:FollowOnPublicOfferingMember2021-01-012021-09-300001689548prax:AtTheMarketOfferingMember2022-01-012022-09-300001689548prax:AtTheMarketOfferingMember2021-01-012021-09-3000016895482015-01-012022-09-300001689548us-gaap:CorporateDebtSecuritiesMember2022-09-300001689548us-gaap:CommercialPaperMember2022-09-300001689548us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001689548us-gaap:CorporateDebtSecuritiesMember2021-12-310001689548us-gaap:CommercialPaperMember2021-12-310001689548us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001689548us-gaap:OtherDebtSecuritiesMember2021-12-31prax:security0001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001689548us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001689548us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001689548us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001689548us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:FairValueMeasurementsRecurringMember2022-09-300001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001689548us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001689548us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548us-gaap:FairValueMeasurementsRecurringMember2021-12-310001689548prax:OfficeSpaceInBostonMassachusettsMember2021-05-31xbrli:pure0001689548us-gaap:EmployeeStockOptionMember2022-09-300001689548us-gaap:EmployeeStockOptionMember2021-12-310001689548us-gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember2022-09-300001689548us-gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember2021-12-310001689548prax:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2022-09-300001689548prax:TwentyTwentyEmployeeStockPurchasePlanMemberus-gaap:StockCompensationPlanMember2021-12-310001689548us-gaap:RestrictedStockMember2022-09-300001689548us-gaap:RestrictedStockMember2021-12-310001689548prax:TwoThousandTwentyEmployeeStockIncentivePlanMember2022-09-300001689548prax:TwoThousandTwentyEmployeeStockIncentivePlanMember2021-12-310001689548prax:TwentySeventeenEmployeeStockIncentivePlanMember2022-09-300001689548prax:TwentySeventeenEmployeeStockIncentivePlanMember2021-12-310001689548prax:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-09-300001689548prax:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-12-310001689548us-gaap:RestrictedStockMember2022-01-012022-09-300001689548prax:UnvestedRestrictedStockUnitsMember2022-09-300001689548prax:UnvestedRestrictedStockUnitsMember2022-01-012022-09-300001689548us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001689548us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001689548us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001689548us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001689548us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001689548us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001689548us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001689548us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001689548us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001689548us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001689548us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001689548us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001689548us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001689548us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001689548us-gaap:RestrictedStockMember2022-07-012022-09-300001689548us-gaap:RestrictedStockMember2021-07-012021-09-300001689548us-gaap:RestrictedStockMember2022-01-012022-09-300001689548us-gaap:RestrictedStockMember2021-01-012021-09-300001689548us-gaap:EmployeeStockMember2022-07-012022-09-300001689548us-gaap:EmployeeStockMember2021-07-012021-09-300001689548us-gaap:EmployeeStockMember2022-01-012022-09-300001689548us-gaap:EmployeeStockMember2021-01-012021-09-300001689548prax:RogConIncMember2022-09-300001689548prax:June2022RestructuringPlanMember2022-01-012022-09-300001689548prax:June2022RestructuringPlanMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001689548us-gaap:GeneralAndAdministrativeExpenseMemberprax:June2022RestructuringPlanMember2022-01-012022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 001-39620
PRAXIS PRECISION MEDICINES, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 47-5195942
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
99 High Street, 30th Floor
Boston, MA
02110
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 617-300-8460
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Common Stock, par value $0.0001 per sharePRAXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒   No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☒
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐   No  ☒
As of November 4, 2022, the registrant had 47,118,578, shares of common stock, $0.0001 par value per share, outstanding.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
•the success, cost and timing of our product candidate development activities and clinical trials;
•our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
•the ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements and collaboration agreements;
•the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates;
•our ability to commercialize our product candidates, if approved, in light of the intellectual property rights of others;
•our ability to obtain funding for our operations, including funding necessary to complete further development and, if approved, commercialization of our product candidates;
•the commercialization of our product candidates, if approved;
•our plans to research, develop and, if approved, commercialize our product candidates;
•future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved product;
•the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
•the rate and degree of market acceptance of our product candidates, if approved;
•the pricing and reimbursement of our product candidates, if approved;
•regulatory developments in the United States and foreign countries;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•the success of competing therapies that are or may become available;
•our ability to attract and retain key scientific or management personnel;
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
•the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, and the ongoing conflict in Ukraine on any of the foregoing or other aspects of our business operations, including but not limited to our ongoing and planned preclinical studies and clinical trials.
In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause


actual results to differ materially from current expectations include, among other things, those listed under the section titled "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.


Table of Contents

  Page
PART I.
Item 1.
Item 2.
Item 3.
Item 4.
PART II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
                   Signatures


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in thousands, except share and per share data)
September 30, 2022December 31, 2021
Assets
Current assets:
Cash and cash equivalents$62,440 $138,704 
Marketable securities61,300 137,207 
Prepaid expenses and other current assets8,572 11,498 
Total current assets132,312 287,409 
Property and equipment, net1,077 1,213 
Operating lease right-of-use assets3,097 3,653 
Other non-current assets416 472 
Total assets$136,902 $292,747 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$10,122 $10,780 
Accrued expenses17,884 26,844 
Operating lease liabilities977 810 
Total current liabilities28,983 38,434 
Long-term liabilities:
Non-current portion of operating lease liabilities2,756 3,501 
Total liabilities31,739 41,935 
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021
— — 
Common stock, $0.0001 par value; 150,000,000 shares authorized; 46,864,327 shares issued and outstanding as of September 30, 2022, and 45,300,514 shares issued and outstanding as of December 31, 2021
5 5 
Additional paid-in capital595,165 567,598 
Accumulated other comprehensive loss(536)(176)
Accumulated deficit(489,471)(316,615)
Total stockholders’ equity105,163 250,812 
Total liabilities and stockholders’ equity$136,902 $292,747 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(Amounts in thousands, except share and per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Operating expenses:
Research and development$30,439 $33,139 $126,711 $76,746 
General and administrative13,851 11,634 46,822 31,929 
Total operating expenses44,290 44,773 173,533 108,675 
Loss from operations(44,290)(44,773)(173,533)(108,675)
Other income:
Other income, net345 73 677 201 
Total other income345 73 677 201 
Loss before income taxes$(43,945)$(44,700)$(172,856)$(108,474)
Provision for income taxes— (5)— (5)
Net loss$(43,945)$(44,705)$(172,856)$(108,479)
Net loss per share attributable to common stockholders, basic and diluted$(0.96)$(1.00)$(3.79)$(2.61)
Weighted average common shares outstanding, basic and diluted45,774,376 44,714,941 45,591,888 41,608,017 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(Amounts in thousands)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Net loss$(43,945)$(44,705)$(172,856)$(108,479)
Change in unrealized losses on marketable securities, net of tax144 25 (360)(25)
Comprehensive loss$(43,801)$(44,680)$(173,216)$(108,504)
The accompanying notes are an integral part of these condensed consolidated financial statements.
3


PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(Amounts in thousands, except share data)
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other
Comprehensive Loss		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202145,300,514 $5 $567,598 $(316,615)$(176)$250,812 
Stock-based compensation expense— — 7,886 — — 7,886 
Issuance of common stock from at-the-market public offerings, net of issuance costs70,410 — 1,368 — — 1,368 
Vesting of restricted stock units81,130 — — — — — 
Shares withheld for taxes for vesting of restricted stock units(17,850)— (230)— — (230)
Issuance of common stock upon exercise of stock options72,278 — 333 — — 333 
Change in unrealized loss on marketable securities, net of tax— — — — (430)(430)
Net loss— — — (68,717)— (68,717)
Balance at March 31, 202245,506,482 $5 $576,955 $(385,332)$(606)$191,022 
Stock-based compensation expense— — 7,611 — — 7,611 
Issuance of common stock under employee stock purchase plan51,645 — 454 — — 454 
Vesting of restricted stock units6,361 — — — — — 
Shares withheld for taxes for vesting of restricted stock units(2,225)— (17)— — (17)
Issuance of common stock upon exercise of stock options13,143 — 67 — — 67 
Change in unrealized loss on marketable securities, net of tax— — — — (74)(74)
Net loss— — — (60,194)— (60,194)
Balance at June 30, 202245,575,406 $5 $585,070 $(445,526)$(680)$138,869 
Stock-based compensation expense— — 6,730 — — 6,730 
Issuance of common stock from at-the-market public offerings, net of issuance costs of $109
1,105,006 — 2,962 — — 2,962 
Vesting of restricted stock units5,312 — — — — — 
Shares withheld for taxes for vesting of restricted stock units(1,638)— (6)— — (6)
Issuance of common stock upon exercise of stock options180,241 — 409 — — 409 
Change in unrealized loss on marketable securities, net of tax— — — — 144 144 
Net loss— — — (43,945)— (43,945)
Balance at September 30, 202246,864,327 $5 $595,165 $(489,471)$(536)$105,163 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(Unaudited)
(Amounts in thousands, except share data)
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other
Comprehensive Loss		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202038,268,543 $4 $437,007 $(149,554)$— $287,457 
Stock-based compensation expense— — 4,666 — — 4,666 
Issuance of common stock upon exercise of stock options352,506 — 851 — — 851 
Change in unrealized loss on marketable securities, net of tax— — — — (86)(86)
Net loss— — — (27,373)— (27,373)
Balance at March 31, 202138,621,049 $4 $442,524 $(176,927)$(86)$265,515 
Stock-based compensation expense— — 5,400 — — 5,400 
Issuance of common stock from follow-on public offering, net of offering costs of $229
5,750,000 1 98,412 — — 98,413 
Issuance of common stock upon exercise of stock options322,113 — 809 — — 809 
Change in unrealized loss on marketable securities, net of tax— — — — 36 36 
Net loss— — — (36,401)— (36,401)
Balance at June 30, 202144,693,162 $5 $547,145 $(213,328)$(50)$333,772 
Stock-based compensation expense— — 6,521 — — 6,521 
Issuance of common stock upon exercise of stock options90,909 — 309 — — 309 
Change unrealized loss on marketable securities, net of tax— — — — 25 25 
Net loss— — — (44,705)— (44,705)
Balance at September 30, 202144,784,071 $5 $553,975 $(258,033)$(25)$295,922 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

PRAXIS PRECISION MEDICINES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)
Nine Months Ended
September 30,
20222021
Cash flows from operating activities:
Net loss$(172,856)$(108,479)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense314 89 
Stock-based compensation expense22,227 16,587 
Non-cash operating lease expense556 942 
Amortization of premiums and discounts on marketable securities, net807 1,454 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets2,326 749 
Accounts payable(658)4,031 
Accrued expenses(8,431)5,481 
Operating lease liabilities(578)(566)
Other56 15 
Net cash used in operating activities(156,237)(79,697)
Cash flows from investing activities:
Purchases of property and equipment(444)(519)
Purchases of marketable securities(83,022)(164,170)
Maturities of marketable securities157,761 14,000 
Net cash provided by (used in) investing activities74,295 (150,689)
Cash flows from financing activities:
Proceeds from follow-on public offering, net of issuance costs— 98,480 
Proceeds from at-the-market offerings, net of issuance costs4,330 — 
Payment of issuance costs for at-the-market offerings and initial public offering(262)(575)
Payments of tax withholdings related to vesting of restricted stock units(253)— 
Proceeds from exercise of options and employee stock purchase plan contributions1,263 1,968 
Net cash provided by financing activities5,078 99,873 
Decrease in cash, cash equivalents and restricted cash(76,864)(130,513)
Cash, cash equivalents and restricted cash, beginning of period139,720 297,208 
Cash, cash equivalents and restricted cash, end of period$62,856 $166,695 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents62,440 165,679 
Restricted cash416 1,016 
Total cash, cash equivalents and restricted cash$62,856 $166,695 
Supplemental disclosures of non-cash activities:
Operating lease right-of-use assets obtained in exchange for operating lease liabilities$— $4,086 
Offering costs included in accrued expenses$— $68 
Purchases of property and equipment included in accrued expenses$— $116 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

PRAXIS PRECISION MEDICINES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Nature of the Business
Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ("CNS") disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. The Company is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using its understanding of shared biological targets and circuits in the brain, to develop patient-guided therapies. The Company applies a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a broad CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For its lead clinical-stage program, the Company expects to announce topline results from the Phase 2b clinical trial in essential tremor in the first quarter of 2023 and expects to initiate a Phase 2 clinical trial for the treatment of Parkinson's disease in the first quarter of 2023. The Company expects the initiation of first-in-patient studies for its lead antisense oligonucleotide epilepsy program in the fourth quarter of 2022 and its lead small molecule epilepsy program in the first quarter of 2023, as well as the launch of an additional clinical epilepsy program this year. In addition, the Company has established a robust pipeline of preclinical stage programs through internal research and in-licensing, including one of the largest portfolios of targeted epilepsy programs in the industry.
Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through September 30, 2022, the Company raised $520.8 million in aggregate cash proceeds from these transactions, net of issuance costs.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.
Liquidity
In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
The Company has incurred recurring losses since its inception, including a net loss of $172.9 million for the nine months ended September 30, 2022. In addition, as of September 30, 2022, the Company had an accumulated deficit of $489.5 million. The Company expects to continue to generate operating losses for the foreseeable future.
The analysis of the Company’s ability to continue as a going concern for the third quarter of 2022 included consideration of the Company’s current cash needs, ongoing research and development plans which are limited to advancing product candidates through, but not beyond their current clinical trial phases, anticipated cost savings resulting from its operational cost reduction plans, including ongoing efforts to eliminate costs not related to the
7

Company’s strategic focus. Such estimates contain significant judgment as the Company’s ongoing efforts to eliminate costs not related to the Company’s strategic focus contains uncertainties as to whether the Company can attain such benefits. Based on the analysis, the Company concluded that its available cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund current prioritized operations and capital expenditure requirements into the first quarter of 2024, which is at least 12 months from the filing date of this Quarterly Report on Form 10-Q with the SEC. As a result, the Company concluded that it did not identify conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued. The Company’s current operating plan is based on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it expects, in which case the Company would evaluate further reductions in its expenses or obtaining additional financing sooner than it otherwise would, which additional financing may not be available or may only be available on terms that are not acceptable to the Company.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. Financial statement disclosures for the three and nine months ended September 30, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements
8

The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements.
3. Marketable Securities
The following is a summary of the Company's investment portfolio as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$44,819 $— $(498)$44,321 
Commercial paper12,996 — — 12,996 
Debt securities issued by U.S. government agencies4,021 — (38)3,983 
Total securities with a maturity of one year or less$61,836 $— $(536)$61,300 
Total available-for-sale securities$61,836 $— $(536)$61,300 
As of December 31, 2021
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$52,214 $— $(31)$52,183 
Commercial paper34,993 — — 34,993 
Debt securities issued by U.S. government agencies12,111 — (8)12,103 
Other debt securities6,398 1 — 6,399 
Total securities with a maturity of one year or less$105,716 $1 $(39)$105,678 
Corporate debt securities31,667 — (138)31,529 
Total securities with a maturity of one to two years$31,667 $— $(138)$31,529 
Total available-for-sale securities$137,383 $1 $(177)$137,207 
As of September 30, 2022, the Company had 9 securities with a total fair market value of $48.3 million in an unrealized loss position. As of December 31, 2021, the Company had 14 securities with a total fair market value of $95.8 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and nine months ended September 30, 2022 and 2021.
4. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:
9

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;
•Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.
The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$58,218 $— $— $58,218 
Marketable securities:
Corporate debt securities— 44,321 — 44,321 
Commercial paper— 12,996 — 12,996 
Debt securities issued by U.S. government agencies3,983 — — 3,983 
$62,201 $57,317 $— $119,518 

As of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$131,372 $— $— $131,372 
Marketable securities:
Corporate debt securities— 83,712 — 83,712 
Commercial paper— 34,993 — 34,993 
Debt securities issued by U.S. government agencies12,103 — — 12,103 
Other debt securities— 6,399 — 6,399 
$143,475 $125,104 $— $268,579 
5. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
September 30, 2022December 31, 2021
Accrued external research and development expenses$12,978 $17,763 
Accrued personnel-related expenses2,648 7,180 
Accrued other2,258 1,901 
Total accrued expenses$17,884 $26,844 
6. Commitments and Contingencies
In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying
10

condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021. This lease qualifies as an operating lease.
7. Common Stock and Preferred Stock
Common Stock
As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.
As of September 30, 2022 and December 31, 2021, the Company did not hold any treasury shares.
Shares Reserved for Future Issuance
The Company has reserved the following shares of common stock for future issuance:
September 30,
2022		December 31,
2021
Shares reserved for exercise of outstanding stock options9,159,415 6,468,501 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan1,364,855 2,667,780 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan929,661 654,204 
Shares reserved for vesting of restricted stock units789,419 440,079 
Total shares of authorized common stock reserved for future issuance12,243,350 10,230,564 

Preferred Stock
As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.
8. Stock-Based Compensation
2020 Stock Option and Incentive Plan
The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of September 30, 2022 and December 31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively.

2017 Stock Incentive Plan
The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan”) as of September 30, 2022 and December 31, 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.

2020 Employee Stock Purchase Plan
The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of September 30, 2022 and December 31, 2021 was 981,306 shares and 654,204 shares, respectively.

11

Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 2021440,079 $41.86 
Issued652,328 15.00 
Vested(92,803)48.11 
Forfeited(210,185)22.76 
Unvested as of September 30, 2022789,419 $23.42 
As of September 30, 2022, total unrecognized compensation cost related to unvested restricted stock units was $14.6 million, which is expected to be recognized over a weighted-average period of 2.88 years.
Stock Options
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 20216,468,501 $16.92 
Granted3,932,802 9.29 
Exercised(265,662)3.04 $850 
Cancelled or Forfeited(976,226)17.99 
Outstanding as of September 30, 20229,159,415 $13.94 8.49$327 
Exercisable as of September 30, 20222,993,364 $14.69 7.55$71 
Vested and expected to vest as of September 30, 20228,956,409 $13.91 8.56$318 
The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock at September 30, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock on the date of exercise for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock on the exercise date.
Stock Option Valuation
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2022:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20222022
Risk-free interest rate2.76 %2.50 %
Expected term (in years)6.006.07
Expected volatility88.08 %89.22 %
Expected dividend yield— %— %
Weighted average grant-date fair value per share$2.16 $6.70 
12

As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $53.0 million, which is expected to be recognized over a weighted-average period of 2.38 years.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Research and development$1,999 $2,787 $8,200 $7,136 
General and administrative4,731 3,734 14,027 9,451 
Total stock-based compensation expense$6,730 $6,521 $22,227 $16,587 
9. Net Loss per Share
The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Outstanding stock options9,159,415 6,414,070 9,159,415 6,414,070 
Unvested restricted stock units789,419 383,196 789,419 383,196 
Potential shares issuable under the 2020 ESPP48,182 — 48,182 — 
9,997,016 6,797,266 9,997,016 6,797,266 
10. Related Party Transactions
On September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon’s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company’s General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material. As of September 30, 2022, the Company had accrued expenses of $0.3 million due to RogCon under the License Agreement.
11. Restructuring
In June 2022, the Company began a strategic realignment to focus resources on its Movement Disorders and Epilepsy franchises, which resulted in a reduction of the Company’s workforce.
The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the condensed consolidated statement of operations during the nine months ended September 30, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment.
As of September 30, 2022, all of the $1.0 million costs were paid.
12. Subsequent Events
13

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. The Company has concluded that no subsequent events have occurred that require disclosure.
14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the "SEC") on February 28, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the six months ended June 30, 2022, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain, to develop patient-guided therapies. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a broad CNS portfolio with multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For our lead clinical-stage program, we expect to announce topline results from the Phase 2b clinical trial in essential tremor, or ET, in the first quarter of 2023 and expect to initiate a Phase 2 clinical trial for the treatment of Parkinson's disease, or PD, in the first quarter of 2023. We expect the initiation of first-in-patient studies for our lead antisense oligonucleotide, or ASO, epilepsy program in the fourth quarter of 2022 and our lead small molecule epilepsy program in the first quarter of 2023, as well as the launch of an additional clinical epilepsy program this year. In addition, we have established a robust pipeline of preclinical-stage programs through internal research and in-licensing, including one of the largest portfolios of targeted epilepsy programs in the industry.
Within Movement Disorders, our lead clinical candidate, PRAX-944, is being developed for the treatment of ET and PD. We expect to report topline results from the Phase 2b placebo-controlled Essential1 Study for daytime treatment of ET in the first quarter of 2023. Following topline results, we intend to meet with the U.S. Food and Drug Administration, or the FDA, for an end-of-Phase 2 meeting in the first half of 2023 and initiate our Phase 3 development program in ET in mid-2023. We plan to initiate a Phase 2, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of PRAX-944 as a non-dopaminergic treatment for the motor symptoms of PD in the first quarter of 2023, and expect to report topline results in the second half of 2023.
Within Epilepsy, we plan to initiate the first dose cohort of the EMBRAVE study for PRAX-222, an ASO designed to decrease the expression levels of the protein encoded by the gene SCN2A in pediatric patients with early-seizure-onset SCN2A Developmental and Epileptic Encephalopathy, or DEE, in the fourth quarter of 2022. Following collection of the safety and efficacy data from the first cohort of patients in the EMBRAVE study, the data will be evaluated and submitted to the FDA to seek authorization for dose escalation. Topline results from the initial dose cohort are expected in 2023. We plan to initiate a Phase 2, placebo-controlled study with PRAX-562 in the first quarter of 2023 for the treatment of rare pediatric DEEs, with initial cohorts in SCN2A and SCN8A DEEs, and expect to report topline results in 2023. In October 2022, we received additional detail from the FDA regarding the clinical hold for our Investigational New Drug application for PRAX-562 for the treatment of pediatric patients with SCN2A and SCN8A DEEs. Based on the feedback from the FDA, we expect that no new preclinical or clinical studies will be required to clear the clinical hold. In addition, we expect to initiate a Phase 1 study with PRAX-628 in the fourth quarter of 2022 and subsequently initiate a Phase 2 study in focal epilepsy in 2023.
Our disclosed preclinical pipeline also consists of discovery programs in development for KCNT1 related epilepsy, three ASOs targeting SCN2A in patients with loss-of-function mutations, PCDH19 and SYNGAP1, respectively, and two additional discovery programs for undisclosed targets in movement disorders and epilepsy. We plan to advance ASO candidate PRAX-080 for PCDH19 into preclinical development in 2023.
15

Following the completion of the PRAX-114 Phase 2 Acapella Study for the treatment of Major Depressive Disorder in the third quarter of 2022, we do not currently plan to pursue further development of PRAX-114 for psychiatric disorders. The PRAX-114 Phase 2 Acapella study (N=110) was intended to provide additional understanding of the dose range and to evaluate the safety and efficacy of PRAX-114 at doses of 10, 20, 40 and 60 mg. Topline data indicated a linear dose response trend on the primary endpoint of change from baseline in the 17-item Hamilton Depression Rating Scale total score at Day 15, but were not statistically significant. In multiple secondary endpoints evaluating 40 mg of PRAX-114 relative to placebo, nominal statistical significance was achieved at Day 4, but not maintained at subsequent timepoints.
We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our preclinical and clinical product candidates, building our intellectual property, or IP, portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a “virtual” research and development model, relying heavily upon external consultants, collaborators and contract research organizations, or CROs, to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the sale and issuance of equity securities.
We are a development stage company and we have not generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our product candidates are still in preclinical and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates, if approved. We have incurred recurring operating losses since inception, including a net loss of $172.9 million for the nine months ended September 30, 2022. As of September 30, 2022, we had an accumulated deficit of $489.5 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will be maintained or increased in connection with our ongoing activities, as we:
•advance our lead product candidate, PRAX-944, to a late stage clinical trial;
•advance our PRAX-562 product candidate in the Phase 2 clinical trial;
•advance our PRAX-222 product candidate in the EMBRAVE clinical trial;
•advance our PRAX-628 product candidate in the Phase 1 clinical trial;
•advance our preclinical candidates to clinical trials;
•further invest in our pipeline;
•further invest in our manufacturing capabilities;
•seek regulatory approval for our product candidates;
•maintain, expand, protect and defend our IP portfolio;
•acquire or in-license technology;
•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and
•when needed, increase our headcount to support our development efforts and any future commercialization efforts.
In addition, as we progress toward potential marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or
16

discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of September 30, 2022, we had cash, cash equivalents and marketable securities of $123.7 million. We believe that our cash, cash equivalents and marketable securities as of September 30, 2022 will enable us to fund our operating expenses and capital expenditures into the first quarter of 2024. We have based this analysis on our current cash needs, ongoing research and development plans which are limited to advancing product candidates through, but not beyond their current clinical trial phases, anticipated cost savings resulting from our operational cost reduction plans, including ongoing efforts to eliminate costs not related to our strategic focus. Such estimates contain significant judgement as our ongoing efforts to eliminate costs not related to our strategic focus contains uncertainties as to whether we can attain such benefits. Our current operating plan is based on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect, in which case we would evaluate further reductions in our expenses or obtaining additional financing sooner than we otherwise would, which additional financing may not be available or may only be available on terms that are not acceptable to us. See “—Liquidity and Capital Resources.”
Restructuring
In June 2022, we began a strategic realignment to focus resources on our Movement Disorders and Epilepsy franchises, which resulted in a reduction of our workforce.
We incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the condensed consolidated statement of operations during the nine months ended September 30, 2022. These costs relate to employee severance, benefits and related costs. We do not expect to incur any additional significant costs related to the strategic realignment.
As of September 30, 2022, all of the $1.0 million costs were paid.
COVID-19 Business Update
In light of the ongoing COVID-19 pandemic, we continue to experience some disruptions and increased risk in our operations and those third parties upon whom we rely. These include disruptions and risks related to the conduct of our clinical trials and preclinical studies as policies at various clinical sites and federal, state, local and foreign laws, rules and regulations continue to evolve, including quarantines, travel restrictions and redirection of healthcare resources toward pandemic response efforts. The COVID-19 pandemic has impacted the enrollment of some of our ongoing clinical trials, including slower patient enrollment and treatment in some of our clinical studies, the impact of which has varied by clinical study and program, but none of which have significantly impacted our overall clinical trial timelines. While we have experienced limited financial impacts to date, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic such as increased inflation, our business, financial condition and results of operations could be materially adversely affected. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.
Financial Operations Overview
Revenue
We have not generated any revenue since inception and do not expect to generate any revenue from the sale of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.
17

Operating Expenses
Research and Development Expense
The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development expenses represent costs incurred by us for the following:
•costs to develop our portfolio;
•discovery efforts leading to development candidates;
•clinical development costs for our product candidates; and
•costs to develop our manufacturing technology and infrastructure.
The costs above comprise the following categories:
•personnel-related expenses, including salaries, benefits and stock-based compensation expense;
•expenses incurred under agreements with third parties, such as consultants, investigative sites and CROs, that conduct our preclinical and clinical studies and in-licensing arrangements;
•costs incurred to maintain compliance with regulatory requirements;
•costs incurred with third-party contract development and manufacturing organizations to acquire, develop and manufacture materials for preclinical and clinical studies; and
•depreciation, amortization and other direct and allocated expenses, including rent and other operating costs, incurred as a result of our research and development activities.
We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated balance sheets as prepaid expenses or accrued expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
As a company operating in a virtual environment, a significant portion of our research and development costs have been external costs. We track direct external research and development expenses to specific franchises and product candidates upon commencement. Due to the number of ongoing studies and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development franchises, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a franchise-specific basis.
The following table reflects our research and development expenses, including direct expenses summarized by major franchise and other exploratory CNS indications and indirect or shared operating costs recognized as research and development expenses during each period presented (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Movement disorders
$9,262 $6,735 $26,777 $12,107 
Epilepsy
7,630 4,942 32,579 15,707 
Psychiatry
2,642 9,188 28,394 19,029 
Other exploratory CNS indications414 1,475 2,853 2,957 
Personnel-related (including stock-based compensation)8,714 8,334 30,590 21,584 
Other indirect research and development expenses1,777 2,465 5,518 5,362 
Total research and development expenses$30,439 $33,139 $126,711 $76,746 
18

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will be maintained or increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional therapeutic areas.
At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:
•our ability to add and retain key research and development personnel;
•the timing and progress of preclinical and clinical development activities;
•the number and scope of preclinical and clinical programs we decide to pursue;
•our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;
•our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;
•our successful enrollment in and completion of clinical trials;
•the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;
•our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;
•our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;
•the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;
•our ability to obtain and maintain patent, trade secret and other IP protection and regulatory exclusivity for our product candidates, if approved;
•our receipt of marketing approvals from applicable regulatory authorities;
•our ability to commercialize products, if approved, whether alone or in collaboration with others; and
•the continued acceptable safety profiles of the product candidates following approval.
A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and require significant development costs.
General and Administrative Expense
General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, commercial and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; commercial-related costs to support market assessments and scenario planning; insurance costs; administrative travel expenses; and facility-related expenses,
19

which include direct depreciation costs and allocated expenses for office rent and other operating costs. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses. These costs relate to the operation of the business and are unrelated to the research and development function or any individual franchise or product candidate.
We anticipate that our general and administrative expenses may increase in the future as we increase our headcount, when needed, to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur additional IP-related expenses as we file patent applications to protect innovations arising from our research and development activities.
Other Income
Other Income, Net
Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts.
Income Taxes
Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. The income tax provision for the three and nine months ended September 30, 2022 and 2021 was not material.
Results of Operations
Comparison of the Three Months Ended September 30, 2022 and 2021
The following table summarizes our consolidated statements of operations for each period presented (in thousands):
Three Months Ended
September 30,		Change
20222021
Operating expenses:
Research and development$30,439 $33,139 $(2,700)
General and administrative13,851 11,634 2,217 
Total operating expenses44,290 44,773 (483)
Loss from operations(44,290)(44,773)483 
Other income:
Other income, net345 73 272 
Total other income345 73 272 
Loss before income taxes$(43,945)$(44,700)$755 
Provision for income taxes— (5)5 
Net loss$(43,945)$(44,705)$760 
Research and Development Expense
The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
20

Three Months Ended
September 30,		Change
20222021
Movement disorders
$9,262 $6,735 $2,527 
Epilepsy
7,630 4,942 2,688 
Psychiatry
2,642 9,188 (6,546)
Other exploratory CNS indications414 1,475 (1,061)
Personnel-related (including stock-based compensation)8,714 8,334 380 
Other indirect research and development expenses1,777 2,465 (688)
Total research and development expenses$30,439 $33,139 $(2,700)
The $2.7 million decrease in research and development expenses was primarily attributable to the following:
•$6.5 million decrease in expense related to our psychiatry franchise, driven primarily by a decrease in clinical-related spend for our PRAX-114 Phase 2/3 Aria clinical trial for which we announced topline results in the second quarter of 2022;
•$2.7 million increase in expense related to our epilepsy franchise, driven primarily by an increase in preclinical activities for PRAX-628 and our earlier stage assets and an increase in clinical-related spend to support the initiation of the PRAX-222 EMBRAVE clinical trial; and
•$2.5 million increase in expense related to our movement disorders franchise, driven primarily by an increase in clinical-related spend for our PRAX-944 Phase 2b Essential1 clinical trial and our Phase 1 healthy volunteers trial.
General and Administrative Expense
The $2.2 million increase in general and administrative expenses was primarily due to an increase in personnel-related costs due to increased headcount.
Other Income
Other income for the three months ended September 30, 2022 and 2021 was comprised of interest income on our cash, cash equivalents and marketable securities and investment premium and discount amortization.
Comparison of the Nine Months Ended September 30, 2022 and 2021
The following table summarizes our consolidated statements of operations for each period presented (in thousands):
Nine Months Ended
September 30,		Change
20222021
Operating expenses:
Research and development$126,711 $76,746 $49,965 
General and administrative46,822 31,929 14,893 
Total operating expenses173,533 108,675 64,858 
Loss from operations(173,533)(108,675)(64,858)
Other income:
Other income, net677 201 476 
Total other income677 201 476 
Loss before income taxes$(172,856)$(108,474)$(64,382)
Provision for income taxes— (5)5 
Net loss$(172,856)$(108,479)$(64,377)
Research and Development Expense
21

The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
Nine Months Ended
September 30,		Change
20222021
Movement disorders$26,777 $12,107 $14,670 
Epilepsy32,579 15,707 16,872 
Psychiatry28,394 19,029 9,365 
Other exploratory CNS indications2,853 2,957 (104)
Personnel-related (including stock-based compensation)30,590 21,584 9,006 
Other indirect research and development expenses5,518 5,362 156 
Total research and development expenses$126,711 $76,746 $49,965 
The $50.0 million increase in research and development expenses was primarily attributable to the following:
•$16.9 million increase in expense related to our epilepsy franchise, driven primarily by an increase in preclinical activities for PRAX-628 and our earlier stage assets, an increase in clinical-related spend for our PRAX-562 Phase 1 trials in healthy volunteers, an increase in clinical-related spend to support the initiation of the PRAX-222 EMBRAVE clinical trial, and the payment of a $2.0 million license fee to Ionis Pharmaceuticals, Inc. in January of 2022 upon exercise of our exclusive option to obtain the rights and license to further develop and commercialize PRAX-222;
•$14.7 million increase in expense related to our movement disorders franchise, driven primarily by an increase in clinical-related spend for our PRAX-944 Phase 2b Essential1 clinical trial, an increase in clinical-related spend for our PRAX-114 Phase 2 clinical trial evaluating PRAX-114 for the treatment of ET, and an increase in clinical-related spend for our PRAX-944 Phase 1 healthy volunteer trials;
•$9.4 million increase in expense related to our psychiatry franchise, driven primarily by an increase in clinical-related spend for our PRAX-114 Phase 2 Acapella clinical trial which was initiated in the second quarter of 2021 and our Phase 2 placebo-controlled study evaluating PRAX-114 for the treatment of post-traumatic stress disorder which was initiated in the fourth quarter of 2021; and
•$9.0 million increase in personnel-related costs due to increased headcount.
General and Administrative Expense
The $14.9 million increase in general and administrative expenses was primarily attributable to the following:
•$10.9 million increase in personnel-related costs due to increased headcount; and
•$3.4 million increase in professional fees, including a $1.6 million increase in legal fees due to increased corporate activity and patent-related work.
Other Income
Other income for the nine months ended September 30, 2022 and 2021, was comprised of interest income on our cash, cash equivalents and marketable securities and investment premium and discount amortization.
Liquidity and Capital Resources
Sources of Liquidity
Since our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all.
To date, we have financed our operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under our shelf registration statement. From inception through September 30, 2022, we
22

have raised $520.8 million in aggregate cash proceeds from such transactions, net of issuance costs. As of September 30, 2022, we had cash, cash equivalents and marketable securities of $123.7 million.
On November 3, 2021, we entered into an Open Market Sale Agreement, or the sales agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings for which Jefferies acts as sales agent. During the three months ended September 30, 2022, we issued and sold 1,105,006 shares under the sales agreement for aggregate net proceeds of $3.0 million after deducting commissions and offering expenses payable by us. During the nine months ended September 30, 2022, we issued and sold 1,175,416 shares under the sales agreement for aggregate net proceeds of $4.3 million after deducting commissions and offering expenses payable by us. We have issued and sold a total of 1,567,413 shares under the sales agreement for aggregate net proceeds of $11.4 million after deducting commissions and offering expenses payable by us.
Historical Cash Flows
The following table provides information regarding our cash flows for each period presented (in thousands):
Nine Months Ended September 30,
20222021
Net cash (used in) provided by:
Operating activities$(156,237)$(79,697)
Investing activities74,295 (150,689)
Financing activities5,078 99,873 
Net decrease in cash, cash equivalents and restricted cash$(76,864)$(130,513)
Operating Activities
Our cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support our business. We have historically experienced negative cash flows from operating activities as we have invested in developing our portfolio, drug discovery efforts and related infrastructure. The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in operating assets and liabilities, which are primarily the result of increased expenses and timing of vendor payments.
During the nine months ended September 30, 2022, net cash used in operating activities of $156.2 million was primarily due to our $172.9 million net loss and $7.3 million in changes in operating assets and liabilities primarily related to a decrease in accrued expenses, partially offset by $23.9 million of non-cash charges primarily related to stock-based compensation.
During the nine months ended September 30, 2021, net cash used in operating activities of $79.7 million was primarily due to our $108.5 million net loss, partially offset by $19.1 million of non-cash charges primarily related to stock-based compensation and $9.7 million in changes in operating assets and liabilities primarily related to an increase in accrued expenses and accounts payable.
Investing Activities
During the nine months ended September 30, 2022, net cash provided by investing activities of $74.3 million was primarily related to maturities of marketable securities, partially offset by purchases of marketable securities.
During the nine months ended September 30, 2021, net cash used in investing activities of $150.7 million was primarily related to the purchase of marketable securities, partially offset by the maturities of marketable securities.
Financing Activities
During the nine months ended September 30, 2022, net cash provided by financing activities of $5.1 million consisted of net proceeds from at-the-market offerings of $4.3 million and proceeds from purchases of common stock under our employee stock purchase plan and from the exercise of stock options, partially offset by the
23

payment of issuance costs for our at-the-market offerings and the payment of taxes related to the vesting of restricted stock units.
During the nine months ended September 30, 2021, net cash provided by financing activities of $99.9 million consisted of net proceeds from our follow-on public offering of $98.5 million and net proceeds from the exercise of stock options, partially offset by the payment of issuance costs for our initial public offering.
Plan of Operation and Future Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
•advance the clinical development of our clinical-stage product candidates within our movement disorders and epilepsy franchises;
•advance the development of any additional product candidates;
•conduct research and continue preclinical development of potential product candidates;
•make strategic investments in manufacturing capabilities;
•maintain our IP portfolio and opportunistically acquire complementary IP;
•seek to obtain regulatory approvals for our product candidates;
•potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
•when needed, add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company; and
•experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.
In June 2022, following the Aria Study topline results, we announced a strategic realignment to focus resources on our Movement Disorders and Epilepsy franchises, which resulted in a reduction of our workforce and future operating expenses and extended our cash runway.
We are unable to estimate the exact amount of our working capital requirements, but based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of September 30, 2022 will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2024. We have based this analysis on our current cash needs, ongoing research and development plans which are limited to advancing product candidates through, but not beyond their current clinical trial phases, anticipated cost savings resulting from our operational cost reduction plans, including ongoing efforts to eliminate costs not related to our strategic focus. Such estimates contain significant judgement as our ongoing efforts to eliminate costs not related to our strategic focus contains uncertainties as to whether we can attain such benefits. Our current operating plan is based on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect, in which case we would evaluate further reductions in our expenses or obtaining additional financing sooner than we otherwise would, which additional financing may not be available or may only be available on terms that are not acceptable to us.
Because of the numerous risks and uncertainties associated with product development and potential collaborations with third parties for the development of our product candidates, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:
24

•the scope, progress, results and costs of preclinical studies and clinical trials for our franchises and product candidates;
•the number and characteristics of product candidates and technologies that we develop or may in-license;
•the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
•the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;
•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our IP rights and defending any IP-related claims;
•the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;
•the costs we incur in maintaining business operations;
•the costs associated with being a public company;
•the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;
•the effect of competing technological and market developments;
•the impact of any business interruptions to our operations or to those of our manufacturers, suppliers or other vendors resulting from the COVID-19 pandemic or similar public health crisis; and
•the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.
Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. Market volatility could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially result in dilution to the holders of our common stock.
If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the
25

disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no changes to our critical accounting policies from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Judgments and Estimates” included in our Annual Report on Form 10-K filed with the SEC on February 28, 2022.
Recently Issued Accounting Pronouncements
We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our cash, cash equivalents and marketable securities are or may be in the form of money market funds or marketable debt securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. However, because of the short-term nature and low risk profile of the instruments in our portfolio, an immediate change in market interest rates of 100 basis points would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations.
Item 4. Controls and Procedures.
Management’s Evaluation of Our Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Based on the evaluation of our disclosure controls and procedures as of September 30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
As of the date of this Quarterly Report on Form 10-Q, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors.
There have been no material changes from the risk factors previously disclosed in the section entitled "Risk Factors" of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 8, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Recent Sales of Unregistered Equity Securities
We did not make any sales of unregistered securities during the three months ended September 30, 2022.
Use of Proceeds from Public Offering of Common Stock
In October 2020, we completed the initial public offering of our common stock, or IPO, pursuant to which we issued and sold 11,500,000 shares of our common stock at a price to the public of $19.00 per share. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S‑1 (File No. 333-249074), which was declared effective by the Securities and Exchange Commission on October 15, 2020.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
We did not make any repurchases of shares of common stock during the three months ended September 30, 2022.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
27

Item 6. Exhibits.
Exhibit
Number		Description
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*Filed herewith.
**    The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
28

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 PRAXIS PRECISION MEDICINES, INC.
Date: November 9, 2022By: /s/ Marcio Souza
  Marcio Souza
  Chief Executive Officer and Director (Principal Executive Officer)
Date: November 9, 2022By: /s/ Timothy Kelly
  Timothy Kelly
  Chief Financial Officer (Principal Financial Officer)
29
 EX-31.1 2 exhibit31120220930.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marcio Souza, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
November 9, 2022
By: /s/ MARCIO SOUZA
  Marcio Souza
  Chief Executive Officer
  (Principal Executive Officer)


 EX-31.2 3 exhibit31220220930.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Timothy Kelly, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
November 9, 2022
 By: /s/ TIMOTHY KELLY
   Timothy Kelly
   Chief Financial Officer
   (Principal Financial Officer)


 EX-32.1 4 exhibit32120220930.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc. (the “Company”) for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:
 
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
November 9, 2022
 By: /s/ MARCIO SOUZA
   Marcio Souza
   Chief Executive Officer
   (Principal Executive Officer)
Date:
November 9, 2022
 By: /s/ TIMOTHY KELLY
   Timothy Kelly
   Chief Financial Officer
   (Principal Financial Officer)


 EX-101.SCH 5 prax-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements Of Stockholders’ Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements Of Stockholders’ Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Common Stock and Preferred Stock link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Common Stock and Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Nature of the Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Marketable Securities - Investment Profile (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 prax-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 prax-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 prax-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Name of Property [Domain] Name of Property [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] Provision for income taxes Income Tax Expense (Benefit) Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Available-for-sale, gross unrealized gain, noncurrent, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 2020 Employee Stock Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Two Thousand Twenty Employee Stock Purchase Plan Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate intrinsic value exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Investments Investments, Fair Value Disclosure Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss Contingencies [Line Items] Loss Contingencies [Line Items] Follow-on Public Offering Follow-on Public Offering [Member] Follow-on Public Offering Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Common stock, $0.0001 par value; 150,000,000 shares authorized; 46,864,327 shares issued and outstanding as of September 30, 2022, and 45,300,514 shares issued and outstanding as of December 31, 2021 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity Financial Instruments [Domain] Financial Instruments [Domain] Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance Line items Depreciation expense Depreciation Vesting of restricted stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Issuance of common stock upon exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Summary of Common Stock Reserved For Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Available-for-sale, gross unrealized loss, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Issued (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Weighted average remaining contractual term vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Purchases of property and equipment included in accrued expenses Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Number of securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Securities, unrealized loss position, fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Assets Assets, Fair Value Disclosure Restructuring Plan [Axis] Restructuring Plan [Axis] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Percentage increase in annual base rent Percentage Increase In Annual Base Rent Percentage Increase In Annual Base Rent. Proceeds from exercise of options and employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Total available-for-sale securities, gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other Assets, Noncurrent Marketable securities Total available-for-sale securities, estimated fair value Debt Securities, Available-for-Sale Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Number of shares exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Supplemental disclosures of non-cash activities: Supplemental Cash Flow Information [Abstract] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Potential shares issuable under the 2020 ESPP Employee Stock [Member] Weighted average remaining contractual term outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating lease liabilities Operating Lease, Liability, Current Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Summary of Investment Portfolio Debt Securities, Available-for-Sale [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Shares reserved for exercise of outstanding stock options Outstanding stock options Share-Based Payment Arrangement, Option [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income, net Other Nonoperating Income (Expense) Restructuring Restructuring and Related Activities Disclosure [Text Block] Common stock, authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Total liabilities Liabilities Statement of Comprehensive Income [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total operating expenses Operating Expenses Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Issuance of common stock from at-the-market public offerings, net of issuance and offering costs Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Available-for-sale, cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Share-based payment arrangement Share-Based Payment Arrangement [Member] Available-for-sale, gross unrealized loss, noncurrent, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Estimated fair value, available-for-sale, current Debt Securities, Available-for-Sale, Current Preferred stock, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Measurement Frequency [Domain] Measurement Frequency [Domain] Common Stock and Preferred Stock Stockholders' Equity Note Disclosure [Text Block] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Restricted cash Restricted Cash Unvested beginning balance (in dollars per share) Unvested ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Summary of Financial Assets Measured At Fair Value On A Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Total unrecognized compensation cost related to unvested restricted stock units Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Entity Shell Company Entity Shell Company Accrued expenses Increase (Decrease) in Accrued Liabilities Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Shares reserved for future awards under the 2020 Stock Option and Incentive Plan Twenty Twenty Employee Stock Incentive Plan [Member] Twenty Twenty Employee Stock Incentive Plan Financial Instrument [Axis] Financial Instrument [Axis] Title of 12(b) Security Title of 12(b) Security At-the-market Offering At-the-market Offering [Member] At-the-market Offering Document Period End Date Document Period End Date Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Office Space in Boston Massachusetts Office Space in Boston Massachusetts [Member] Office Space in Boston Massachusetts Payables and Accruals [Abstract] Payables and Accruals [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Available-for-sale, gross unrealized gain, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Debt securities issued by U.S. government agencies US Government Agencies Debt Securities [Member] Total assets Assets Amortization of premiums and discounts on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Accrued personnel-related expenses Accrued Personnel Related Expenses Current Accrued Personnel Related Expenses, Current. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Accrued expenses Total accrued expenses Accrued Liabilities, Current Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Total available-for-sale securities, cost Debt Securities, Available-for-Sale, Amortized Cost Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Accounts payable Accounts Payable, Current Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Aggregate intrinsic value vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Net Loss per Share Earnings Per Share [Text Block] Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Nature of the Business Nature of Operations [Text Block] Accrued external research and development expenses Accrued External Research And Development Expenses Current Accrued External Research And Development Expenses, Current. Entity Filer Category Entity Filer Category Related Party Transaction [Line Items] Related Party Transaction [Line Items] Proceed from stock offerings Proceeds from Issuance of Common Stock Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Weighted-average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average remaining contractual term exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring Plan [Domain] Restructuring Plan [Domain] Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 6) Commitments and Contingencies Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Issuance of common stock from at-the-market public offerings, net of issuance and offering costs (in shares) Stock Issued During Period, Shares, New Issues Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance Table Subsequent Events Subsequent Events [Text Block] Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Shares reserved for vesting of restricted stock units Unvested restricted stock units Restricted Stock [Member] General and administrative General and Administrative Expense General and Administrative Expense [Member] Entity Address, City or Town Entity Address, City or Town June 2022 Restructuring Plan June 2022 Restructuring Plan [Member] June 2022 Restructuring Plan Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Operating expenses: Operating Expenses [Abstract] Long-term liabilities: Liabilities, Noncurrent [Abstract] Cover [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] RogCon Inc. RogCon Inc. [Member] RogCon Inc. Estimated fair value, available-for-sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Restructuring and Related Activities [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Asset Class [Domain] Asset Class [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Remaining restructuring costs Restructuring and Related Cost, Incurred Cost Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Payments of tax withholdings related to vesting of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number 2020 Employee Stock Incentive Plan Two Thousand Twenty Employee Stock Incentive Plan [Member] Two Thousand Twenty Employee Stock Incentive Plan Treasury stock (in shares) Treasury Stock, Common, Shares Related Party [Axis] Related Party [Axis] Research and development Research and Development Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Available-for-Sale, cost, noncurrent Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities. Accounts payable Increase (Decrease) in Accounts Payable Payments of stock issuance costs Payment of issuance costs for at-the-market offerings and initial public offering Payments of Stock Issuance Costs Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Subsequent Events [Abstract] Subsequent Events [Abstract] Total current liabilities Liabilities, Current Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Due to related parties Due to Related Parties Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Corporate debt securities Corporate Debt Securities [Member] Other income: Nonoperating Income (Expense) [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Shares reserved for future awards under the 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan [Member] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Forfeitures (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Entity Interactive Data Current Entity Interactive Data Current Change in unrealized losses on marketable securities, net of tax Change in unrealized loss on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Money market funds Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Unrecognized compensation expense related to unvested stock based awards Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common Stock Common Stock [Member] Summary of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] 2017 Stock Incentive Plan Twenty Seventeen Employee Stock Incentive Plan [Member] Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Shares withheld for taxes for vesting of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Current assets: Assets, Current [Abstract] Non-current portion of operating lease liabilities Operating Lease, Liability, Noncurrent Offering costs included in accrued expenses Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Other Other Operating Activities, Cash Flow Statement Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring Fair Value, Recurring [Member] Name of Property [Axis] Name of Property [Axis] Shares withheld for taxes for vesting of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Related Party Transactions Related Party Transactions Disclosure [Text Block] Accrued other Other Accrued Liabilities, Current Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Statement [Line Items] Statement [Line Items] General and administrative General and Administrative Expense Assets Assets [Abstract] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Other debt securities Other Debt Obligations [Member] Total other income Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total available-for-sale, gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Asset Class [Axis] Asset Class [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Research and development Research and Development Expense Research and Development Expense [Member] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Operating lease right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Unaudited Interim Condensed Consolidated Financial Information Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block] Unaudited interim condensed consolidated financial information EX-101.PRE 9 prax-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-39620  
Entity Registrant Name PRAXIS PRECISION MEDICINES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-5195942  
Entity Address, Address Line One 99 High Street  
Entity Address, Address Line Two 30th Floor  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02110  
City Area Code 617  
Local Phone Number 300-8460  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol PRAX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,118,578
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001689548  
Current Fiscal Year End Date --12-31  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 62,440 $ 138,704
Marketable securities 61,300 137,207
Prepaid expenses and other current assets 8,572 11,498
Total current assets 132,312 287,409
Property and equipment, net 1,077 1,213
Operating lease right-of-use assets 3,097 3,653
Other non-current assets 416 472
Total assets 136,902 292,747
Current liabilities:    
Accounts payable 10,122 10,780
Accrued expenses 17,884 26,844
Operating lease liabilities 977 810
Total current liabilities 28,983 38,434
Long-term liabilities:    
Non-current portion of operating lease liabilities 2,756 3,501
Total liabilities 31,739 41,935
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021 0 0
Common stock, $0.0001 par value; 150,000,000 shares authorized; 46,864,327 shares issued and outstanding as of September 30, 2022, and 45,300,514 shares issued and outstanding as of December 31, 2021 5 5
Additional paid-in capital 595,165 567,598
Accumulated other comprehensive loss (536) (176)
Accumulated deficit (489,471) (316,615)
Total stockholders’ equity 105,163 250,812
Total liabilities and stockholders’ equity $ 136,902 $ 292,747
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 46,864,327 45,300,514
Common stock, outstanding (in shares) 46,864,327 45,300,514
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 30,439 $ 33,139 $ 126,711 $ 76,746
General and administrative 13,851 11,634 46,822 31,929
Total operating expenses 44,290 44,773 173,533 108,675
Loss from operations (44,290) (44,773) (173,533) (108,675)
Other income:        
Other income, net 345 73 677 201
Total other income 345 73 677 201
Loss before income taxes (43,945) (44,700) (172,856) (108,474)
Provision for income taxes 0 (5) 0 (5)
Net loss $ (43,945) $ (44,705) $ (172,856) $ (108,479)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.96) $ (1.00) $ (3.79) $ (2.61)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.96) $ (1.00) $ (3.79) $ (2.61)
Weighted average common shares outstanding, basic (in shares) 45,774,376 44,714,941 45,591,888 41,608,017
Weighted average common shares outstanding, diluted (in shares) 45,774,376 44,714,941 45,591,888 41,608,017
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net loss $ (43,945) $ (44,705) $ (172,856) $ (108,479)
Change in unrealized losses on marketable securities, net of tax 144 25 (360) (25)
Comprehensive loss $ (43,801) $ (44,680) $ (173,216) $ (108,504)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements Of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020   38,268,543      
Beginning balance at Dec. 31, 2020 $ 287,457 $ 4 $ 437,007 $ (149,554) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,666   4,666    
Issuance of common stock upon exercise of stock options (in shares)   352,506      
Issuance of common stock upon exercise of stock options 851   851    
Change in unrealized loss on marketable securities, net of tax (86)       (86)
Net loss (27,373)     (27,373)  
Ending balance (in shares) at Mar. 31, 2021   38,621,049      
Ending balance at Mar. 31, 2021 265,515 $ 4 442,524 (176,927) (86)
Beginning balance (in shares) at Dec. 31, 2020   38,268,543      
Beginning balance at Dec. 31, 2020 287,457 $ 4 437,007 (149,554) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Change in unrealized loss on marketable securities, net of tax (25)        
Net loss (108,479)        
Ending balance (in shares) at Sep. 30, 2021   44,784,071      
Ending balance at Sep. 30, 2021 295,922 $ 5 553,975 (258,033) (25)
Beginning balance (in shares) at Mar. 31, 2021   38,621,049      
Beginning balance at Mar. 31, 2021 265,515 $ 4 442,524 (176,927) (86)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 5,400   5,400    
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs (in shares)   5,750,000      
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs 98,413 $ 1 98,412    
Issuance of common stock upon exercise of stock options (in shares)   322,113      
Issuance of common stock upon exercise of stock options 809   809    
Change in unrealized loss on marketable securities, net of tax 36       36
Net loss (36,401)     (36,401)  
Ending balance (in shares) at Jun. 30, 2021   44,693,162      
Ending balance at Jun. 30, 2021 333,772 $ 5 547,145 (213,328) (50)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 6,521   6,521    
Issuance of common stock upon exercise of stock options (in shares)   90,909      
Issuance of common stock upon exercise of stock options 309   309    
Change in unrealized loss on marketable securities, net of tax 25       25
Net loss (44,705)     (44,705)  
Ending balance (in shares) at Sep. 30, 2021   44,784,071      
Ending balance at Sep. 30, 2021 $ 295,922 $ 5 553,975 (258,033) (25)
Beginning balance (in shares) at Dec. 31, 2021 45,300,514 45,300,514      
Beginning balance at Dec. 31, 2021 $ 250,812 $ 5 567,598 (316,615) (176)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 7,886   7,886    
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs (in shares)   70,410      
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs 1,368   1,368    
Vesting of restricted stock awards (in shares)   81,130      
Shares withheld for taxes for vesting of restricted stock units (in shares)   (17,850)      
Shares withheld for taxes for vesting of restricted stock units (230)   (230)    
Issuance of common stock upon exercise of stock options (in shares)   72,278      
Issuance of common stock upon exercise of stock options 333   333    
Change in unrealized loss on marketable securities, net of tax (430)       (430)
Net loss (68,717)     (68,717)  
Ending balance (in shares) at Mar. 31, 2022   45,506,482      
Ending balance at Mar. 31, 2022 $ 191,022 $ 5 576,955 (385,332) (606)
Beginning balance (in shares) at Dec. 31, 2021 45,300,514 45,300,514      
Beginning balance at Dec. 31, 2021 $ 250,812 $ 5 567,598 (316,615) (176)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 265,662        
Change in unrealized loss on marketable securities, net of tax $ (360)        
Net loss $ (172,856)        
Ending balance (in shares) at Sep. 30, 2022 46,864,327 46,864,327      
Ending balance at Sep. 30, 2022 $ 105,163 $ 5 595,165 (489,471) (536)
Beginning balance (in shares) at Mar. 31, 2022   45,506,482      
Beginning balance at Mar. 31, 2022 191,022 $ 5 576,955 (385,332) (606)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 7,611   7,611    
Issuance of common stock under employee stock purchase plan (in shares)   51,645      
Issuance of common stock under employee stock purchase plan 454   454    
Vesting of restricted stock awards (in shares)   6,361      
Shares withheld for taxes for vesting of restricted stock units (in shares)   (2,225)      
Shares withheld for taxes for vesting of restricted stock units (17)   (17)    
Issuance of common stock upon exercise of stock options (in shares)   13,143      
Issuance of common stock upon exercise of stock options 67   67    
Change in unrealized loss on marketable securities, net of tax (74)       (74)
Net loss (60,194)     (60,194)  
Ending balance (in shares) at Jun. 30, 2022   45,575,406      
Ending balance at Jun. 30, 2022 138,869 $ 5 585,070 (445,526) (680)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 6,730   6,730    
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs (in shares)   1,105,006      
Issuance of common stock from at-the-market public offerings, net of issuance and offering costs 2,962   2,962    
Vesting of restricted stock awards (in shares)   5,312      
Shares withheld for taxes for vesting of restricted stock units (in shares)   (1,638)      
Shares withheld for taxes for vesting of restricted stock units (6)   (6)    
Issuance of common stock upon exercise of stock options (in shares)   180,241      
Issuance of common stock upon exercise of stock options 409   409    
Change in unrealized loss on marketable securities, net of tax 144       144
Net loss $ (43,945)     (43,945)  
Ending balance (in shares) at Sep. 30, 2022 46,864,327 46,864,327      
Ending balance at Sep. 30, 2022 $ 105,163 $ 5 $ 595,165 $ (489,471) $ (536)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements Of Stockholders’ Equity (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]        
Payments of stock issuance costs $ 109 $ 229 $ 262 $ 575
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (172,856) $ (108,479)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 314 89
Stock-based compensation expense 22,227 16,587
Non-cash operating lease expense 556 942
Amortization of premiums and discounts on marketable securities, net 807 1,454
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 2,326 749
Accounts payable (658) 4,031
Accrued expenses (8,431) 5,481
Operating lease liabilities (578) (566)
Other 56 15
Net cash used in operating activities (156,237) (79,697)
Cash flows from investing activities:    
Purchases of property and equipment (444) (519)
Purchases of marketable securities (83,022) (164,170)
Maturities of marketable securities 157,761 14,000
Net cash provided by (used in) investing activities 74,295 (150,689)
Cash flows from financing activities:    
Payment of issuance costs for at-the-market offerings and initial public offering (262) (575)
Payments of tax withholdings related to vesting of restricted stock units (253) 0
Proceeds from exercise of options and employee stock purchase plan contributions 1,263 1,968
Net cash provided by financing activities 5,078 99,873
Decrease in cash, cash equivalents and restricted cash (76,864) (130,513)
Cash, cash equivalents and restricted cash, beginning of period 139,720 297,208
Cash, cash equivalents and restricted cash, end of period 62,856 166,695
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 62,440 165,679
Restricted cash 416 1,016
Total cash, cash equivalents and restricted cash 62,856 166,695
Supplemental disclosures of non-cash activities:    
Operating lease right-of-use assets obtained in exchange for operating lease liabilities 0 4,086
Offering costs included in accrued expenses 0 68
Purchases of property and equipment included in accrued expenses 0 116
Follow-on Public Offering    
Cash flows from financing activities:    
Proceed from stock offerings 0 98,480
At-the-market Offering    
Cash flows from financing activities:    
Proceed from stock offerings $ 4,330 $ 0
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of the Business
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business Nature of the Business
Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ("CNS") disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. The Company is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using its understanding of shared biological targets and circuits in the brain, to develop patient-guided therapies. The Company applies a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a broad CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For its lead clinical-stage program, the Company expects to announce topline results from the Phase 2b clinical trial in essential tremor in the first quarter of 2023 and expects to initiate a Phase 2 clinical trial for the treatment of Parkinson's disease in the first quarter of 2023. The Company expects the initiation of first-in-patient studies for its lead antisense oligonucleotide epilepsy program in the fourth quarter of 2022 and its lead small molecule epilepsy program in the first quarter of 2023, as well as the launch of an additional clinical epilepsy program this year. In addition, the Company has established a robust pipeline of preclinical stage programs through internal research and in-licensing, including one of the largest portfolios of targeted epilepsy programs in the industry.
Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through September 30, 2022, the Company raised $520.8 million in aggregate cash proceeds from these transactions, net of issuance costs.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.
Liquidity
In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
The Company has incurred recurring losses since its inception, including a net loss of $172.9 million for the nine months ended September 30, 2022. In addition, as of September 30, 2022, the Company had an accumulated deficit of $489.5 million. The Company expects to continue to generate operating losses for the foreseeable future.
The analysis of the Company’s ability to continue as a going concern for the third quarter of 2022 included consideration of the Company’s current cash needs, ongoing research and development plans which are limited to advancing product candidates through, but not beyond their current clinical trial phases, anticipated cost savings resulting from its operational cost reduction plans, including ongoing efforts to eliminate costs not related to the
Company’s strategic focus. Such estimates contain significant judgment as the Company’s ongoing efforts to eliminate costs not related to the Company’s strategic focus contains uncertainties as to whether the Company can attain such benefits. Based on the analysis, the Company concluded that its available cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund current prioritized operations and capital expenditure requirements into the first quarter of 2024, which is at least 12 months from the filing date of this Quarterly Report on Form 10-Q with the SEC. As a result, the Company concluded that it did not identify conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued. The Company’s current operating plan is based on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it expects, in which case the Company would evaluate further reductions in its expenses or obtaining additional financing sooner than it otherwise would, which additional financing may not be available or may only be available on terms that are not acceptable to the Company.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. Financial statement disclosures for the three and nine months ended September 30, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements
The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following is a summary of the Company's investment portfolio as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$44,819 $— $(498)$44,321 
Commercial paper12,996 — — 12,996 
Debt securities issued by U.S. government agencies4,021 — (38)3,983 
Total securities with a maturity of one year or less$61,836 $— $(536)$61,300 
Total available-for-sale securities$61,836 $— $(536)$61,300 
As of December 31, 2021
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$52,214 $— $(31)$52,183 
Commercial paper34,993 — — 34,993 
Debt securities issued by U.S. government agencies12,111 — (8)12,103 
Other debt securities6,398 1 — 6,399 
Total securities with a maturity of one year or less$105,716 $1 $(39)$105,678 
Corporate debt securities31,667 — (138)31,529 
Total securities with a maturity of one to two years$31,667 $— $(138)$31,529 
Total available-for-sale securities$137,383 $1 $(177)$137,207 
As of September 30, 2022, the Company had 9 securities with a total fair market value of $48.3 million in an unrealized loss position. As of December 31, 2021, the Company had 14 securities with a total fair market value of $95.8 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and nine months ended September 30, 2022 and 2021.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;
•Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or
•Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.
The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$58,218 $— $— $58,218 
Marketable securities:
Corporate debt securities— 44,321 — 44,321 
Commercial paper— 12,996 — 12,996 
Debt securities issued by U.S. government agencies3,983 — — 3,983 
$62,201 $57,317 $— $119,518 

As of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$131,372 $— $— $131,372 
Marketable securities:
Corporate debt securities— 83,712 — 83,712 
Commercial paper— 34,993 — 34,993 
Debt securities issued by U.S. government agencies12,103 — — 12,103 
Other debt securities— 6,399 — 6,399 
$143,475 $125,104 $— $268,579 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following (in thousands):
September 30, 2022December 31, 2021
Accrued external research and development expenses$12,978 $17,763 
Accrued personnel-related expenses2,648 7,180 
Accrued other2,258 1,901 
Total accrued expenses$17,884 $26,844 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and ContingenciesIn May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021. This lease qualifies as an operating lease.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock and Preferred Stock
 9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Common Stock and Preferred Stock Common Stock and Preferred Stock
Common Stock
As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.
As of September 30, 2022 and December 31, 2021, the Company did not hold any treasury shares.
Shares Reserved for Future Issuance
The Company has reserved the following shares of common stock for future issuance:
September 30,
2022		December 31,
2021
Shares reserved for exercise of outstanding stock options9,159,415 6,468,501 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan1,364,855 2,667,780 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan929,661 654,204 
Shares reserved for vesting of restricted stock units789,419 440,079 
Total shares of authorized common stock reserved for future issuance12,243,350 10,230,564 

Preferred Stock
As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2020 Stock Option and Incentive Plan
The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of September 30, 2022 and December 31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively.

2017 Stock Incentive Plan
The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan”) as of September 30, 2022 and December 31, 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.

2020 Employee Stock Purchase Plan
The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of September 30, 2022 and December 31, 2021 was 981,306 shares and 654,204 shares, respectively.
Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 2021440,079 $41.86 
Issued652,328 15.00 
Vested(92,803)48.11 
Forfeited(210,185)22.76 
Unvested as of September 30, 2022789,419 $23.42 
As of September 30, 2022, total unrecognized compensation cost related to unvested restricted stock units was $14.6 million, which is expected to be recognized over a weighted-average period of 2.88 years.
Stock Options
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 20216,468,501 $16.92 
Granted3,932,802 9.29 
Exercised(265,662)3.04 $850 
Cancelled or Forfeited(976,226)17.99 
Outstanding as of September 30, 20229,159,415 $13.94 8.49$327 
Exercisable as of September 30, 20222,993,364 $14.69 7.55$71 
Vested and expected to vest as of September 30, 20228,956,409 $13.91 8.56$318 
The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock at September 30, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock on the date of exercise for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock on the exercise date.
Stock Option Valuation
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2022:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20222022
Risk-free interest rate2.76 %2.50 %
Expected term (in years)6.006.07
Expected volatility88.08 %89.22 %
Expected dividend yield— %— %
Weighted average grant-date fair value per share$2.16 $6.70 
As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $53.0 million, which is expected to be recognized over a weighted-average period of 2.38 years.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Research and development$1,999 $2,787 $8,200 $7,136 
General and administrative4,731 3,734 14,027 9,451 
Total stock-based compensation expense$6,730 $6,521 $22,227 $16,587 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Outstanding stock options9,159,415 6,414,070 9,159,415 6,414,070 
Unvested restricted stock units789,419 383,196 789,419 383,196 
Potential shares issuable under the 2020 ESPP48,182 — 48,182 — 
9,997,016 6,797,266 9,997,016 6,797,266 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party TransactionsOn September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon’s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company’s General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material. As of September 30, 2022, the Company had accrued expenses of $0.3 million due to RogCon under the License Agreement.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In June 2022, the Company began a strategic realignment to focus resources on its Movement Disorders and Epilepsy franchises, which resulted in a reduction of the Company’s workforce.
The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the condensed consolidated statement of operations during the nine months ended September 30, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment.
As of September 30, 2022, all of the $1.0 million costs were paid.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. The Company has concluded that no subsequent events have occurred that require disclosure.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.
Unaudited Interim Condensed Consolidated Financial Information
Unaudited Interim Condensed Consolidated Financial Information
The accompanying condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. Financial statement disclosures for the three and nine months ended September 30, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.
The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements Recently Issued Accounting PronouncementsThe Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Summary of Investment Portfolio
The following is a summary of the Company's investment portfolio as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$44,819 $— $(498)$44,321 
Commercial paper12,996 — — 12,996 
Debt securities issued by U.S. government agencies4,021 — (38)3,983 
Total securities with a maturity of one year or less$61,836 $— $(536)$61,300 
Total available-for-sale securities$61,836 $— $(536)$61,300 
As of December 31, 2021
Gross UnrealizedEstimated
CostGainsLossesFair Value
Available-for-sale securities:
Corporate debt securities$52,214 $— $(31)$52,183 
Commercial paper34,993 — — 34,993 
Debt securities issued by U.S. government agencies12,111 — (8)12,103 
Other debt securities6,398 1 — 6,399 
Total securities with a maturity of one year or less$105,716 $1 $(39)$105,678 
Corporate debt securities31,667 — (138)31,529 
Total securities with a maturity of one to two years$31,667 $— $(138)$31,529 
Total available-for-sale securities$137,383 $1 $(177)$137,207 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Financial Assets Measured At Fair Value On A Recurring Basis
The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands):
As of September 30, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$58,218 $— $— $58,218 
Marketable securities:
Corporate debt securities— 44,321 — 44,321 
Commercial paper— 12,996 — 12,996 
Debt securities issued by U.S. government agencies3,983 — — 3,983 
$62,201 $57,317 $— $119,518 

As of December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds$131,372 $— $— $131,372 
Marketable securities:
Corporate debt securities— 83,712 — 83,712 
Commercial paper— 34,993 — 34,993 
Debt securities issued by U.S. government agencies12,103 — — 12,103 
Other debt securities— 6,399 — 6,399 
$143,475 $125,104 $— $268,579 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses (Tables)
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Summary of Accrued Expenses
Accrued expenses consisted of the following (in thousands):
September 30, 2022December 31, 2021
Accrued external research and development expenses$12,978 $17,763 
Accrued personnel-related expenses2,648 7,180 
Accrued other2,258 1,901 
Total accrued expenses$17,884 $26,844 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock and Preferred Stock (Tables)
 9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Summary of Common Stock Reserved For Future Issuance
The Company has reserved the following shares of common stock for future issuance:
September 30,
2022		December 31,
2021
Shares reserved for exercise of outstanding stock options9,159,415 6,468,501 
Shares reserved for future awards under the 2020 Stock Option and Incentive Plan1,364,855 2,667,780 
Shares reserved for future awards under the 2020 Employee Stock Purchase Plan929,661 654,204 
Shares reserved for vesting of restricted stock units789,419 440,079 
Total shares of authorized common stock reserved for future issuance12,243,350 10,230,564 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Restricted Stock Activity
The following table summarizes the Company’s restricted stock unit activity:
SharesWeighted
Average
Grant Date
Fair Value
Unvested as of December 31, 2021440,079 $41.86 
Issued652,328 15.00 
Vested(92,803)48.11 
Forfeited(210,185)22.76 
Unvested as of September 30, 2022789,419 $23.42 
Summary of Stock Option Activity
The following table summarizes the Company’s stock option activity:
Number of
Shares		Weighted
Average
Exercise Price
per Share		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic Value
(In years)(In thousands)
Outstanding as of December 31, 20216,468,501 $16.92 
Granted3,932,802 9.29 
Exercised(265,662)3.04 $850 
Cancelled or Forfeited(976,226)17.99 
Outstanding as of September 30, 20229,159,415 $13.94 8.49$327 
Exercisable as of September 30, 20222,993,364 $14.69 7.55$71 
Vested and expected to vest as of September 30, 20228,956,409 $13.91 8.56$318 
Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model
The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2022:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20222022
Risk-free interest rate2.76 %2.50 %
Expected term (in years)6.006.07
Expected volatility88.08 %89.22 %
Expected dividend yield— %— %
Weighted average grant-date fair value per share$2.16 $6.70 
Summary of Stock-Based Compensation Expense
Stock-based compensation expense was allocated as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Research and development$1,999 $2,787 $8,200 $7,136 
General and administrative4,731 3,734 14,027 9,451 
Total stock-based compensation expense$6,730 $6,521 $22,227 $16,587 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share
The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Outstanding stock options9,159,415 6,414,070 9,159,415 6,414,070 
Unvested restricted stock units789,419 383,196 789,419 383,196 
Potential shares issuable under the 2020 ESPP48,182 — 48,182 — 
9,997,016 6,797,266 9,997,016 6,797,266 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of the Business - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 93 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]                    
Proceeds from issuance or sale of equity                 $ 520,800  
Net loss $ 43,945 $ 60,194 $ 68,717 $ 44,705 $ 36,401 $ 27,373 $ 172,856 $ 108,479    
Accumulated deficit $ 489,471           $ 489,471   $ 489,471 $ 316,615
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities - Investment Profile (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale, cost, current $ 61,836 $ 105,716
Available-for-Sale, cost, noncurrent   31,667
Total available-for-sale securities, cost 61,836 137,383
Available-for-sale, gross unrealized gain, current, before tax 0 1
Available-for-sale, gross unrealized gain, noncurrent, before tax   0
Total available-for-sale securities, gross unrealized gains 0 1
Available-for-sale, gross unrealized loss, current, before tax (536) (39)
Available-for-sale, gross unrealized loss, noncurrent, before tax   (138)
Total available-for-sale, gross unrealized losses (536) (177)
Estimated fair value, available-for-sale, current 61,300 105,678
Estimated fair value, available-for-sale, noncurrent   31,529
Total available-for-sale securities, estimated fair value 61,300 137,207
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale, cost, current 44,819 52,214
Available-for-Sale, cost, noncurrent   31,667
Available-for-sale, gross unrealized gain, current, before tax 0 0
Available-for-sale, gross unrealized gain, noncurrent, before tax   0
Available-for-sale, gross unrealized loss, current, before tax (498) (31)
Available-for-sale, gross unrealized loss, noncurrent, before tax   (138)
Estimated fair value, available-for-sale, current 44,321 52,183
Estimated fair value, available-for-sale, noncurrent   31,529
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale, cost, current 12,996 34,993
Available-for-sale, gross unrealized gain, current, before tax 0 0
Available-for-sale, gross unrealized loss, current, before tax 0 0
Estimated fair value, available-for-sale, current 12,996 34,993
Debt securities issued by U.S. government agencies    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale, cost, current 4,021 12,111
Available-for-sale, gross unrealized gain, current, before tax 0 0
Available-for-sale, gross unrealized loss, current, before tax (38) (8)
Estimated fair value, available-for-sale, current $ 3,983 12,103
Other debt securities    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale, cost, current   6,398
Available-for-sale, gross unrealized gain, current, before tax   1
Available-for-sale, gross unrealized loss, current, before tax   0
Estimated fair value, available-for-sale, current   $ 6,399
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities - Additional Information (Details)
$ in Millions
Sep. 30, 2022
USD ($)
security
Dec. 31, 2021
USD ($)
security
Investments, Debt and Equity Securities [Abstract]    
Number of securities | security 9 14
Securities, unrealized loss position, fair value | $ $ 48.3 $ 95.8
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 119,518 $ 268,579
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 62,201 143,475
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 57,317 125,104
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0 0
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 58,218 131,372
Money market funds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 58,218 131,372
Money market funds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Money market funds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 44,321 83,712
Corporate debt securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Corporate debt securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 44,321 83,712
Corporate debt securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 12,996 34,993
Commercial paper | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Commercial paper | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 12,996 34,993
Commercial paper | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Debt securities issued by U.S. government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 3,983 12,103
Debt securities issued by U.S. government agencies | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 3,983 12,103
Debt securities issued by U.S. government agencies | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Debt securities issued by U.S. government agencies | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments $ 0 0
Other debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments   6,399
Other debt securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments   0
Other debt securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments   6,399
Other debt securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments   $ 0
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued external research and development expenses $ 12,978 $ 17,763
Accrued personnel-related expenses 2,648 7,180
Accrued other 2,258 1,901
Total accrued expenses $ 17,884 $ 26,844
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Additional Information (Details)
May 31, 2021
Office Space in Boston Massachusetts  
Loss Contingencies [Line Items]  
Percentage increase in annual base rent 2.00%
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock and Preferred Stock - Additional Information (Details) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Stockholders' Equity Note [Abstract]    
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Treasury stock (in shares) 0 0
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) - shares
Sep. 30, 2022
Dec. 31, 2021
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Common stock reserved for future issuance (in shares) 12,243,350 10,230,564
Shares reserved for exercise of outstanding stock options    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Common stock reserved for future issuance (in shares) 9,159,415 6,468,501
Share-based payment arrangement | Shares reserved for future awards under the 2020 Stock Option and Incentive Plan    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Common stock reserved for future issuance (in shares) 1,364,855 2,667,780
Share-based payment arrangement | Shares reserved for future awards under the 2020 Employee Stock Purchase Plan    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Common stock reserved for future issuance (in shares) 929,661 654,204
Shares reserved for vesting of restricted stock units    
Schedule Of Common Stock Reserved For Future Issuance [Line Items]    
Common stock reserved for future issuance (in shares) 789,419 440,079
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Unvested Restricted Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total unrecognized compensation cost related to unvested restricted stock units $ 14.6  
Weighted-average period (in years) 2 years 10 months 17 days  
Shares reserved for exercise of outstanding stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average period (in years) 2 years 4 months 17 days  
Unrecognized compensation expense related to unvested stock based awards $ 53.0  
2020 Employee Stock Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized 7,449,480 5,184,455
2017 Stock Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized 5,937,763 5,937,763
2020 Employee Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized 981,306 654,204
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Unvested restricted stock units
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Shares  
Beginning balance (in shares) | shares 440,079
Issued (in shares) | shares 652,328
Vested (in shares) | shares (92,803)
Forfeited (in shares) | shares (210,185)
Ending balance (in shares) | shares 789,419
Weighted Average Grant Date Fair Value  
Unvested beginning balance (in dollars per share) | $ / shares $ 41.86
Issued (in dollars per share) | $ / shares 15.00
Vested (in dollars per share) | $ / shares 48.11
Forfeitures (in dollars per shares) | $ / shares 22.76
Unvested ending balance (in dollars per share) | $ / shares $ 23.42
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2022
Number of Shares  
Beginning balance (in shares) 6,468,501
Granted (in shares) 3,932,802
Exercised (in shares) (265,662)
Canceled or forfeited (in shares) (976,226)
Ending balance (in shares) 9,159,415
Number of shares exercisable (in shares) 2,993,364
Vested and expected to vest (in shares) 8,956,409
Weighted Average Exercise Price per Share  
Beginning balance (in dollars per share) $ 16.92
Granted (in dollars per share) 9.29
Exercised (in dollars per share) 3.04
Cancelled or forfeited (in dollars per share) 17.99
Ending balance (in dollars per share) 13.94
Exercisable (in dollars per share) 14.69
Vested and expected to vest (in dollars per share) $ 13.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Weighted average remaining contractual term outstanding 8 years 5 months 26 days
Weighted average remaining contractual term exercisable 7 years 6 months 18 days
Weighted average remaining contractual term vested and expected to vest 8 years 6 months 21 days
Aggregate intrinsic value exercised $ 850
Aggregate intrinsic value outstanding 327
Aggregate intrinsic value exercisable 71
Aggregate intrinsic value vested and expected to vest $ 318
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate 2.76% 2.50%
Expected term (in years) 6 years 6 years 25 days
Expected volatility 88.08% 89.22%
Expected dividend yield 0.00% 0.00%
Shares reserved for exercise of outstanding stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average grant-date fair value per share (in dollars per share) $ 2.16 $ 6.70
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 6,730 $ 6,521 $ 22,227 $ 16,587
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 1,999 2,787 8,200 7,136
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 4,731 $ 3,734 $ 14,027 $ 9,451
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities (in shares) 9,997,016 6,797,266 9,997,016 6,797,266
Outstanding stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities (in shares) 9,159,415 6,414,070 9,159,415 6,414,070
Unvested restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities (in shares) 789,419 383,196 789,419 383,196
Potential shares issuable under the 2020 ESPP        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities (in shares) 48,182 0 48,182 0
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Additional Information (Details)
$ in Millions
Sep. 30, 2022
USD ($)
RogCon Inc.  
Related Party Transaction [Line Items]  
Due to related parties $ 0.3
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring (Details) - June 2022 Restructuring Plan
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Restructuring Cost and Reserve [Line Items]  
Remaining restructuring costs $ 1.0
Research and Development Expense  
Restructuring Cost and Reserve [Line Items]  
Remaining restructuring costs 0.6
General and Administrative Expense  
Restructuring Cost and Reserve [Line Items]  
Remaining restructuring costs $ 0.4
XML 53 prax-20220930_htm.xml IDEA: XBRL DOCUMENT 0001689548 2022-01-01 2022-09-30 0001689548 2022-11-04 0001689548 2022-09-30 0001689548 2021-12-31 0001689548 2022-07-01 2022-09-30 0001689548 2021-07-01 2021-09-30 0001689548 2021-01-01 2021-09-30 0001689548 us-gaap:CommonStockMember 2021-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001689548 us-gaap:RetainedEarningsMember 2021-12-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001689548 2022-01-01 2022-03-31 0001689548 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001689548 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001689548 us-gaap:CommonStockMember 2022-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001689548 us-gaap:RetainedEarningsMember 2022-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001689548 2022-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001689548 2022-04-01 2022-06-30 0001689548 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001689548 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001689548 us-gaap:CommonStockMember 2022-06-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001689548 us-gaap:RetainedEarningsMember 2022-06-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001689548 2022-06-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001689548 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001689548 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001689548 us-gaap:CommonStockMember 2022-09-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001689548 us-gaap:RetainedEarningsMember 2022-09-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001689548 us-gaap:CommonStockMember 2020-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001689548 us-gaap:RetainedEarningsMember 2020-12-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001689548 2020-12-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001689548 2021-01-01 2021-03-31 0001689548 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001689548 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001689548 us-gaap:CommonStockMember 2021-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001689548 us-gaap:RetainedEarningsMember 2021-03-31 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001689548 2021-03-31 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001689548 2021-04-01 2021-06-30 0001689548 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001689548 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001689548 us-gaap:CommonStockMember 2021-06-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001689548 us-gaap:RetainedEarningsMember 2021-06-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001689548 2021-06-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001689548 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001689548 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001689548 us-gaap:CommonStockMember 2021-09-30 0001689548 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001689548 us-gaap:RetainedEarningsMember 2021-09-30 0001689548 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001689548 2021-09-30 0001689548 prax:FollowOnPublicOfferingMember 2022-01-01 2022-09-30 0001689548 prax:FollowOnPublicOfferingMember 2021-01-01 2021-09-30 0001689548 prax:AtTheMarketOfferingMember 2022-01-01 2022-09-30 0001689548 prax:AtTheMarketOfferingMember 2021-01-01 2021-09-30 0001689548 2015-01-01 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001689548 us-gaap:CommercialPaperMember 2022-09-30 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001689548 us-gaap:CommercialPaperMember 2021-12-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001689548 us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001689548 prax:OfficeSpaceInBostonMassachusettsMember 2021-05-31 0001689548 us-gaap:EmployeeStockOptionMember 2022-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2021-12-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockIncentivePlanMember 2022-09-30 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockIncentivePlanMember 2021-12-31 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockPurchasePlanMember 2022-09-30 0001689548 us-gaap:StockCompensationPlanMember prax:TwentyTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001689548 us-gaap:RestrictedStockMember 2022-09-30 0001689548 us-gaap:RestrictedStockMember 2021-12-31 0001689548 prax:TwoThousandTwentyEmployeeStockIncentivePlanMember 2022-09-30 0001689548 prax:TwoThousandTwentyEmployeeStockIncentivePlanMember 2021-12-31 0001689548 prax:TwentySeventeenEmployeeStockIncentivePlanMember 2022-09-30 0001689548 prax:TwentySeventeenEmployeeStockIncentivePlanMember 2021-12-31 0001689548 prax:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-09-30 0001689548 prax:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001689548 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001689548 prax:UnvestedRestrictedStockUnitsMember 2022-09-30 0001689548 prax:UnvestedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001689548 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0001689548 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0001689548 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001689548 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001689548 us-gaap:EmployeeStockMember 2022-07-01 2022-09-30 0001689548 us-gaap:EmployeeStockMember 2021-07-01 2021-09-30 0001689548 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001689548 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001689548 prax:RogConIncMember 2022-09-30 0001689548 prax:June2022RestructuringPlanMember 2022-01-01 2022-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember prax:June2022RestructuringPlanMember 2022-01-01 2022-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember prax:June2022RestructuringPlanMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares prax:security pure false 2022 Q3 0001689548 --12-31 10-Q true 2022-09-30 false 001-39620 PRAXIS PRECISION MEDICINES, INC. DE 47-5195942 99 High Street 30th Floor Boston MA 02110 617 300-8460 Common Stock, par value $0.0001 per share PRAX NASDAQ Yes Yes Large Accelerated Filer true false false 47118578 62440000 138704000 61300000 137207000 8572000 11498000 132312000 287409000 1077000 1213000 3097000 3653000 416000 472000 136902000 292747000 10122000 10780000 17884000 26844000 977000 810000 28983000 38434000 2756000 3501000 31739000 41935000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 150000000 150000000 46864327 46864327 45300514 45300514 5000 5000 595165000 567598000 -536000 -176000 -489471000 -316615000 105163000 250812000 136902000 292747000 30439000 33139000 126711000 76746000 13851000 11634000 46822000 31929000 44290000 44773000 173533000 108675000 -44290000 -44773000 -173533000 -108675000 345000 73000 677000 201000 345000 73000 677000 201000 -43945000 -44700000 -172856000 -108474000 0 5000 0 5000 -43945000 -44705000 -172856000 -108479000 -0.96 -0.96 -1.00 -1.00 -3.79 -3.79 -2.61 -2.61 45774376 45774376 44714941 44714941 45591888 45591888 41608017 41608017 -43945000 -44705000 -172856000 -108479000 144000 25000 -360000 -25000 -43801000 -44680000 -173216000 -108504000 45300514 5000 567598000 -316615000 -176000 250812000 7886000 7886000 70410 1368000 1368000 81130 17850 230000 230000 72278 333000 333000 -430000 -430000 -68717000 -68717000 45506482 5000 576955000 -385332000 -606000 191022000 7611000 7611000 51645 454000 454000 6361 2225 17000 17000 13143 67000 67000 -74000 -74000 -60194000 -60194000 45575406 5000 585070000 -445526000 -680000 138869000 6730000 6730000 109000 1105006 2962000 2962000 5312 1638 6000 6000 180241 409000 409000 144000 144000 -43945000 -43945000 46864327 5000 595165000 -489471000 -536000 105163000 38268543 4000 437007000 -149554000 0 287457000 4666000 4666000 352506 851000 851000 -86000 -86000 -27373000 -27373000 38621049 4000 442524000 -176927000 -86000 265515000 5400000 5400000 229000 5750000 1000 98412000 98413000 322113 809000 809000 36000 36000 -36401000 -36401000 44693162 5000 547145000 -213328000 -50000 333772000 6521000 6521000 90909 309000 309000 25000 25000 -44705000 -44705000 44784071 5000 553975000 -258033000 -25000 295922000 -172856000 -108479000 314000 89000 22227000 16587000 556000 942000 -807000 -1454000 -2326000 -749000 -658000 4031000 -8431000 5481000 -578000 -566000 56000 15000 -156237000 -79697000 444000 519000 83022000 164170000 157761000 14000000 74295000 -150689000 0 98480000 4330000 0 262000 575000 253000 0 1263000 1968000 5078000 99873000 -76864000 -130513000 139720000 297208000 62856000 166695000 62440000 165679000 416000 1016000 62856000 166695000 0 4086000 0 68000 0 116000 Nature of the Business<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ("CNS") disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. The Company is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using its understanding of shared biological targets and circuits in the brain, to develop patient-guided therapies. The Company applies a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a broad CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For its lead clinical-stage program, the Company expects to announce topline results from the Phase 2b clinical trial in essential tremor in the first quarter of 2023 and expects to initiate a Phase 2 clinical trial for the treatment of Parkinson's disease in the first quarter of 2023. The Company expects the initiation of first-in-patient studies for its lead antisense oligonucleotide epilepsy program in the fourth quarter of 2022 and its lead small molecule epilepsy program in the first quarter of 2023, as well as the launch of an additional clinical epilepsy program this year. In addition, the Company has established a robust pipeline of preclinical stage programs through internal research and in-licensing, including one of the largest portfolios of targeted epilepsy programs in the industry.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through September 30, 2022, the Company raised $520.8 million in aggregate cash proceeds from these transactions, net of issuance costs. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses since its inception, including a net loss of $172.9 million for the nine months ended September 30, 2022. In addition, as of September 30, 2022, the Company had an accumulated deficit of $489.5 million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis of the Company’s ability to continue as a going concern for the third quarter of 2022 included consideration of the Company’s current cash needs, ongoing research and development plans which are limited to advancing product candidates through, but not beyond their current clinical trial phases, anticipated cost savings resulting from its operational cost reduction plans, including ongoing efforts to eliminate costs not related to the </span></div>Company’s strategic focus. Such estimates contain significant judgment as the Company’s ongoing efforts to eliminate costs not related to the Company’s strategic focus contains uncertainties as to whether the Company can attain such benefits. Based on the analysis, the Company concluded that its available cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund current prioritized operations and capital expenditure requirements into the first quarter of 2024, which is at least 12 months from the filing date of this Quarterly Report on Form 10-Q with the SEC. As a result, the Company concluded that it did not identify conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued. The Company’s current operating plan is based on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it expects, in which case the Company would evaluate further reductions in its expenses or obtaining additional financing sooner than it otherwise would, which additional financing may not be available or may only be available on terms that are not acceptable to the Company. 520800000 -172900000 -489500000 Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. Financial statement disclosures for the three and nine months ended September 30, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div>The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and ASUs of the FASB.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2022 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K, other than as noted below.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. Financial statement disclosures for the three and nine months ended September 30, 2022 and 2021 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ended December 31, 2022, any other interim periods, or any future year or period.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div> Recently Issued Accounting PronouncementsThe Company does not expect any recently issued accounting pronouncements to have a material impact on its financial statements Marketable Securities<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's investment portfolio as of September 30, 2022 and December 31, 2021 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,836 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,716 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,678 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one to two years</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had 9 securities with a total fair market value of $48.3 million in an unrealized loss position. As of December 31, 2021, the Company had 14 securities with a total fair market value of $95.8 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and nine months ended September 30, 2022 and 2021.</span></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's investment portfolio as of September 30, 2022 and December 31, 2021 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,836 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,716 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,678 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one to two years</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 44819000 0 498000 44321000 12996000 0 0 12996000 4021000 0 38000 3983000 61836000 0 536000 61300000 61836000 0 536000 61300000 52214000 0 31000 52183000 34993000 0 0 34993000 12111000 0 8000 12103000 6398000 1000 0 6399000 105716000 1000 39000 105678000 31667000 0 138000 31529000 31667000 0 138000 31529000 137383000 1000 177000 137207000 9 48300000 14 95800000 Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:<div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 58218000 0 0 58218000 0 44321000 0 44321000 0 12996000 0 12996000 3983000 0 0 3983000 62201000 57317000 0 119518000 131372000 0 0 131372000 0 83712000 0 83712000 0 34993000 0 34993000 12103000 0 0 12103000 0 6399000 0 6399000 143475000 125104000 0 268579000 Accrued Expenses<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12978000 17763000 2648000 7180000 2258000 1901000 17884000 26844000 Commitments and ContingenciesIn May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021. This lease qualifies as an operating lease. 0.02 Common Stock and Preferred Stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company did not hold any treasury shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">929,661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,243,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,230,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, $0.0001 par value.</span></div> 150000000 150000000 0.0001 0.0001 0 0 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">929,661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,243,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,230,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9159415 6468501 1364855 2667780 929661 654204 789419 440079 12243350 10230564 10000000 10000000 0.0001 0.0001 Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan”) as of September 30, 2022 and December 31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan”) as of September 30, 2022 and December 31, 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP”) as of September 30, 2022 and December 31, 2021 was 981,306 shares and 654,204 shares, respectively. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, total unrecognized compensation cost related to unvested restricted stock units was $14.6 million, which is expected to be recognized over a weighted-average period of 2.88 years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,932,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(976,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993,364 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.69 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,956,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock at September 30, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock on the date of exercise for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock on the exercise date.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Valuation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2022:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $53.0 million, which is expected to be recognized over a weighted-average period of 2.38 years. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,587 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7449480 5184455 5937763 5937763 981306 654204 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 440079 41.86 652328 15.00 92803 48.11 210185 22.76 789419 23.42 14600000 P2Y10M17D <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,932,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(976,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993,364 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.69 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,956,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6468501 16.92 3932802 9.29 265662 3.04 850000 976226 17.99 9159415 13.94 P8Y5M26D 327000 2993364 14.69 P7Y6M18D 71000 8956409 13.91 P8Y6M21D 318000 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2022:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.0276 0.0250 P6Y P6Y25D 0.8808 0.8922 0 0 2.16 6.70 53000000 P2Y4M17D <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,587 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1999000 2787000 8200000 7136000 4731000 3734000 14027000 9451000 6730000 6521000 22227000 16587000 Net Loss per Share<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,414,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,414,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,797,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,797,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,414,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,159,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,414,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,797,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,797,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9159415 6414070 9159415 6414070 789419 383196 789419 383196 48182 0 48182 0 9997016 6797266 9997016 6797266 Related Party TransactionsOn September 11, 2019, the Company entered into a Cooperation and License Agreement (the “License Agreement”) with RogCon Inc. (“RogCon”). Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon’s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Pursuant to the terms of the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the associated research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. One of the founders of RogCon became the Company’s General Counsel in June 2020. The Company continues to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. Expenses incurred during all periods presented were not material. As of September 30, 2022, the Company had accrued expenses of $0.3 million due to RogCon under the License Agreement. 300000 Restructuring <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Company began a strategic realignment to focus resources on its Movement Disorders and Epilepsy franchises, which resulted in a reduction of the Company’s workforce. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the condensed consolidated statement of operations during the nine months ended September 30, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, all of the $1.0 million costs were paid.</span></div> 1000000 600000 400000 1000000 Subsequent EventsThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. The Company has concluded that no subsequent events have occurred that require disclosure. EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 173 197 1 false 36 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://praxismedicines.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements Of Stockholders??? Equity (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements Of Stockholders??? Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements Of Stockholders??? Equity (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements Of Stockholders??? Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 0000009 - Disclosure - Nature of the Business Sheet http://praxismedicines.com/role/NatureoftheBusiness Nature of the Business Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Marketable Securities Sheet http://praxismedicines.com/role/MarketableSecurities Marketable Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://praxismedicines.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Accrued Expenses Sheet http://praxismedicines.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 0000014 - Disclosure - Commitments and Contingencies Sheet http://praxismedicines.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 0000015 - Disclosure - Common Stock and Preferred Stock Sheet http://praxismedicines.com/role/CommonStockandPreferredStock Common Stock and Preferred Stock Notes 15 false false R16.htm 0000016 - Disclosure - Stock-Based Compensation Sheet http://praxismedicines.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 0000017 - Disclosure - Net Loss per Share Sheet http://praxismedicines.com/role/NetLossperShare Net Loss per Share Notes 17 false false R18.htm 0000018 - Disclosure - Related Party Transactions Sheet http://praxismedicines.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 0000019 - Disclosure - Restructuring Sheet http://praxismedicines.com/role/Restructuring Restructuring Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://praxismedicines.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 0000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 0000022 - Disclosure - Marketable Securities (Tables) Sheet http://praxismedicines.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://praxismedicines.com/role/MarketableSecurities 22 false false R23.htm 0000023 - Disclosure - Fair Value Measurements (Tables) Sheet http://praxismedicines.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://praxismedicines.com/role/FairValueMeasurements 23 false false R24.htm 0000024 - Disclosure - Accrued Expenses (Tables) Sheet http://praxismedicines.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://praxismedicines.com/role/AccruedExpenses 24 false false R25.htm 0000025 - Disclosure - Common Stock and Preferred Stock (Tables) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockTables Common Stock and Preferred Stock (Tables) Tables http://praxismedicines.com/role/CommonStockandPreferredStock 25 false false R26.htm 0000026 - Disclosure - Stock-Based Compensation (Tables) Sheet http://praxismedicines.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://praxismedicines.com/role/StockBasedCompensation 26 false false R27.htm 0000027 - Disclosure - Net Loss per Share (Tables) Sheet http://praxismedicines.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://praxismedicines.com/role/NetLossperShare 27 false false R28.htm 0000028 - Disclosure - Nature of the Business - Additional Information (Details) Sheet http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails Nature of the Business - Additional Information (Details) Details 28 false false R29.htm 0000029 - Disclosure - Marketable Securities - Investment Profile (Details) Sheet http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails Marketable Securities - Investment Profile (Details) Details 29 false false R30.htm 0000030 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 30 false false R31.htm 0000031 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 31 false false R32.htm 0000032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 32 false false R33.htm 0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 33 false false R34.htm 0000034 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails Common Stock and Preferred Stock - Additional Information (Details) Details 34 false false R35.htm 0000035 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Sheet http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Details 35 false false R36.htm 0000036 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 36 false false R37.htm 0000037 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Details 37 false false R38.htm 0000038 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 38 false false R39.htm 0000039 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Details 39 false false R40.htm 0000040 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Details 40 false false R41.htm 0000041 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Sheet http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Details 41 false false R42.htm 0000042 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 42 false false R43.htm 0000043 - Disclosure - Restructuring (Details) Sheet http://praxismedicines.com/role/RestructuringDetails Restructuring (Details) Details http://praxismedicines.com/role/Restructuring 43 false false All Reports Book All Reports prax-20220930.htm exhibit31120220930.htm exhibit31220220930.htm exhibit32120220930.htm prax-20220930.xsd prax-20220930_cal.xml prax-20220930_def.xml prax-20220930_lab.xml prax-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "prax-20220930.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 173, "dts": { "calculationLink": { "local": [ "prax-20220930_cal.xml" ] }, "definitionLink": { "local": [ "prax-20220930_def.xml" ] }, "inline": { "local": [ "prax-20220930.htm" ] }, "labelLink": { "local": [ "prax-20220930_lab.xml" ] }, "presentationLink": { "local": [ "prax-20220930_pre.xml" ] }, "schema": { "local": [ "prax-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 312, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 12, "keyStandard": 185, "memberCustom": 11, "memberStandard": 19, "nsprefix": "prax", "nsuri": "http://praxismedicines.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://praxismedicines.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Marketable Securities", "role": "http://praxismedicines.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Fair Value Measurements", "role": "http://praxismedicines.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Accrued Expenses", "role": "http://praxismedicines.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Commitments and Contingencies", "role": "http://praxismedicines.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Common Stock and Preferred Stock", "role": "http://praxismedicines.com/role/CommonStockandPreferredStock", "shortName": "Common Stock and Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Stock-Based Compensation", "role": "http://praxismedicines.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Net Loss per Share", "role": "http://praxismedicines.com/role/NetLossperShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Related Party Transactions", "role": "http://praxismedicines.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Restructuring", "role": "http://praxismedicines.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Subsequent Events", "role": "http://praxismedicines.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Marketable Securities (Tables)", "role": "http://praxismedicines.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Fair Value Measurements (Tables)", "role": "http://praxismedicines.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Accrued Expenses (Tables)", "role": "http://praxismedicines.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Common Stock and Preferred Stock (Tables)", "role": "http://praxismedicines.com/role/CommonStockandPreferredStockTables", "shortName": "Common Stock and Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://praxismedicines.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Net Loss per Share (Tables)", "role": "http://praxismedicines.com/role/NetLossperShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i95c36c188b81434b80a91edbe61c29c4_D20150101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Nature of the Business - Additional Information (Details)", "role": "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails", "shortName": "Nature of the Business - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i95c36c188b81434b80a91edbe61c29c4_D20150101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Marketable Securities - Investment Profile (Details)", "role": "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails", "shortName": "Marketable Securities - Investment Profile (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Marketable Securities - Additional Information (Details)", "role": "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails", "shortName": "Marketable Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i0014af973fa14502bc865b82631f1026_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "role": "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i0014af973fa14502bc865b82631f1026_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "role": "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifc13d72f6aba4b2cbb3110a45a486f62_I20210531", "decimals": "2", "first": true, "lang": "en-US", "name": "prax:PercentageIncreaseInAnnualBaseRent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifc13d72f6aba4b2cbb3110a45a486f62_I20210531", "decimals": "2", "first": true, "lang": "en-US", "name": "prax:PercentageIncreaseInAnnualBaseRent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)", "role": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "shortName": "Common Stock and Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)", "role": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "shortName": "Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "id027e27be12d447b8cdca63dd3b37efb_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia9b9f62a504d4e2797a0308446f43727_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia9b9f62a504d4e2797a0308446f43727_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia0f9460311324dba98df0274e8e21d0c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia0f9460311324dba98df0274e8e21d0c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ic95cb6f1931744d4996167e6e3936721_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ic95cb6f1931744d4996167e6e3936721_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)", "role": "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)", "role": "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "shortName": "Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i804b4be0035a47c38169320e13290bb0_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i804b4be0035a47c38169320e13290bb0_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i88be90ec61de4e0d9dca9a40889efd85_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Restructuring (Details)", "role": "http://praxismedicines.com/role/RestructuringDetails", "shortName": "Restructuring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i88be90ec61de4e0d9dca9a40889efd85_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i036d0764f33a4106be6ec351a86b8746_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements Of Stockholders\u2019 Equity (Unaudited)", "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements Of Stockholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "i5c6f53ab6d4a40f38fd017b8b7116a0b_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ifcb69843cdda4f229f1e94c6560591b6_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements Of Stockholders\u2019 Equity (Unaudited) (Parenthetical)", "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements Of Stockholders\u2019 Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ib93f629ea76e4ebda11e7a0aaba06212_D20210401-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Nature of the Business", "role": "http://praxismedicines.com/role/NatureoftheBusiness", "shortName": "Nature of the Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prax-20220930.htm", "contextRef": "ia2f73d1665c648e4861f661ee85477a5_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://praxismedicines.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "prax_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued External Research And Development Expenses, Current.", "label": "Accrued External Research And Development Expenses Current", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "prax_AccruedPersonnelRelatedExpensesCurrent": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Personnel Related Expenses, Current.", "label": "Accrued Personnel Related Expenses Current", "terseLabel": "Accrued personnel-related expenses" } } }, "localname": "AccruedPersonnelRelatedExpensesCurrent", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "prax_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market Offering", "label": "At-the-market Offering [Member]", "terseLabel": "At-the-market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax", "terseLabel": "Available-for-sale, gross unrealized gain, current, before tax" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax", "terseLabel": "Available-for-sale, gross unrealized gain, noncurrent, before tax" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax", "negatedTerseLabel": "Available-for-sale, gross unrealized loss, current, before tax" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax", "negatedTerseLabel": "Available-for-sale, gross unrealized loss, noncurrent, before tax" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "prax_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on Public Offering", "label": "Follow-on Public Offering [Member]", "terseLabel": "Follow-on Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "prax_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities.", "label": "Increase (Decrease) in Operating Lease Liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "prax_June2022RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2022 Restructuring Plan", "label": "June 2022 Restructuring Plan [Member]", "terseLabel": "June 2022 Restructuring Plan" } } }, "localname": "June2022RestructuringPlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "prax_OfficeSpaceInBostonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Space in Boston Massachusetts", "label": "Office Space in Boston Massachusetts [Member]", "terseLabel": "Office Space in Boston Massachusetts" } } }, "localname": "OfficeSpaceInBostonMassachusettsMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prax_PercentageIncreaseInAnnualBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Increase In Annual Base Rent.", "label": "Percentage Increase In Annual Base Rent", "terseLabel": "Percentage increase in annual base rent" } } }, "localname": "PercentageIncreaseInAnnualBaseRent", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "prax_RogConIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RogCon Inc.", "label": "RogCon Inc. [Member]", "terseLabel": "RogCon Inc." } } }, "localname": "RogConIncMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Common Stock Reserved For Future Issuance Line items", "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]", "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Common Stock Reserved For Future Issuance Table", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]", "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Common Stock Reserved For Future Issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "terseLabel": "Summary of Common Stock Reserved For Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockTables" ], "xbrltype": "textBlockItemType" }, "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "prax_TwentySeventeenEmployeeStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Twenty Seventeen Employee Stock Incentive Plan [Member]", "terseLabel": "2017 Stock Incentive Plan" } } }, "localname": "TwentySeventeenEmployeeStockIncentivePlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prax_TwentyTwentyEmployeeStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Twenty Employee Stock Incentive Plan", "label": "Twenty Twenty Employee Stock Incentive Plan [Member]", "terseLabel": "Shares reserved for future awards under the 2020 Stock Option and Incentive Plan" } } }, "localname": "TwentyTwentyEmployeeStockIncentivePlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "prax_TwentyTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Employee Stock Purchase Plan [Member]", "terseLabel": "Shares reserved for future awards under the 2020 Employee Stock Purchase Plan" } } }, "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "prax_TwoThousandTwentyEmployeeStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Employee Stock Incentive Plan", "label": "Two Thousand Twenty Employee Stock Incentive Plan [Member]", "terseLabel": "2020 Employee Stock Incentive Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockIncentivePlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prax_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Employee Stock Purchase Plan", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "prax_UnauditedInterimCondensedConsolidatedFinancialInformationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited interim condensed consolidated financial information", "label": "Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block]", "terseLabel": "Unaudited Interim Condensed Consolidated Financial Information" } } }, "localname": "UnauditedInterimCondensedConsolidatedFinancialInformationPolicyTextBlock", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "prax_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock Units", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock Units" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://praxismedicines.com/20220930", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r57" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r13", "r28", "r29", "r30", "r379", "r394", "r395" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r27", "r30", "r36", "r37", "r38", "r70", "r71", "r72", "r275", "r303", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r70", "r71", "r72", "r260", "r261", "r262", "r280" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r218", "r264", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r8", "r65", "r107", "r109", "r113", "r132", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r273", "r276", "r291", "r312", "r314", "r364", "r377" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r17", "r65", "r132", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r273", "r276", "r291", "r312", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r283" ], "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r121" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Total available-for-sale securities, gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r122" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTotalLabel": "Total available-for-sale, gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r119", "r139" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Total available-for-sale securities, cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r116", "r120", "r139", "r366" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Marketable securities", "totalLabel": "Total available-for-sale securities, estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r118", "r139" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Estimated fair value, available-for-sale, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r6", "r118", "r139" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Estimated fair value, available-for-sale, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r59", "r60", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r5", "r58" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r53", "r58", "r62" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r53", "r292" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r368", "r383" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r161", "r162", "r163", "r169", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r70", "r71", "r280" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized; 46,864,327 shares issued and outstanding as of September\u00a030, 2022, and 45,300,514 shares issued and outstanding as of December\u00a031, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r32", "r34", "r35", "r41", "r371", "r386" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r208", "r216", "r396" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r59", "r60", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Offering costs included in accrued expenses" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r119", "r139" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "totalLabel": "Available-for-sale, cost, current" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "auth_ref": [ "r119", "r139" ], "calculation": { "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "totalLabel": "Available-for-Sale, cost, noncurrent" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Investment Portfolio" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r126", "r141", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Securities, unrealized loss position, fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r127", "r142" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r56", "r147" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r220", "r221", "r254", "r255", "r257", "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r67", "r176", "r178", "r179", "r183", "r184", "r185", "r307", "r367", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r42", "r75", "r76", "r77", "r78", "r79", "r83", "r85", "r87", "r88", "r89", "r93", "r94", "r281", "r282", "r372", "r387" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r42", "r75", "r76", "r77", "r78", "r79", "r85", "r87", "r88", "r89", "r93", "r94", "r281", "r282", "r372", "r387" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r90", "r91", "r92", "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost related to unvested restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to unvested stock based awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Potential shares issuable under the 2020 ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Shares reserved for exercise of outstanding stock options", "verboseLabel": "Outstanding stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r36", "r37", "r38", "r70", "r71", "r72", "r74", "r80", "r82", "r96", "r133", "r204", "r205", "r260", "r261", "r262", "r269", "r270", "r280", "r293", "r294", "r295", "r296", "r297", "r298", "r303", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r283", "r284", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured At Fair Value On A Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r283", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r186", "r188", "r189", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r284", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r283", "r284", "r285", "r286", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r186", "r208", "r209", "r214", "r216", "r284", "r320" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r186", "r188", "r189", "r208", "r209", "r214", "r216", "r284", "r321" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r186", "r188", "r189", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r284", "r322" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r186", "r188", "r189", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r123", "r124", "r129", "r130", "r131", "r134", "r135", "r136", "r137", "r138", "r143", "r144", "r145", "r146", "r187", "r202", "r278", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r39", "r107", "r108", "r111", "r112", "r114", "r361", "r369", "r373", "r388" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r149", "r153" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r66", "r81", "r82", "r106", "r268", "r271", "r272", "r389" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r55" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r283" ], "calculation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r128", "r362", "r375", "r397", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r65", "r110", "r132", "r173", "r174", "r175", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r274", "r276", "r277", "r291", "r312", "r313" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r65", "r132", "r291", "r314", "r365", "r381" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r4", "r22", "r65", "r132", "r173", "r174", "r175", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r274", "r276", "r277", "r291", "r312", "r313", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r97", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of the Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r54", "r57" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r31", "r33", "r38", "r40", "r57", "r65", "r73", "r75", "r76", "r77", "r78", "r81", "r82", "r86", "r107", "r108", "r111", "r112", "r114", "r132", "r173", "r174", "r175", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r282", "r291", "r370", "r385" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r107", "r108", "r111", "r112", "r114" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r300" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r300" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r299" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r56" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r7" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r26", "r28" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized losses on marketable securities, net of tax", "verboseLabel": "Change in unrealized loss on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r125", "r140", "r208", "r288" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other debt securities" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "verboseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r52" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of issuance costs for at-the-market offerings and initial public offering", "terseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r51" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments of tax withholdings related to vesting of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r47", "r48", "r117" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r190" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r190" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September\u00a030, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r50" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceed from stock offerings" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r50", "r259" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "verboseLabel": "Proceeds from exercise of options and employee stock purchase plan contributions" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from issuance or sale of equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r148", "r314", "r376", "r382" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r215", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r215", "r306", "r309", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r304", "r305", "r307", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r267", "r347", "r408" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r5", "r62", "r363", "r378" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock units", "verboseLabel": "Shares reserved for vesting of restricted stock units" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r150", "r152", "r155", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r151", "r154", "r156", "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Remaining restructuring costs" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r205", "r314", "r380", "r393", "r395" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r70", "r71", "r72", "r74", "r80", "r82", "r133", "r260", "r261", "r262", "r269", "r270", "r280", "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r301", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r252", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r151", "r152", "r153", "r154", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r217", "r219", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r225", "r240", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeitures (in dollars per shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested ending balance (in dollars per share)", "periodStartLabel": "Unvested beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant\u00a0Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise\u00a0Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails", "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63", "r69" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r25", "r36", "r37", "r38", "r70", "r71", "r72", "r74", "r80", "r82", "r96", "r133", "r204", "r205", "r260", "r261", "r262", "r269", "r270", "r280", "r293", "r294", "r295", "r296", "r297", "r298", "r303", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r70", "r71", "r72", "r96", "r348" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Share-based payment arrangement" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r10", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock from at-the-market public offerings, net of issuance and offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r204", "r205", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r10", "r204", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r204", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock from at-the-market public offerings, net of issuance and offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r25", "r204", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r14", "r15", "r65", "r115", "r132", "r291", "r314" ], "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r205", "r207", "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock and Preferred Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental disclosures of non-cash activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r123", "r124", "r129", "r130", "r131", "r187", "r202", "r278", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r68", "r208", "r374" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Debt securities issued by U.S. government agencies" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r98", "r99", "r100", "r101", "r102", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r89" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r83", "r89" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r409": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r410": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r411": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r412": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r413": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r418": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r419": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r420": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r421": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r422": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" } }, "version": "2.1" } ZIP 60 0001689548-22-000125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001689548-22-000125-xbrl.zip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

    __[^0U*6 M*W;U-R>+U.SJWP&:'_>P(%@I>/Q4Z\O7I1 M^UU8802(?#QVW8YO]5."R_;V2R.*''#K#(=C6/<(LS!LB@7/V"J'%4E:::)( MX"EB:PU.D6'&DV6 8K>*M&W6,[^=7O:/COJ]TNCTHF5*G1\QH-,XZ#=&Z49& M:;[BCE281V\2PEBIW)+/(Q,T1=(8:C'G2DJU HQ44T+_6**3-WE3RC%<).=XNO'_I).Q M25F'HP*H!E9AP+\A^6;]]N"2E'E5 WSR>R M!EQ%0M :?;H1/\X5^F-(J^J@0 M2SXB3BS@$XV 3TE[;XV.ALJ5=2J;-.6GI*-WEJ;JW)@D_\+$!_#KH^/S&,"M&4"JOGJ/0!"F#EF$(XN(1ZL1EK'B&0(SAMPO:<-;;)&HR1]]H@CKU")CCP$EB47M$0 MK,)-%./!-D[BCSCPG6',C*-_G.>\BEC$H^-N_R3&FGLT6\==&&96X4'' MC=;/F9Q.;CEZA%#^%AWG&>[N%G; MU5HW&S&+P[[=^0R0*"@)G"/PLA3B\ =R##M$HW'*$NZ(5ROK9)7*>5+3Y'\\ M;ARXTT-5#0XL-P[,I2>G@)FD*&GB$'>2(,-91%[(9 ,ST93"I*M&SG=+>?2I M(X_M_-5E6C-9I.:$Q5U V'R!.^:PIR0'DIVCB -B(4=40B99 MJG7RS@F7F\[A2QH^_9X3MQR'KA88OGE60+!P^M, P0,!P6Q6BF3>Q7R./"B- M>&* =Y91"VSCEG*C"!$\VT#-III9;1V26LUIQG5Q_]QNH M0-Z-RI&><_M,^?WG?#_,= M]6JO[_4/?V![^_&#'<77*47?%/Y:(%[.U_.+3&HP>0$E8$J(4Z*0-2P@%KQ7 M$KB3SGBIY*J6MRD.W)Q4?PJ0<20,DO!*,,^;Y(;9PWB-F8*AL$A M4RG:0&/$)M?S87A5D-OLEC>GW6^C]R^O3;E66R[N=WJ].O'GN&C;B.\DXD81A3G@1LCB5111F:85)1\V,$3,E%:5$0 0-1DIYBG6'-K"K:'%QZ:@J.77*P^!833SG%R6!,8W)< M6$J99I6"XT;!'Y."S_(68QD5T2'B>$2<18^T(!(QIYPGF%L30<&I4:N@Z4ND MX$\V0G03BA+AQ2O)R1UZ< M6$?W1Q'#:A#O62*>EB8P("[8.(\)\698*DD> M6Y$(8CAY<$,U1E83@U3@,G(.YD[;W*E#KLI'4F#V"838+B\H^2&"+!M%;?3X?O5XAHK*D'B.C2+F"4><"H^<(11139BV5F$5 M2*:B8E6J^;+FC_[DP/)QB0\+R)5[NELXBV(0%QW?!D5NA"+SY2 %%2)03I&P M MB 51YIB<&K=13 A/F\![.RSLFMXW?-GNJ2*>2BJ,"L0C8V?X':.GM6T$;/ MF Q(6TU!6X-'1M*(?.2):R:P"+E1["I>*GU]^KW:=OHCV[U%'GVS8? L-PR: M+=(GAMCS=3"-5!IS$Y -2B(NA$7:A%SF)K"0DC88BV:+M$&\9X)XS1;ITT.\ M&8[*K2"*2)'K_>:JHA(0SR6#># X&@5$U8EFBW0IMD@_CH^/NS&7Q /V&CI# MW^T/QT!5\V8I+ HJ5'9![?>:7=''LRNZ?1P'MI2:[98SPD5'4#^A,?QAA\.8 M:]6ZD84OYO+UK5B?\2JE[OLS7^YVK.MT+ZV4T^5# M'L=V^C2,&UG0MFLQV^Q-#A*^Z0^F\OF?+&'_J07LI"G3N1"3/E^J+H0@M+,4 M6>4#XLQ(Y**BB&EE/?BK'.<@\9-M5MC U*.'J857G%D83#7NQRVQ:L;]L,DZ M&TA$A/*$N$T$61L9\EY@ZA3Q-KL??!7K1<5;&A?C9U2R[F94]T+JE+( %6NT MW@_&\&O\D6M0WH =7I^N/QE$ON$C/VZP7CBG?!7=Z$+KF,V>'P\&,;P:9]EL M]WO9T]T>O+.#W(FK_GMG $];C;9AE@M!Z_G*@N#LA ;]GBGZ+9RJ+@#]&I2[& _ M>XZ,)@&1%#6V+BC NI7UV]=WOA^ >[)ASW=U'XL2_SX>Y$#FZ*1J>/'?<>>X MM/=<"(&]N&M1/>C<4CTG@%_HA#QN^%\X^7UICSLCVWV=A31T1GE_9V( _AR/ MVOW1;AR]LYW0<-R%H/]\D4<2G.8Z*>0]SQNB"= ?2X4T9Y%+%QA?8).C16K2 MDH==&_ALX//NV?/UX;.!R9O!Y Q)9L:K*+!#%CN6^R$I9#WE($8^).*\+R<1 MR.TSFYG ?2P?;@SB,62E# M)L79%/1*/D[I8EOW3X&/#T?P0NG&N#9=N=EYJ(?!Z9H2,-3C_K"3%_Q%Z8G; M^1;_^-X)HX,)2)S[8KVH^.PKUL$@QJ.KO_*PO_=@/XZB6C?8"YG,MJ*G/Y[L/&_[?YL?7NP^N7FQ\WM]NM MK=>O-E]NME]_7&UMME]>+6[GU$[>H]9=_A3M[9W7'UL[VZV7VX#@[8^O7^7? M/F[_9_/5Q@[\\6:SO=%^N;GQG];''7AAZW5[Y^/C>+)_?.K9,9C2&/XY/^#K M23K'*[^&S7M]*++6JEE*>WP$E_ +\.IF>IS83#ZV4[VK7/JR/231P%L3H@&? MWW[;/MK^_/=7( V=+2 .NSL!B 80C)TWW;V=#;J[\P:(@S\!TM"-__OA9.]S M.,X9P%L[&WR7[HJ]SQ^ -&R>MM\"4:&;>.O5!I"5OX%H[!UL?=[E[=._$HP; M;^U_$23S :81PR*7X'$666L\PD0*DIC#TKF*%'9ZXQ@VLD-KF8\J"1D59CP: MXC03)":?. LX4K/2BL#>CC-T#<81E*_,=6W-6G^.A[#>P^&$>-0K/(."\%Y] MTZK@3%F;7]_XXD"9!Z9JX2$<\9QHZJ@1A :"M;5,^[3R2[7N9+L[>D%Y0?%[ M-6+O!O9'9]AZ-P Z/I ^#M^;76/[*32_$?U0?+'^2/5G]09KE^ M[V7%,^HW_]F""]J6AYL5+@6L83^V7*=_?& '1];'<>%8K9J=M$8Y:MVMT@_W M8R_"N\!0AGF0>?-YU"^W"O%;[/:K@%ZUQ@-@^G57.X7AP/^CWX:OSAP6?(4@#+ M<=!QG4H@CISMYB#\6JN=(RW=EAO83J^5QKW*K1GD,&-.O[4PPBX\UP@>M?I* M'N;954M,\OR5>V?W]IV!'W=&,.7?#SK^(/\3>ZUP,AS$_7%I>YV/J/5RY;V7(JS_YW@@4(-9'["8/GFXD!Z(BTC"PZC,P@W#AZC99:S*]G?FV[64G%>81QE7W8>Y&/QJ +IP, MRYR.O>Q>9(X.[@[H89YUF(*#_!Z,NI]R1F^ND16/C!)2_?^Y1 MC\;=4>>XFR6@#^["$5S7#_K#(3S.M^(&G%.L\FB5))V _'9@R*D_'LRB %PI MC'UNT@@2DMT+&/D;4. L T6ZYS^?[WSQ.7+LWH^*N-I>#]Q$T#7 TPQN^= F MC+H6\?RE=Z7+-773*\,*95\FIT /A[F_:GDI'N515%*8.B#"K?^.P3F*@RP1 M8-Y9]81G=X:+P5>SF$UN,7N'5(,D7-R.)KCU#A8;]+#?^[_#B<+^]+87Y7QZ M_X,X&4!=)ZU\&9 +U1(!U@,6L8;'Z>Q:>-QA=O%:L-3[_=[8=V-_!)HU7;O) MC$\'!8L(:WEQ5+0"L\E5AR#B6<9!LL?=GUSJLN=;;8%0?H_P?5L]5M?">A[D MMT$)LM=>:])TF?*2;42_?;Z)G9<.JPL(8 MYAYJBHA #6"8@Y-K>4!G@8>'9Q3?;4'-_@">N(01X(& +(L*]_M'H! >7NU/ MF7'] 7E1XO/"I6Q5*GD[]_'C 4#K $9=HI8PCRO %E/,84&8FK[_6L8V_?X0C%XI00B#[??J3TP$H411.@4\CL<@51X^ M667-@42#UG2[_>\(OC7S9KF#'2&X/BJX/YJ^51O/\I@@H]T\Z/T.K'VEX]/8 M"P!F'F&GV(#\SF1('^'O> 3&KXJM,;Q:=/6B(H"!S0&>_[E!>-8(SZ0G6CM- M..-.8VM(#"Y*XJGQ//M!1%R]NR6NU?AZ\!&F>SOE(W_73;>5S\R9VCI\S;T< MY4@*7'%U!SL?,M?Z7V&OJ# MDXH( GNO>, \^UJ]X%>!/Y3O##>&+UN'S3B5JMGK539*D\^SZ0RT&OC*=^D +W M^9GS--<)^7DYAL WLJ-RCB14&S_YS6PTSIF+-7!Q:\M:-H)Z(S <%>">GX'O MH!D3GZYT7NL "P?6=/XF%TS_^2\#90?K/CR_Y.=7[^*J 1F8V(-+UBM/7B?S MQWYE*P%%QKO?X&;FLGG3G_3BL:A]8Z_1DCR/QU82UBODQN%A1\03C=+2A4X@6<*G)?G MS73/: />'?>*L'S,<0$[ .OR9Q_^F8:6WFQ\_',:.[KT\Y^.,UI-O[#Q\=/T M\\ ].")B=6J![F?Y+I^-5]/SV%GS/ETP(];U ?]A;*_A[]&98FR< =K+.JZ8 M?2';>MO/D_ R._N#7NL?'\<.%AVX),4"GS[=)2X50-6X,EL',<=F M2H F%H7.NXF=,^S.JIFQ,6\M@L,YJ#R"@N@3"I*O;T<511"L/..[FC M>@(OPY9S-L%?F,+]?G6,I9K"+)UPS^R597>Q5?;6JN!BEJYR\QOOA)9GS6PH MAL?CH\UZ6)TZ.R*3"/BE' 3O#W-6Y3#[&:TJ1%<['.?MFRU\,'\V"_Q-O(K; MYLR)*SNCMN-H$QS/H_@?&-;S=19.]UE[XTM@"O#92Y0<(8@';9"%.0< $2XI MK7RD:F6=*+HV7V^V-?$3)I&L7@Z4 !<>'0QS^RB0EZG/V9JXFS-!&%L$XUJN MZ4$)4&5S,CZJHMZPWCD(.KJI;/UFC:ZK1>I#K(Z*OK:#W-1SN'$VQE?5$!N/ M]7(A_$I "%4P!NL FNPBB%Y,N6"I3(@DI8C#$K-D5]:Y-FM7%9>I)?&*:.@Y MV(??\\9&V0 X5]6B K.)',._@/*QA(/2.'/=QP7=%LC\R; SG 07?],>3@/4 M!QU@8[,AWFG6_,1B3V/-E]VR=JJJ*$(OAQ!6P=!6][O283KNPD14>U[%C)XY MQH @W[*I+2[4K-,ZB7BM3CUJ%T_ZE7_8&9P-Y6(X_K@<$U@M,7#?.2[XDH,7 MX"!\*^&W:NL@W[+X#Q?"C66[#O=733IR:'"_(#]0KP95R MDC8/M>1!5<^8YW$F*V=F0_J99E:IJS.K'C9)ZGZR52Z?E,N3%7Z=?#"KJ26B M'/?!D4A]/P:O_>,8U"^'(XZ*_7#D<-GQ?I1T;%"O"* M(Y#5WWZSG6ZU:7!UF=@JC%\^50)2GM'Q]4#E\<\LF4K\%LA-" HWP?]LK-4!T'/IG+<#:U<+\;1RQ8E?#R(Y*%HVM7LEW)UO M-CE EQ>HJBM6_,&S8&,]6?#BS"CZ^8K?\S*6FTW$\=*OYGFH#/PY980[YM?[ M/9##BV^ ?L?!43V'F5'D[X)# 6I8/G 1>-;F[>TE^QC7S&YDO\INO(/@XD]# MB?3.LQL_GEF(LZC=NWXW(]IP!^[T9[?OOSZTRW,R<7FRB_+^Q];;S1_M5]VO M[5_O5Z^^[AZ\Q7#_?#\;< M[;2/P!$Z^L2WP>79WH$Q[W3!Y7G-VOM?. '/VTN%B'4&7!ZBD+4R(I5P@IGPP'LD9:%++E5V M+'M5>N5CV2^9.YASDU#S@05"X&+LY7W%8UO'T.%[.?:4.4ZU@5KB'UTPCI7E MR^E.9Y O!*N>]P]V[C^U"M.]\=1H?\PKQM%0>UTN^7MQL:[R7X+\+J<19+3 M9LJN;W6-8:P/&&7//>=B^F)N<])FV1>"]3J*MF*YY;L32VS'HX-,CG=%LI,:>/CIVF().\Q/:X@SX7MW'/K M5T-Z9GUECBI1.!^$&QED8:!"K3=^?Q'EG')EZHP<4+=&*?C@?WQ8GIV9C-'4CI'+R>+\_+<1$QW3#=[5209UK.Q M7=L;7Y3 PC!&$14.(YX(08Y8C:SD',>HL,7ZFK9K"3;XI[+0JH6A-96&UGEQ M.+>#?DX@GIJ5FYR4&![$.+K.7M$5USD''7"%<^&26V$;?#K#S0WNG)]X$ _J MC)FR+7K?(\@AJ@1P-[S.KMT5]YO&&:YURY(8>]#OYG, =="C!,F CRSBX8N- M&4_4I@JQ3/^L$K)!BZ[+E^H0X!#0.8=?.L-)2'-R05O9EE_:J-4Z8ZI\N7_< MZ=7V]\CV['ZLT]=2/NS1RMGQ-AR.AZ/ZFW7\K3)R51RC/M!SMO]^[@NM7LRI M4=G5F^Y@V<[@;#!7;T<3IY- MQ_FV" L3P3-=*-M8_2IB6:]A7N+S=ZW#L:'T'X9"3 ,>G8__0L[3D;"BI^9+_&<_N3Y03-['Z)3:ED\1<(REYAANES.=!5_Y/\U7.M M32IS%R[D;%9!S?UJK_.R+[6J),%S^V(W3!>LJ=5EPYSNJ812Y?/VYPMTLW1K6^=^+V:N&X6^R(8I4- );SYU/)1WH#T^8F2]?4- M\R,,.K%<_^79Y^.%6^7G&IR+;52W/MN2@]?RME9.8&Q][?6_]]9:&WXTKO;U MBMFK=OU")Q\<:^4+9XV&<==;ECGZ,KWE+RS6TD+C71?FB-_/;10,^M4IXB+Y MS;9!L;9\:^.+Y\'#_P*2*@G$D]1(1^N12$8[AYD56L[N \$Z2&:4DL193A77 M*6H9">?..\7IW";6A^BKPSB;90O]PN[5A77Y^1Y6DSE5U$8_@LRI96 PE^]Y M7F\/<_Y[OY3Y"PGWH1^K=*C*<2G>QF"B!54BR<4-F_-:D E1"6O8*?*W.G!= M7^+@V:^^S)I?HAYSKUSB:%XS]4$N6^H#N_/4A\W>MUA'9S9[N5C[1B]L31/! MJD/,'Z?98/#FRRJ!;6=@<[)HZ3\T/#LMM"QVIMV9V)GN 5SS9.L([,S.+MSS M/=]^V^ZT/V_B-OW$]G;^^MH^_*O3/OWK<-;.;'\&^_)J\P3L#&D?[L,8]_DN MW22[A^_A>Z&[=?2>PG79UE$[;>_LTR^2.2HH2XA0DC>G14(&E DESV+R$330 MSM5<(DQPZDETQDH.#J#V'FM+X*-2,,?8K)4Y6YO6V;+\1E;$+^][U\0ER]HY MP9JD/KWIE_/S._GW9RQ,Y N#>815P8A%K("R6(9L) EY%XF00H7@XO4S'1[< M3NV4TPK9:RD5EH:E3M$TZ^?BUFAGBDGGJOG\/ \U.RV7ALA(ZQ_%/>F/8?1A M^,\7T\2X.M-UPH]*Q568@ZX]'L87DU_^ *?ZN&M/7G1ZY9G*E_ZHY[8F59E0 MS-1;+;-=O7W&-=9PQ3?J[@7UG>NWU\I;,^5CJ_<$6]/JZK?Q&KGRO9]=EM U M;N1O7?;G[S'-%SY8N6;X[TU!,]9?"(' ]%J7_47GC5_V0*9D[K.75#^O7(V' M[TZ]<1%NIJ<"+Q1ZONV4G*M/_\L>XG=[$7.#BRSQJKTM5=T^]>HZ"N$Z/-(F <1P1[+]"*8@=Z:ZAJP\K8=^FX\D7?G4\C$]RG_*L=AGMX)O9<>&*Y21PS M3TR4E&)Q17&12UM\7AW)VSC*N_ZG.4=\.'I9G2!]%$WH?S?L5_DVV3K]^ MW]O9I7EO](^]:)]N$7VWFZ=[A[M'>T='AQN?WY].MO+:&OGT^GVSI_= M]N$NWOZ\^1W&Q&!,=.LTUSAI=^";1]MOM\3N3CNU7U9]C+8^XGQ]LO7^"^/& MRL 9HI3EKL8"(Y>W/D/0$M8R[W7F'O1\59/Y2CF_U_/S$74N;G#IR>-2.:KR M"U Z*WM40@9G$8/L%-4H]6?,Y75V[(]E;T[Y6)#J= :IL)91^UBVRCCBDF.D M>60H6BDLB](RDA;=?[V!J@:J?O% _W@L6)6C'O-8U6#233")S&!2TIIRZSB* MA (P!:N0PY8 )J5$J108"P?LRP)N;A9\S8+H(4XTK MMW@P8C-@)#05EG"*O+&YYJE*2/M$$).)4ZE4B#E1!UPY1LD2\:/?C3\_@NC8 MI()]Z]@>Q\&5<65ZLX>]%%(?'P0!\!@9O+8 /UP09YAUQ*DD=!0A\B:@]!A0 MZ.-<0(GD0DF2.^0Y !"/P2)-DD!,.Z6IY=)JH$2$KAJSJ/;8]TF-KKN+T.CT M[^AT$XQ94BV?#<9HXC3U(J* 4\Q<@R"-C42!*F,B5RPO\:*",8V:-VK^JSA& MH^:+4//9^$;TAE!84\0I^!4\R8 <,0(I&Z1TQCJ-?:/FC9HW08)EU>C9((&T MA'E%,4K,6L1S8PJ3[7CB,49,0V16+B$]?[(I-*\N)LY,#D*ZD]:GM8]KY[L" MVOW8\Y?DUEP+I*X;F7U\(*6$LPQH)P\D@ P;PUT.RF-M'0]2^R:,\ APJC,7 M1G!12<<8H!/C'AP,PY'A\!NL+XTI8!Q*!C-A(D;/:($K!MXC,2!/$$T[I>(IJ?I-TB ?5\R8=XO;Z M/!LNH($'FR+8:Z?A!],..6X3(C8*PJ-C"I.5=?:TLB&>HA8_ /]N@@0/I\>S M00*G4J)),Z14KCV.J4)6!XY4),1I2RQ5$?1XU6BV1%;YR282[/1'I8CN-$A0 M:D>62DCYE5(38]K JS]H=>/P^B=P;G2:[TED<]WLB1\W.O]F2^ F.K), 'TR M%QT1*5BK,T [RG-C(Y];' 44 *NUED*J',659%6S145QKWW<]R$W;!J4:U#N M-U"N"1@M*>[-!HRHC\1A[U"BPB%NJ$4F)9#YX"0CSF OPJ+WHQO@:X!O:4-H M#XI\30CM]@@W&T+SP@9MK43,:Y[WYR5R0EL4DT^65)ROKXA):=_T86@-L M#; ]<4;71!4?'MKF4H^X#2JG$&J:C(2*7$9$9G^M\ +TT>F^8R**8R/;\&44X\!-QER3!# 3261Q8ZAF*),."7B*5MLJ+^!RP8N'SM<+@%:7K6)T/CL"T3+ MV=T#+ $;F34H]RE%G%B!C(L<>>5P\A@\]23O9O?@05"SA&W_51K(K5^OK>SY M9B-Y_Z%I6-WS(O6]*MK^M4U_>J:?G7/ M9 6;?G5-O[IFA$V_NJ9?7=/AX.;!OT@(L2(%(IWFW@>7/".,Q$BQHR2H$OPC MA#+2G'R]<1CP:.^P_>I#=^_S)MG;V3O8@GOL'NV*K;>O3]L[G^#>&S"^/SN[ MAY_FPH![1S#NMW]W=P__[K:/7O]HOSKH[!U^_;Z[LT7:.QYOO>I^W7H+][N\ M7YW4*EA80R2HROWJ@D3.4X)DT)X(XZC!865=T%5*^!+5)F@ZKS2XM!A<:LZJ M+BE2S:;%6)^L5)HAS/(9?<(4LLJDW&C364Z5-(D_X>)F#50M)U3=)-WD0;'J MZ9XNO3],FBO0)C5W-@%=LM;G'IH6::PP(E1S%;EDHA1VFB^I^I@+M#5(M)Q( M] #.7',<].&P:#:AP] 0 Y @Y+V3B!NAD([*@R>G&!=&6AUE\>1(4V7N?H)C M3;NZGT"0%4P+(T3@C'.6B#-&NT"PM"I)+UD33WH$*#1_%(S'@*,'%.( $,"( MB$76.(&(HUQZ)KCU'A@17S7FUBC4-+AY8CK=Q&*65,MG8S&>!,XU9TAJ#WZ/ M 9IAA:'(I, 5RV$9L[A83*/FC9H_YW9U]Z?FL^$-8PCF(EG$E-6(4TJ0,Z#P M>5/(*RX#%:Y1\T;-FR#!LFKTW*D/2Z01!(/-SC](DLB2J)$D@A+%(F=>+B$] M?[(9-$V[NEN"E,=!6!$LY3QR$Z1AA'M+C-0Z$NE3$T9X!#@UWZ[.)(HEL1:$ M2DK J6B14<8BQVRTC$:FM2UM-0EI^M4U.MV$$1Z%EL^&$0SQ"FM"$=>8 "71 M"KF0^]6Y8+073@@;GW!*QU-4\YND0SRHGC?I$+?7Y]EX07!*<\D,*N6+N-0$ M&2)L"$%R2KRC9M,@GM0Q^W101S\ZHC-,P]61BX,%2'X1!28(&5D$ [S2# - MG,CF>,IC@*+YQFQ<10VRD)"A,B!NC4;:!XPTC848+4# MIY]R%!QW6:,9,AX4W&3V32BLL:45_S9+I,]/-EW@3CO77[L?TE,[V/4LBO>" MUH+Y3<0P0&<>N#$2,#G*R R3BI(F0++\ +T]7[^#B!1<"#E P@7BAE/DO",M=!,$A24,H@3K\&X4HX$C3(P MK@S+A_$96952+5%6;I-FOPQZ?>NPYIF6-UDT"]?TDXN:[A(A,EB.?(H)<0:\ MV2BL@4:'P*T@/'+2'(M[5*K^J*H$7ZKKC4[?2*?;,]:;PE(&&SVR7%+$N0A( M8T&0BTQZJQWV(8)#S)K#<AXG>DS#,&VMAD G<8*4G +&,FD?:* M(&ZI-M(S9W)T"ZBXH+=.BVL.R"TN+6[4;XV^]TMVW/73XF[4[NY);#[<[(D? M-T0_0%I<@])W@=*OYP(F"I.8''9(N'QVD#J.K%41Q:BIHPHG8L.B B8W[8GY MD,<4&J1KD.XA,N.:$-(=8M]L" D'RE3"*% .V,>T0UH9B3SA5GE#&6=IT2>Q M&O!KP&]I@VH/GCO7!-5NCW*S0;48I- B,914B(AS3Y!C)(%;3C&LM-:6L=L& MU1IP:\#MB3.[)LRX)/ V0^*$$MJ[I! 6C*-\I!H9%312%E/'? PD'Z=?3)CQ M7F#NR:8G50%(.]$?!%J!AB#[/TE4NF8V8_4L+QC,>.B/X=K5:CPC)%_D?#0X M?QG.S]#:\['*/^VP,VQ0?G$HOSD7IM2,.4' -P\\24!YHY$%0$\S;'I;R,R1TP8R?Q"I F.LA0 4C-DJOGM\-\]<-S@98.7CQTOEP NKXK$-I[Y0N'R M9#:!"%;/2XH8 _><6QR02=DS=UAR@BW&SE2>.<6+.G+UD+A9PK/_&F6Y@W]# MY]OZY*':XR-0';_^;WAQ\@A'=K#?Z96QR E^=7HA]D8O*%]3U<'H!2@IP;_2 M4IJU=&.8LSP_QN-1/')Q4,T^PZLMT#BZVAH=Q-;+_A$,YZ1U8$/K2J6N([8G M,YH=,%61*A<)#9PKIWWP5K(0F&,J)EM;[8[CEF4_N<&N/][TH'$(H3C>C9 /C=! M.=R@7XCA#J:=(N5S?1W,"#*$9[\)8=#ON^ MD^,LE2!F>((5RVPJWVLJ@YW1\&)7ZA:PJER 8W "5PZMXP$L\@"H6VL02]BF M'*V!B_D#V]LOUZK%N@/2.HC#42L7[X"+=GH^MH[' _C@,*Z6BUT<>&>4;W?4 M'\16M_,UPBW@Y5ZKUQ]-W_\.LP/?:F41S3<^Z'=#&?),;9#\WN0(4)FK08DD M741EVP-"W#DNH[.M-(9+#Z+/?;?+L:'\43O9$07E@R=Q>4]T,DNSMX013D\= MY8>#H=MNM__=YN?^;H?E0?(-]GOYBFM3_Z#0[Y<_*5I_NG*1:M +_ 7?+]1P>#&,L*]+)P'\'S'0SSJ.!:4R>A-?$/R@W[[\^L"78_CBQ!)YO?]X\V=O9^K%U MM 77?@_(O2EVCSZ1[5=?3^$^)^W3]N'6YZW364O0/MT7NX=_=0'E3W9/WWQM MO_)@%;J=/7!+MG?:7[=.P0K0K1^[IR6CBVY]_\((3["8"DF6#WY+G9#CP2*I MB)+>,BPXKZPZ"%D,&]F>&L*4=V#)L;;<4JD9EAZ6PD82!7-@4R.8UV.8^-%@ M'%?6\[2WRKRWMJ+-LYYU9SCGO5\#:Y;!E?_WC-955O>F-AA.L/#I;LU8 MM+N(CQY>V>\/8/Z&+1@A&)).SC7+MQU.OAKRI=+9XX")@M?@[O;\JP>="!;< M'U3&$( [&Z8,F)=])D_)>%@]J^_"[3KI9/[^TQOU'2SVMV*1.[WC<7XX@-1Q M;_[UR46K^^7GG[WJBTMP]RK1K06'TR*F?TRHT8MB-V"M_OC>":.#223WW!?K M"!L^^XIUPWYW/+KZ*^>B:3YF7G.O6F%F3-.YGP?3LH3'=C\B![3O*[()1OC" M=K_;D^'*OR[J.RC[S,3-/G/U9.O_=H-_K5]VXTM5]-/M_YO]A>7*$S[LP)WM8(*E#=^?WS"+S: MBIVJE7 '+-D(#%7YQN2OU6I08S<<9:<(W):3"IZS3P18]SG_'$^]X$/\[AN6:K/-4#,":'8 \@5.90(-! MJVM__.Q*Y]=NSC;/N#WWY"1L%+FO&6O8[GW(GESVX$K6\;/V&_:_>) 8FKQ$ M(HF$N.(":9ARE 0SA!#N*/:S?L RQP\N,LZRR3@$8(O#;(,ZO2J6F 75NOYX M=#Y$4TXIJS^NSWX+[QU,A*F.UV21SUB7Z72Y>K?H7:T6ES+@\:A31<] F4+, M")A#"<,Q0.O9YW-0[2<[C^6^E^\.M/X!@#XZZ(]A6L/PGR^N@Z9UN>G"IZ=$ MMNP)P^IU[?$POIC\\D?H#(^[]N1%IU=6HWSIC_I:-?O-S&]F2[C(2?7V&2E< MPQ4QK,_NU'>NWUXK;\UL<%?O<;D&CMJ5;^,UO(W.?O21QJ_(*[S-C:2[0AR_)A9B&.2\DH]SV,-YO ME36_::G^99S=0M@J*"=7EA]?R"0T4XS_H,T4W_44LV:*[V2*RZG@VV'N\E5@ MO,KBU(';WQ"DI]J,HQEAT]#DZH8F=GC0RL$<<"+S7MWOJ$EB22/XZS+;T:+Z[,NNR=M^J&3(\![ MG]^3O5:/K9V][MZK MO[^VWW["VY_?=+=?O8;7W]/=SS"&G3\[N_1-:L^WD5<\8!^"121ABSBL+;(F M<)1K16KCG'&$K:P+O4K)K=OU_03/EK1N6@-'2P]'U$HB//<2.\V)!(D5F'G. MX8>0U*8[AJ,E+%W[2)!HMM\[28%893Q2.;>>$V>1#AXC'!)+G"E-75ATY=H& MBAHH6AP4!6!#+MJ0E"-<2^$<9X[AH*7%,5C;0-&20M%L>W;LJ&' ?Y#%E"'N M!$766XN '0G.K=*2V :*&BA:7BCBTNE@& <#&CD+WA(AF8P\*8DM&-+&25MF M/)IKJJZDQ,)1Y,&R($ZE02X9P*-$$Y:.>,G$$CII3S:&NU4B7%4NSO004A/( M?2[7>/J!W,5V7;\N;7A\9I9:Z[5/7B7'N'%<*V&P,5$J+($E7E7^8<[,;O:^ MQ>'HJ*'Y=VA6.W.Q3TDT"81@Q C.!7B31<8ICBP+VBB08Y?B$Z;YSUQWF28I M&D%-$I)[K8R5#ALM$\W%%<*U*?)-=+?AQ;=2X-F0H8XAFJ@2HEIHQ*VER'$9 MD+")N"BD-%*OK'.^RNBMR\$V^KMD^FN#9YP);W.TGW"LG(1Q:1%LX@G*(E-M=QEJZQO4]5=XFVVBINDR*2:ZYU M,*"S\)IG6GE"&]N[= H\&Y/BGDH;G$ 2.R#/+C%D"2?(^< %2<[;8);0]BXH M)K74OOO141R4TW+']C@.?LMEO^2IGPCTL!"C2-0QD2L"$J ,1$A,F<:*"I98 M0QN6!W5.YEQV@9,/F#LDI%6( XH@@XU'A#E*@Z012[\PVO 3U7^@RN3/7'<% M]F!;-&$*7';"O:71@;U)H+Y2"*D;VK!T"CSKLN>M*H<91BPH#[R?,^2,$@B< M.%A48861?&6=T%5C9*._3TQ_4Y*!,P,4GP>N@M!<@A^HL+$2$ZJOG3K%&.F.Y74+;^_2W MVU_-U!+N#(?C&%KNI/5I[>-::S\7)>Y517;W8\\W^_"SX*0L-CH"A32.<)(K M$0*]A*L&S:1R0C;@M%S@M#U_$(D%1Y@7 CG'P#$P@2'M$T4VL @N@_6"J95U MMFINWPNWV0Y8,O65X!38Q&Q4&O.@P2B)Y(!6$$&2I8P M9HX$I$("S0TJ(F<31P%TF#*OJ/"JV)2$N =<"T\QS98:Y.C M_&[\@D9W?U=WY[;A@2JNTXHABU6 MRA#&*>;.BL1#Q%X3I3ENXNG+I\"S/KW GCI& TI"Y\Z^F"'C?4)&4B\MK"27 M=/EH\Z)+$%ZSFEC3L7>1\_'(L4][$I0$ALH#I]H8B04/WH(Q%)A>/WVP*H#6 MP-Y=PM['N6A!L+G=DK8H:9&SCQA'+@F!&/P:K)22F;BR+NDJQ;?./EJ@SC2- MS1N87(*)N$EHAK%H([9,!\4)EUI1RJ('YR"1D.BUTZ4:F+P/F)P-S> 8K2 B MH*@U!O>."F2(RJ$9F8PS@;)<4T6H54:>0A_S!B8;F'R@@Z ZX$B4)\Y'+I4V MPN"("64J<.$6SB:; -CO(N1L "P"570D@=<<:$3<"XXL,1H%+Z/@6F'O%A< M:R"R@)H"0<7V_E<(DM3R4@BF%Y[DZ]ADO>!DW-Q1DZQ%C[ M?$I@DM%8Y*C0I5A?M#+AI/3*.B%F5=R^!LT2X&2)4/ZKU'A9/VO,='5SS*9K MTQ/J+=0,MNG:=.]=FR:]XEJ3-G%-TZ:F:=-CF^*F:=.=3W'3M.ENIKAIVG23 M9WQR#8>:$39-FYJF3Z^!@[^TF/,=KW#[]ZZ#]]L/7W1U_ND7_ MNJQI$Y'>$JHYXLH)Q#DSR%E#D0Z$!08+++5<62>,K#)%ERCML^E/T.!1W9\@ M$8N-,1T]M__S^H&BNGHOB6D:E4:3!(2ZI0I:P MA)RAQ$GM/15/N8YC T6/'HJ2#UJ$$ ,6D>4Q&*\P9 M ),VSCCF[YH5-5[:K?!H-F7&)"\3E0$EK8 :61:0BSYWD2,&EMD[K]DR>FE/ M-HK;M&UZUM=X^J'RLR4<_310NMX[@(;E$N'(D$!F4M#I=U\X^YYH5 M]V57Y]LV,8M5Q%0AJ21!G&&%8"T) EIOA8H^VLB?,,]_YKH;+'=)5\SQX MIDVB"C.:E!#&IG 7NML0XULI\&S,T$KFK<42Y2)!>?M"@J,>.(I*J KFY+0 M*^N:K2JR3+RXT=^%U)&-.E@;O0"MY=$F YCM0)%%PC*7=V]L[S*I[FR,S;A( MB8?)Y#Z ZBKID"&"(:*\TT1&ZV53+^KIZJY4*ED3A #;2XTQ*F%&B*78.L;C MG?#FQO;>2H%G@U+@&%J?$D51>H.XD0$Y9@VBV%D<@H>U6T;;V[1MNA;T7/+4 M3P5ZN(] $8 F4L$#-8ZGP!7AQ"JKK=4-;5@>U)EOVP0+I&#=% I4,<1M )>= M1($\C1XLB9?4ZZ9UQ%/5W6AY[K&D4>*[& M,Q$J<2$0T3PB#@X\LCXK,'.6X>@)_W=ZT;;KM*0"1H@%(XM+#?UAJZT@$:K.Y&:2@%F^L,3]D=L,)+8I)-,1H._S6ZNTRZ.W?61;'H%'.( MX201#\$AQ[E%(9BD,?<6M+?1W:>JNS8&Y5ST#!27,V)=BC9&[5C$D8/#W_#F MI5/@6:?>8V8QY@0):10H<'3(!FD09TP+Z2U7T2XA;W[Z^_#;HX,X6$C^_-,- M*D:E O'<.-68WB>KNS3E M*@[1&YT\#T%J+3BG5 F,8\3I3G2W,;VW4N!9MUT; ^!+$O(A;W?![\A%G5#@ M"A;1*A(P7C[3>]NM^)N6FFFZ/]W!?#QN[(O$1RNML\QY;JW2G )IX5@H*IWD MURY ^IR[/]T3[&WM;&3(*V&#]HYG[9W77ZAS(CKL$;%8(QZD1\X1BP@LG6- M2I7W*^N$LU6NQ(+BE8^A35X#E U0+A8H0:M8C$P'DRBX]M90K;2ABB4MB#.N M V-P8CP?$1<)(^^01%8$G^-/;5/9UQ"K!O '*!B@;H/S= M0#:UP1O)E0L4>*1V!'N/A3-1*!SIM;WI9]IR^1XQLCU#)L&\$24219A;5Y\& M93@@$N%%1;A7<>%%)!J,;##R&6*D)3 3R1G!)8^@;L%1+C1- KQN&J^=H-N0 MR?L!RI-9KSO8Y#%#!GY#7 J#-*PC4KGVBH&E]$&LK%.I5X6Z=;QQ"8#RDJ;+ M]4.UQT>@*[[Z.XMXIS>VY2E+Y^4B74YS*@E.4G'XGY>&ZUSF,7>ZD1:DB0EB5$+ MKI057UZ5END$$W36.WU&<[V'11X-W]F3/*T;O0"O#,8Q_*=C7:=;LIO.U'D' M;OUGM^^_/JS"DJU.K;"@G%E)MM]N?@=%$ENEX?EKT:9_?6T?[75W/__5W3WT M;._S7UGYNO%_/YSL?0['H!IR]_ KWGL+RGJX<0K*_3TW/-_:^2X0:KRT)G#%$XBOWC./:&.:]L M5KQK92U".B/JM93_ZI;K=RQ1'_U!#.-NW$[SDK239>SY"M'NE^28#)1*I%5N MS\2"1 XK@Z0*BFJBM07$GA&**\!(3DA8IQ=B;_2"\C4E[@R?YJA&P:>)O,9: M7K,P#3O#$;S43ZW1003SW^WVOP/PM_[1Z<$K_3'<+PS_^>*B*%_^B-7CU!6Y M:[M4&1AXK*X]'L87DU_^")WA<=>>O.CTRC#+E_ZHKU4;JYQ/.F-?R@16;_]1 M=R''> U7/*K>$:OO_.L&YHJL$4H7WQ>=KG$C'TL3]SQ8O8@F[O=2 'R)^PU_ MC,>CNN$[+@W?;]4[^YE,VJOHZSDC9[&#Y[U#[=/=W>^0#._=Y!^^@]V3I\_P/^Y=MO7Y]N'8:CV<# UN'N M:?OP/=!)&./A%MS[S=>]H]=T[]6G$[@O_+O/=W>V3MIT+VW-9_ +S$(4W"(N MN$$\:(4TMQ&!K$M-A14TA7)XR"B]V+# DXB0-B#WM$#.&^&=3,0PHC@/W!A) MI(HR,L.DHN174!$G&%.(>8-01Q6&#GXB1(7/ILQ#.L+(*=6 ME5S4"DJ M=V9EG:Y*?FL:UASF6#(=7B3I M:'3X_G1XEF;H)(S6SB/C"?A2/ KD(H[(\T"TD\&)7(A!K1*-ETB'GWRDJY_+ M,#3E$A=*&R8[>*7$Q?SF78,VBT:;^48(0;FD!" M\?>PJ"OK9-5@LD3J^_2+-NWT1[;;LC/9"C>>G#'+STDY5D6BC%UZ6F:M;GBS?X8+V]#30)[JW\V=GE^X=;.W\ MW=G;>7^Z]>IO^/T3VSW=AWMVNUNO#@[A>WPV+[R]L]?=>OO7(6C9CS9H<_O5 MUO?V9_A])QQNO_IPN/WYT_?MMULPQH/4AG%\2=QK8QE!.$4&.F9B3ME12$<" M&*D4HX[,GBZ@'FAFD$%3(GB*SL+"*$9<4)Q&POUL(OFY52AY@1?6X>='#98W M!?WR4Q"_GIJ+4^FI%YXISE@NN<65]ABGX#43@A,FP\KZ9J^U94]*3NEJR6R' MV82'/&F5S%?P*CN]4;]E6\,,4W886W9_$&/)N033U.JGU/&Q!?,"/T'(R_9W MI]?ZLS\<]7NK<.WAT/J#\3".8'5&![:D:G8&<=B"9_K+PM,-3B99K7*U];TS M.FCU^JW^<7EHN#68P?B]!;>"X1QU>G"#5K2#[LE::P=&Z_*0LJ6$F_I!'N P M-R*RQ\>#_@\PDJ/8/6E=:='!H+HXF#'JR1,6%$VY:@]WU#O'",&6"PL0D61= M91R+BT:=7MC@>A<'.778[L?->EB;O8T>/&SW3_C]0['LM?%&])GAPM;AIY,O MEO$893[BQW,_[LAYWD*62%L?J%?)"6'!]LZ9W?\#&IZG<;+^$VFM>U#95A<$ M+6:Y;,&\A\XHBU 6ZRX@ ^AK:$UR-.K7ZV+7)["4Q_UA9[1:O5+ULP(Q'0%H MY(][.SP \3SH^ .X&;R3NK&\D246!+YLW(#D]I"OJ%O+EL.C6R*@X[>181K&EDX,']5OUZ8.L>Z $E4'X+ZAC)^5&<#;;7X#N.+#9 %?O MKUU'V*]),?6R44QUYQ3SXPB8XT&_"X[!\/5_QX!4[?XH+A^[W'XYL2)[G=VC M]R=;AU_I[M%?1VU _RW:[K1I^Q"N<;*[ [X>?8VW/^^>S%F1H[\Z>Z\V3[9W M\C5V\_U.=^DFVZ4PME=_'8"O=[J[\U[L'?Z5VJ^^GGP!,R'A_QX1GA3BFNG< M'3(@28S0 ASS).,L)0I1**^39EA@;JTP@02=DL'>>R6TO8Q=@MZ5=2@J\0ZP M/PZRA2BO_<99UE\.X1[1IUSG16<$.NRO(?#G9^.Q4.F-WT2YB@_;\>B@/X#; M90YPG"<*1IUEH3X).F4@/=\=!_C4E6QS>&"!4"PDA+39?G.9+]KOE87Y6&ZT M,1WX]:)(^)DAR-;.)OFBN2%,.X4\CP3Q1"BXIB$AB1U+D29/E?])2/#2)?V] MS9-F21>TI%Y1J1)/*(#3EH\*461\,LAC;ZRG01+F@&T*O I@D_^;*52S=FMGZTD9"?3,&\% M,2C&7-HB,(6L4. ^<&R5 4-+OP\WG_%$MZ%AC=+>-D2AJB=EK!Z$>?"X]08 MI(/#B"MAG9%<8B96UDMI@_G4DWD]/K:#UK<\NVO7(2^$/GKV,F$GH7-38K(P M&=_)\:_QX*1(>2WP]0U_46CP^4G\5_%%*^6D3!H%EP]76*Z1X38@9115N78R4GK7S =/ -W*2\>_!F/!H/8FMS.!SGL-2< MZWP'<942GC^KY73. $]&]J8_J,8U&=9257=Z@#C+Z1?J!)>"2&2M!]NK#08O MR0A$B:#,$^MDG(N;+'% X/S&P8$=EJHB128O5G:ZG/07P4V5X'9J"6FJ/C55 MGYJJ3]>N^E3V7)K*3S>N_#29MV=2_:EF#(/SC"'^B /?&<:,ROWQ:#@"!ZA@ M=162+5D#OW?L_O:U4I8]?_%2UX G&[C0+#DE>*+4DH")TTP82KBUYG="&2^K M.'FU?E?2JB<=PJQR&X\^=-N?7Y^4:Y[^?0B\B@"GZFSM?.ALORUUD;_N'F[] MV*(?YG(;]]Y^(KL[FWG\K/T9[O3J[Z.MH\T?[;>;?&_G/=Y^^Z&S=?KZ=._M MI:62@L?<&:$1=Z7CHO5(:Q80C5C!&A,M8UA9-ZM$F%5.%MRZ:+FK)35H<#4: M:.--,CI8[2274AGMO09?"_MH-0W^=V+3#1K<.QK,'?;GVANJ(S+:.,0)9LAZ M$I!@@/.6.QQ2Z9S,0+6G*A0 M4$'GOO*.PX+F@F-2K:JF8-%2LI371\?=_DF,-5UY-Q[X@YP^_-L4Y:E43+E\ MQY9:H;GQR4;%!<5:,6D"@)@EC%!B&XKR"(!LO@X2]APS@"S$(TV(4^R13=HA MB;$TGBLP6?\_>^_:W#:.K8W^%59.[W-ZJD0/ 8*W3NU4>>(D;^8=V^G$W=G) MEQ0(@#832=0F)3O.KS]K 21%W6S)EFU*9D]-MVU1)(AUP;H^*WCQ*J(1J+(V M0:ET2$C;#(D(G!L MUXU"FQ'?M\,8%!?QXHC1V!4B!#,D"#$W=.\!FUVL[]!^=V49)U 1JGA83-9L)F3>&R,$HZ7Q5[]_SU]C'+=E+K/43;3J?U'EGK M+=:Z."),XM!1-G5]<+Z F'9$J6L[@1>H0#@.#X4>"T:9VW.]>X>'6S Q_.E* M83I5\F!-G)TJ>715,F] !9XK8R9=VX7C ,PF[M@Q5\R67DPB)Q)8&(5(-3WJ M.CW/WU8HI^6P@#>BY=0?/E5CT0(>1X=*T1Y4BIHX'8K!!BU7Q^XW)_1=5SJQ M';"0@B8")11)AF%ESF)01@%QW">S?SNJWI&J2C?P.M3FCLNQ+)O87(*]*@)7 MA9'B(&I$GR]W@:; A'L!"EXC?8UJK7@/J(H'8I@.ZF"!-\ZOOKF>#ZK5=6P: M("0B 08)PU#9CA,(\&X2[HGH3F@5#Z3,.RHNHZ(?P*XZ'K55X"8V$R*P8RD2 MVXUX(D@8*(=$6P"LN ]2LT_:!J,7/CB,WA0P3_=\XZ 4O6_EY,'763$N-/_?T#/)]?Q[\^ M7AQ_?N.=G+VG\YQ\^ADX^.P-.3T[^7$"/\/:"/S?^?KYXX^O9\>_3MZ]^?GE M[ )!2=A]?SG"2) M'3\)@L!EH4OB1,0\$$ZD/"E\X M1<@W;(BP?L+Z<1(X$6$\"D,> MQXER8\0+"0+IK&U939564WH.\YP/SS5,][^N%_3:(19HGNC-/DUVTGI_ HWX M_OJ;&WL1#1%%S$<8#"Z4'5+XR0^#F''/3V)$E@MZC$4]MJ0,N6)KY*3-V(7@ M$2YEQ&+794XDN0R9[TA&91B"Z>:N;<)U[/)(['),OX7"2;Q $CL))1R?*I!V M!*>-'2L1."X<.,KU7[SR>B1D/;:D'Z5DEQYF!T=*H/Y"V/,5X;=6QN; * M* M==P=3M;*W:A/)/C\J4XD$;(XB8GR/>:SQ.4Q-L2YOBN 5;V(R.Y$:I>*P1$+ MWX)$!0J(8CNNHC8+'-_FB7)LXH4RE(YTO>2FF,'R'G!?^@YE+IPOBLDPX.*QY8A\/K6K7Q:BB+'K=AZ<$L!G)E7LMIK89*2* .[/=!*4Y&Y2@,E23F M-!NJHJ@2%K4UKK7:,+.22:Y':I3=1%=IOV_%RCH'[L'XYI+G+2+AM?ID7+_/IPX>G."FY$)%($JK\2+$XDG$@.7-<-TD\$B1^=U*V34'^ M^N%^8^!;4]?#Z7X46TB=T(XH\Q 0A[LR48H*4)!12'JNXV_1!AL I'QL*/21SZ0JW?\-,QRZ,PR^G1FY]@5C$&2L*SW<@#LRI*I!W"CW88 M"G#]_2!4?K"ZG61>S/G0+K=0ZBX&ZHND\" MUNNYJQ_:@?4^->:LT;(=..^M&_59_Z*D-AD.83E@BNB?WV&4PCB:1WQL_O:6 MI[FE*V6> KX7U-QC5M/_59[?I5_>1#&V%A",.U#.QVG6O+,+:09/OA_"03O1 MA3&G&)H[N^!#DV0O:GOMI)RHO,>NI>E1^'X(:SGY"9_]2;Z>_>F! M5<:^GAW2+]_?N*?O/@Z^_/K[QWR/PK&N/_O3^_(+W^\'6'A_]W&*J4^(Y]HB8N"<*L^S.?QNBR1*E*^H\#&MN*4F MSUT"]GU O=&.;M+?'H9L&Y#KZ37DZC+775*3E>%0V@S:7$!# 6T$;2)T2G(S M);G0"<\#Q504VUZ0N. 64]\.2:A 9\:,4G"8'2RT9^0@7 SVME%%;@FHQ^@V MMW7F(C8W@AG=X>_,XYGZH?!2\,6@7QTX#W;M'9V5#-TAL^6M<.\X>-&?IPX,K&%\IC-PH3:<2PBVU4^ M]I5Y,14!3K\^6-)Y&.%97($QR+W062QG_T0$DMTHE/*EQ\]AJ MH;-OMJP:YNT;+AP2>2*Q@R!R;29Y8O.$A39+'.'Y*@E%B(&=\("T"3]]S\,W M;[,\4>E=39P=<];VV,2IZ=A9.=M694M0F"5X:#)R(SMDF,@36,3EQ@KL'9D0 M2:4*8W#5*'%Z)%SL#ES?S.EB.)V9LRW5, $%U]DX6U8,"S8.]0@+);$9^#!/=.7K4OAM,RTV:ND&EFCKUUXPS[#E/UJ89- M='5.NZ<%%^N<_)B1V/,\.Z9<(E:>8\<(B$ADP (J'9+HDR8(1\GL,&&)+7@2 MNXI2X3D2C%#W@-$]4+[KH6 OPTJD+>B:NA%+NE>VYT^&N1+9^;":/E++)?Q2 MC*W<("$BNL.DLGF7CTG3+?,WPLG.5V9&<93XE'L.DTS1( HXXA\QYB?,#6BP M7*_8WKQ:J8 !/JG\,A5JN9:I-816*(6>P-+\'*$>3[+Q%P6+J[9C/3O.WTU% M'WPA7C@O'@NTP3]F,Q]AA2(6M9*B<,')DP),7KP@[6.6, IOW MX;>>=761B@LK+2SU$_NB#;/%RFKP97:)D!_65:G=;6[4NS72X4CD\ILZ3WWB M.JYT0N'%P&H^X4E(!.@PSW692^-DC<[3!^,Q$U!]F^7EG_ Z,L-X(/WB#SG) MKQ7/GQVKO;DZN?H6J,CE>-P0Y#(6)Y[-7M M6$2 >21TVPT;K)L E8_:5_U)7"@YZ:L2#6*!L?7"RG5U7=:FRYH='X(OZ@>4 M@D_JDP@[3K=)K-Z#OUR:L;"=_\U/E(BV4L:<_ M@&5@_@Y6L:7WJMNJ:JL^J@%/A[!Z_=MKN!$Z(Q/>U[^?J7SP[/;J\/P\5^<5 M#,%[V)%T6*3",-,6 FVB/EP>Y!G&X@2SWV%+>;5W]\/C2NW4-[2;>-FVVC$ M>WR13> ^D='YVD)V=O?LVG=^ =KK[@ MA-//[^G7H_[WDZ,O#JR)??G^E_OEU_G5R=&/JV/ZGAR?G2SK(@U=H<+0Y[9+ M0V(SWQ4VCV1L>\J-$QJ3*&'TQ2N_Q_RPYRT95?5TM=2/E"??UWSW'N:MVZC" MYO+3E0>G?;=.=VVFN^93TTZ $PF\Q)8R<6P6TL .<_%*^(? M1-M*3;=(;^W-/?:\)^:=&53P'#IB-H2SNTL:ZT'5MB954?6\O,NSHNALSZWI M[\7V7AZ*(!0>LQ,1B;*^G;B^K0+?=Q,B! G9BU=N+W*QP_?>.KSK?VFIW?8$ MFJ#82!5T1MSVE,"\$4=9PA,G5+8/K&^S0'IVI"+'YCR((T]%H2?!B(L.Z+UK MNULL_[M^CSW';:D$OH-N>10S#DM,#%S4T22'+3-*V"2#FY5)-5DZ*VU;"GI) M>W(2.UZH/&D'A/HV\X/0CA,A;,]S(]_Q'$4]L-*H[_5\?]%&ZU!8VB7=^V&> M59+?66@/H #F+32?>$3+5 M8VFO1>B%.$P"SJBT68CS3Y50-@^%9PL94>KYPO-=L/RBP.]1NMCUUR%3M4O\ M]\/U6Z(#.N=O>RI@ 4<\!KO"2<#O<^,(V_\#.U:QM(F _Q%?T-@# X8$!U$7 MGV_O/9Y+G>^#P'(]&^ MZ=! T2!6A$K&@C@44G#?E=*-W4 E\: )?>[8$7=#.W88\[@;^SYSP-AU M#Z)MI3IV0@MNR6)LEQYX,&@5E./X=E&/-Q;UNJ6YT20)&%QX$F'LQ>OP@,6+6##W:57M1'<@H!HWA"YLG@;(])6*/D) I+WKQRJ7! M_F7Y6A82*LUA#3*UU9#0(AK /#!I%Q-Z4!>H0=DN)K1EC;;8FN/3D#N>3.Q0 M, ?':WEV&$O7IL2)6>#&4> F+U[17A2Y/=>_MS>TF70]<5;@(77$KAEK&[[R M+JG#'0@+-71B%Q;:GC)<@$#GON<'RK.)[R88%E)VQ'S'IM0/7!H%(1.103[> M5@YT-Q3AELS&=BF"ML:%5LOZJKC0OJ%*/[8:F(\+!6X@PU!ZX-9%.*YIA>RKJ;'+]L1#QH6VHUIFXT*D"PQMIC+F M T/*%4I&C-H\\L"-3+F=+C8&4Y< ^;W =GBB M!Z^[=DB5"]P9.HZGI'(5]K;T(L_O,6=;H_E:E!?O4G.[9X*U/:1SNV;K(CW; M4VGSD9Z ,,\AE((B [W&B,_!7F/@\=$XY*$;<9[XI@!H#Y%0NS*?1PSG;"SG M793G853 ?)2')Q2;WH0M? 2E XZP>>#"3Y&?4$;CP$,5$!YX?E?]TYD8.U3] M<[O&J0>$=-5!]]$H"T$@SU7"8;'- @=ABN/0YCSDMB3,CR3W'.""%Z]<$K;( MI-CM.;@XUXY7S&RE%3=;E\C.&.QI3K$KK&PJ CU+38.A/1TONKPA=)06%NR@ MF)B1N=R,S)-IDJA<#86R8C6^4FJH_US>6%DCM-1Q%?A7()_*^]?8PC:[*'R> M_EHQ!I6 MT]XFD]?8=EP/I$-!MFPO!%8!7!15JBY&X\O^-BZX')N0875SZX4 M?H4/[_=@N/V*$<0'UH:4J98H6[W3F7FLQ%>"Z^O'/QD%LKE]P)6U;R;JJ/EHS' M @KNS#38P#GPW. AQH &8;@[,TN#:.T%+?%^*SH";ZK-KWQ6&]%[ M@Z)G!J(VQ>_9#; \075T[SUI"Q>N;/U<4N771FK,>?WWO'WW]H@D3:>55FNE>R((=EJI]5II MOH9"1A'1/3)AY+FHE1P[(I&T8Q(*D4A06E*B5MH:YO'ST$J/;#7N2+=WE8]1 M^<#Z/=WFS/C6*^"EX>\[&8%;JFQ9IF'K7//^5JH\DJ)=[-&F82)5R(7-'8YY M9>G9<1BY-DT05][S!><@__Z!XSQ&/]+SD;&GK![K9.QA96S>F&%>X#A)X-@^ MP9X_WPOLV!?,)MR-DL!WHBATM8P%=Y"Q+A!TPY%^F?5!*/KI^/I9]^'L7JBG MHN#?-0$[MVI33;1D#%^8,"9B$=I4TMAF/(EMGH3<%B&R0,P#JKP7K\+PP&E) M'5FKO*=N]M]^16XZ);,5)3-O[L3*Y0F0UY9@W>!$=F&'04AMF2B/1I'C^U2" MDHD.Z+VGL>^ADNE"-#?8ZN3]*>2 M]B^59YT2WD@)+T[=8D'B$.6 I>?YD*'-):$J<90CP_C%*UWY2U^V M SFB56JX&_:UG[9>IWP>0/DL9.^2*%*<1+:7Z.R=B.W8]< @]%TXG_S0\WS: M*9_6V( [$=.K.IFMJG)^>7'[2.66AIVY5[-HUP3[]&?,:IP-ZM$@4M)GS",, M=$H8AY)%OA)8R!0(=8N52[?=%/L..7'5($G]X1%P:7TJ=6?*[6?*DCHUZ0;P MC[#]P&ZRPU9%"?@H2>N M!*N8A(R&O@P2-Z#"X8ZZQ4CN=-S@.E"]"QR8L!GN8DL2.B.*V0Z5' M8N7%B0PQ 1QLJYKMX737%DS3FQ$!\'>4F'1H>F)GN@%+Z6-4=V^^'&5%BM?\ MD2N,X%^J:8_>?\VV@I8=?L[T*SPNLOYDO/HKRUH-'Z]9E-#9ELCFOR_R:5_, MN;+C7/$?-D]@B7_P_A6_+E[\<[:',AW:R-LS/N@T7,ELO,A MW!>9?*IAX1=L+U$&2F"O'FSX4W9=ON)Y5?ID(M/R9.LG+1^D0HSO"5FY^_AG<\R<9? M%"RNVH5FX_IZR)C^;AX:]^A>A\, #5;A2AKB!#@GM!ES0.E[L6\#;5DD?>J' M)'CQRG,/5BE]X/0^_-:SKBY2<8'@%4WHD%A9#=;,0)5;?+&]?*2/=63TFXK1 M[F24/!*_&[A<_&<03Y.@7=#/W%"PFT7Z&$S0CT[BL$V]B(>"N)R)D*U0R ?AD-UR>VL MO8"Z>U@H;1!PPQ,&@ZA"SOA= WUD$WBZ+/ZQ%B*&M^N(&-HLYZ"[HO(D.T2Q 8CX4+LE.;LBDNR'TKK>[3^O),,"[N]_[/?(/) M4_=G[<$>MH-)=W\?R?TTYT[4)WQ4!;C2XD)CWDEUJ?K9"),M6VM$GR?W/B7Z MUG_I'2**717#'L01B:E#V"V5"XMXWH>5)[D\^/#& M.)WKQ6EW&IG[N^Q_^7S2__KN"_UZ]O7[U^]_TM//'R].W_V='A_]Y7X9?*'' M1\<_3WZ=_)A/[IW0OR^^4+CW]Z_]DP'\[^B+]_7=&_;U\_NKDS.9PMJOCG^] M<8_IQV4 .CZE+(B3T)88@6,R8#:/J8+MC7Q'AMSE 8[[Z$71MJ87;7(BM+EL MH5-U>ZSJ7.%QRE@8JL1E@4Q"1V):D."DXYBZ@59UI%)UI%-U+51U\W4,Q(T\ MAPO?=BAV=L4J!%7'E.VY$7.HHH'K89ZA%X1!I^HZ5?=<5)UR(S\('>8SR1A/ M(I"+,(Z8B'G 9!+S6VJZ.E77 E4W/\$IA(E LL1]< C8;:FZ M_6R#?Z>&*N=]'6'D MPM]]Y71AMK9KJ46@0ND'))0TL&G"P/<,(M>.@L@!!Q34ENMY)(CEBU>L%[CW MGJJ[G8[2KKE\>V%S$-W8\Z67,#"^XX KZH<)!I6D$\&1TL62VB_/\[$DG-\5 M*91G$H+50?W(#EF4V$G 72^4,DZD]^*5"_+,.GG>,WEV8X\',5&Q$I2Y&"-6 MC@H3UW,(X2&)NX!)^^5Y/F"2""684J'M"$%M%OJ)S4GLV *.YBAFRG%"\"(( MZSGTWL'A3J!;)M"4G@2QXP.*E?O(IZS&N3P;V?Q46Z4\IT%M[06W#',$Q9 MZ^_"CLML@IT#>N[%/8;,['80]W[[L=N*_)X @ITB?VI%O@3T68*)':G L6.* M:%R*$IL+Y<%/W*4L\,*$(/H >%I;3F7=2Y!V(\O5Z"QG22!'S7B-HD M4"(0;DQBP5^\HK1'[Q\1[)1GISR?K?)T"0T4D1&5<\R*?!W \OGA%P/+<=JW]DRC/ M.P,#:MZ*D>.)D_@!@W^$#WQ/9!!)EWE^$$7)-Y^]>'QLHQN1C**#&Q&YMH!3 M](;G0R!+40&1M@5GZ.1U)9"'<%\)@O&&(B[GE^\??QP?O?=.S_ZB7W[]R4X_ MO[WX@E!J[[ZX\SA#QT*M#6)M,^Q,L,/RDQ"1/QZDJWOP4_8E4\FV>#?!0F(Q+<*N.WRI^.[_Z MQN/8"V,I[("$CLT$XW9$N6LG,2CU$/[-I;M#J%9G%ZK$J0(*6Z-L# M),2.% MA-8XFB(;#+*A25'UK!'\%>$'I&6R5? )'\"1,X9K)^-BS(=X8EA\;"DN+BJ4 M0C64/>M*YIPN#H$ ]Y;A(]=*]NFY)FG:*X45'X;NRQ0,*_1,@C[LO$B11S71D0PF\I2^H41>L5Q7S1 M4B*)#'@0V)'$HJ4 %06!7T//]URJ0NXB(IT/2H+UG*W-G.H4Q8XKBA@T!8FH MEPCN,QDF$04KE?LA4=2EG(I;:G Z1=%Z1;'0LR<=UU.>^"ECL2;1\(I]W<93=5F:+2$*N M%T=^(A*P=>+(9K[/[5 0"LH,#C051J'O."]>!2'://>&[.Z@"MHG\E$04$&4 M8DR!_>)YL1AB.TP(I[-'.'8&GLHBHCK M^TD<$Q&\>.6&;@]4?B?R^R?R1"@J Q(&*@X8H0P.]A@\&.K[CJ1RSRKBM=QTM"WPU\ M)I,H\E7HQ-0'3]93P 5=E&+717XA2A$0UZ,DL&G(B,VBT+-C*H7M!1X+N2-" M7[(VGO+[6>7Q8;Y*/"V*B2Z(AC=1ID8;!,^QWGSZ\.$^E1_[J;Z$&T=AS&-' M\HB%$8N8")F',&M<:%( M8NX)&8#Z8F&/A'1+$=8=3;CLI\03,$]XP)4BH6(^8S%CB7093QP_"F)ZV\2L MQY#X)/VII/U+Y5DG[)L)^T)$PG>$3YFPP1L%6\5QB?ZI\!F5'(LNF+$(VT\WQ^LG6Z- M..2#01OMJ+JX%Q1O9R"T7&=\6@@ D%BX,B2NG21!;#-7@8% "+/#D(0;44P=P$SK5,R#U7]=#_,VD[)M%[)S <>0C\FE ,]?1)%-HM] M%V=X1W88QYX'_J=/N4$#!R5#_4[)=$KFWDKFGN"NG9)IO9)9A'[U(L4\9?M< M@<_C*=<&A\BWDXA'*G;!SO%49\ET2F:;Y1[W T'ME$SKE_1ON>WAU_.[8FP>R_/KNWX.O@[\')^_^3K]^/_]Y7[^=77HW-V MX1B^^^57/SD^>W]U?/Z->4'LNJ%O1[YT;,:"V.9NDMB!&WNAEW#X M)9B'3@V#0/@\=H(@EBR.W9![- RB,, AD4$DYJ$O2R)8F@I6DPPW0ZBV%S%S M.;KKK?ORZG1HU5AG1D$1TK. A:.>KIC"0X9) M.![^/ZE B&[K\#Q7:@ 76[_CMS'>3)V7"Y_JOY.7_["NTO&%]3$[?PWW>3\4 M!];OY5?,WZKK#JR_ZAJNA9OUJAN< QV1JK#"YM+YT.![%G"R]JRK+._+JU0J MJU_>R)2'31](@I>(XCE6_;X2XPGO6Z,Z,2*,\%Q<].,PO53\;Z?=' M.%*5"R CT ROEQ,Q+FILT'&N^%AO2Y98O-_7Q[3&,56CM*]&!:Y2_A.N'JH) M?-G<&;\ 3Y=IH;4\+LK@EPI>($+I!*%.8_SJM34H+0.\)S[QT^L3>FB=JZ$Z M,&3],,F+">Q/M3M 3K."%7O:W,&K%)8,W(4OU4,4U12!5:^&\+=BK-^_G AH MOE9MD?ZD\2X6RMBEMFLL7A1PWAABI>-&B1Y\D,$^EBV%YCZC/A\> ']8>*;A M6\XN+RWPTA%(;XH'(VYZKM)!#&^,D$\E=^"?\6I<<]%\C.;!==9[_(N" X[4,UOU+SW#JB6 ^%?P[<* MU4>R_WLR--6+!]99X\TK+5@8SC3OK)IOG!H(7#M+[!$<*6I##R:K)>[ *B'Y&_>18+$BQ"YP2H6$.T7EU2"[PVQL@6VJ4-D=6(=Z M,^9TC^N@[J%TEKX77,(2!6CNFM'TEW_;8&9!Z+"8Q3$L?/M_=(Y+][\\7TT46=9XPR'/7N-&S <'P[E269V8UU#W']V)_P;QZA(+=>%(7\]<#9S6F:OD$?/\+:WH)+^';P MY?-[6-N_+[Z"JWCZ^>3[\:\_R?'9U_3T\_NKT\__3DZ/SJ^^Q4*Z$7B -N.^ M:[/(\VWX$UBMV/7)'3'@,]<%XG%T:8_6H-K'P^']3V60)&)3B(H7C!NS&BU1H,V'2'VL[&)X' MY]Y$-*VN^9,.EMMX@R'SOEP@_KP39^ZC:Z?C[\<_ORD12!<\/CN. M V6SV'5LGDC7YHY#0J!7I&(*Q\G!(I)*?>+JF0MH.>:E[USZ$0U)Z^%%1DXV MX1>PP#@; ML(\O9<):%D@.GBR@@,HFE&W;L\\CL\^M/YQO%$R"( IO''K%9XA.; MATK9E%(B A%Q#]6-<\ V9I_STC5&)N%RD Y3?>:GEVK*0'"9GN"2X1F*(1+X M20?&N0$G@O]4H9@ZB%54_BM^1O-!]> ]ABI!>P-77:E/_<59;UYFL'KTDO%5A#9<] &LPQ95 MZ /[&T'?IDDJ,)JS5"'F.C[>7SVY?KT MZ,>OXZM[6"F&0RK=861"QYQ&/)4'LWQ_GXQ5X+8N!$ ?/ 3P:1(7&.('7U-OWZ7@^-?XAHMY9.C-^[QT<6/XU^P;N#DD\&?[.O9X<_3=V_A M:/MQ]4W$D2N(&]N1'TJ;"4?:7(K(=I(P8"+V7!$L#/:CL>]Z*G(3"IP4.P%W MN0B2V/6=V"<\8?-^_G3#+;/C:R>E2M;0X[6 ?499H<^,/_3Y (?D='+7?\WZ M^F5ZV9E^A<=P9D[&J[^R; #9XQT1Q)V3ZL:_+_+IQ)-S9<=P"/X 30)+_(/W MK_AU\>*?L_(+PCNW<_,O;5[ME9X-M.S![0V;+(\$W5 MY_D*HRU)AW"5QG:HS#>=\ACEV26F\AK&D<(_X!TQL2%4/N:8-2O&*:8>S,K! MK$)RI,DUYB/&^%[Z!3"1D^8S=Y-U='/65$/S%%983@W4WQYF5C$5W'*C])0_ MO3%Y=5WUE,:MUXE1/S\)9ZLE?(,3VW_1.K7PZ$;">Q 98R*!M7#,A_#Z519> MARDQAC\IBBJ9?PB:Q#-M$[X?]2!4'W):>U$':Q9+;'ME]?W M^2,= Z^*-3CK2S8!I:2G< (/R#)#6TT;E;.;P1N;D8%^FZHB,;,A^71#&E[E M.#M7^G\^@06/?/ =&C\D^I-M NLGX8K5\8+-8H.'H7O M<#@<8EG$XF/^;Q4GOP+]F*3]*KNN*Q+JHD839/\I+OCP7*O406KV6]>,O/CT MYO6+?^B[JCB'=[JV:%@YW9^R07U6-->-RA,4O5FBWHV59 0M ,<1?!76M>$F M]AJC7)M/KRH(*J\=]PAK%LR;EM[XM3Z1\*-X4L!2BUGZEO08GE,I)2E>3 4ZRWYJ*R, >NK?,?^&8WLV!5#5.D/V?#*SJM M,_7O\4[<5-Y44B6TM,HT24"6JB*"_O5T7F]U(6R;R-.XY-7<2@>C?FK*9(R8 MK]S1.19:0R4L47=K'DI1V]S(TTN57Z;J:E?*W3Z#(D-+S1+PF:Y?!4J",HG3 M;'3!02Z%FNBZ5JS,TA:;ME?11@)Z8A01/@5"%WC/PE2U(N33[U&H1:H-@Q-P+O],KRGR[JT>?I3I*92 M"[;O(HW- 9(.2F/YP#I!K=*WXASMU@3D65]0&HTHSE+U]7SIVK[&*K+ZKII! MFW<>3I\MTEQ,TG&5S,3_J*$EKXM:;O5F]JR)+N-"K6"JJ*I9?O#BNC1?(MFK[XV!455Y=E8O7$FTWM0>KJ.J MW1O!IL&C[?-):@SYDM[F[?#-RAV/\4@WJQ[E_!P5O\"EB]2HA1&X(ASWM*_C MON>Z%@H< CAK-2-5W*<),_38?8N 0 M-@_69=Y38:%B#IP/6@DW OV:_(?>.PQ)#S4*'I9!)DDJ\'WQO2]*!RI+L#@, MG1DUPB.EVA,=G,ZSR?F%.1FGKWBEC%\#7A7<.07_#G0B;&X&; ."8*'F!^69 M9N9@'(!B3D=]719YGG,LG!,YSE ?5.EW.9-^KTHB>^;KB;::9L6\++!$;I7: M@(+%OBU/5\V]B]?CD_72I\%U/AQF>&#"SR-4,?4A4I\J'RZPTI+&]?V %,9D M@I'/6JT^/%!C5^E]S("(+P-GFUK62570?A%2S5?6D^0CFY^NF;IZNC:@]./+\UM_!9227=(?%#EP9ZGZ MZHW%8?6%+K$" I]GPXGHJVP,PJ-73M"HF%T4U5M2W[X8 M8'!_D %#3X!C5MYJV>OU+(Y17_@^UZ:KU>= W0M=;7:WEGK/A_]C1XSUL"0X5MIT,XJ^+'1=$*4W9WKW/QS-R ;6TFKS]7;% &:^ M4'&&^A,T59B#6)Q A8_=+?CU.!XM/OUE>W]8FZ-Q*-$LB)PWU23W M"%OM:?UU\ F_FDG];D?YY-PZ;.1*D:'+O7A[=-@K"Z/1%,>#H%)$>$MSJC<6 M>,'[R8PNJS48TL5\U9TQHAJ":]YVD$J[5D;H)"U7A+UE.VMT(AYI8#%,=,85 MEJ9/-2[@O"AXHL;P7^W%@@[)>9SVT_&U5IHE;Z!RX'#B#FV9C8!EP9C#1.F4 M+A6?#+(Q^HK7@]$X,Y7R'XYNTS\SVGT%#Y6W ,\I@\N;.[I#&=I20M],C^HE MQ)SNE,QTJOQ"NX1&F[TY_M?'P[_?Z%/&B(BF$-4)WB&>).C+U3T"4HD<#SI# M\9]86JX-+S2W^G4? W#;6.'A/!29G'I]:(N6'1%HWX!=Q7%646WI&-$!9=R_ MA@U)?TUR96=#](/-EXYF^C&F)8)H [Y!NPFHF*%)=:TEZ^C-F][-AUY3LD6F M^TP:582&C0TWE;R-X7,^53]F5Z<;6K](^=29S36UDOH&NI$C5K7\& U13.)! M.F[4#X!:P!\+I7Y8?#*&IZ2_C)V@51D2$S-6QB(%,W&5EC2 M5^C-BX)9<2K&&9:2F&#'%5XD%)CYSV/*SVOG(43=65. '1FT&^LJ%AOVM)]624CR[;@P/H7QWAF5NZ^4A*[ M66?6/F-YE]F2(2RM82^AY-0_5[9GQ;"E_ZLY%"Q.GB]NP:+)=H.A31;XQZ?A M&H;J-,/3OUYFOIN[HN>>S1B8-?UW1L.? C.5*2HE9^A4V[N\7V0F-UB8P#=> M#S9;/FN#-LT!9+;_^_KDC-1QSZFW!P:R4JCXB]*H14Z?:NT9/H15%6BMU)&) MJO\-!/+#ZZ/_0R+#I%].WAU^(+TJ. M2UJ_L@ZML/M$WMW1ZXP^X_)2AVGP1*MM5<-S3N@8630KUE&HYDXW=Z[BH"XS^ HGP[8^][\@ MQ.X#)+YNW*:&\Z SZX-17S7-#,V"A+!:>1UB$4J_SQMNR\+!<,R_HX6CC $& M+G'EFU7*$^S"7,[K3JV.9::+&\L..="?E82,L#45U"YJ7?C.7 RV7B:N!X1+ M7)0G4RU[)C6_^G6,4O[]Y+\)S M7L@RHZVY>FZL8*TGB4YU]"SFZ.M]QQJ<3\TH;:D!T^@H+\89\*^\M+O*1E=- ME6%]YH[R=("),OC3*$O-OI7I-7T*Q[ C^MXED4A@IV,UL/X/<7UO$Z^DZCKJG$W,H< *@Q@*B-HI3]8E<1_^, MP]-<95'M(#Z/X2;,[%BEN#21C '8@P>"Q)99TO*AC4>"FD7R4AG/FRJ0O@41@>?+:JB;>M#$=]D4VL]+F M O_ ^I3BEJ4Z]#L3Z (9S'2U-&S0F.MH!H;"3>$MVIG37JII-+V*TC>/,+V& MVG)8"-LB8=*^K+ZYM.M>^U3O/_2F@:_>-(6*.F2H8V8Y3W6> *0^K=PT(]M5 MRF=%X7@Q&6F;O=1W&-J<5C3HL)"NZ09!+!.AEVF."ZQRH"M;&G2$'FT/DQ^Y M4/P2Z&Y-0(#!-BVC@&@_@8C 'L-FH"_(8R1C5IH4VN/A8CQ]2I:?\V'ICQ4F M^?3QU$3ZRQ;]FXDP;?:^@?XF&ZU,9+;!.4;1X%MH,PSV5X"YWW#Y"MXW^K%9 MV87&.^C&HJX V*%09)5H;!+61'9%C2\AZWU#%6-8S3C7UT"W2S6J[5V]13.H4$IJV1L_B50G(7/E][;-)-<+SJ>+Y\IPJ M)@)41I%,9FU;?6ABP=S$)&QK*(TZ.:'#X+E)&*Y\<;-%F*8"W:\E5].D;F+, MD?]T\4S)T? 3.A*P9<6\($PC\!P1'6;2F4CK=YS<6O3+])L$)GIJUIX[VK]\%_0+THG M"I/)>((L7Y0^=)6@60,B8\X'U\'Z\D'(_@U%,H!C.>EC\P2R66/!55%':4&" M)K K8Q*?B[* ?\/_]DHN,WD28WVF@])D:V8-3>"XJ%-->D]@D9/<] )GVNY< MZ_U0'\!Q*-*1,?SX>'K'HA&P:-@96(4R--%+?3:#EAZ6 ;^Z*BP;GF>:V>I' ME=FL/];1E(AO5^)]V3B)3?L:,ZK3?L"*DN6*4Y^.?@UW]E@/GMT'P@[T@5'Y MX'7V:$%Y-)-'&N%(-W25BGZ&C5ZN6R/3461-BM2AR 6J5/[*\NQX1XD'H02E M-U"BRBQTE'@$2F!,^A:9(!TE'I@230.Z863K1,2,>=%M_3:VOHH"ICJ1556< M5SF';H\?;H\'?#C!&G#3""_XR#AT8(MVN[Z-7=?I]++4-LNO2T^U+/);[M%V M&[^-C:]\L5[IS?9,G8@8EYY>HDJ_\/V':8RQV_JM'*3"-#MJ']BN$%=A[R^& MNE"YV^5M[')=EHHEYR:TJ O =:2GK-D'&R6>E"T!2>'N!.-G@HLF/JFK-3 1-,ZPL0OT][@L MRU_DT!H"^(8(\M7-T=0EFUA%_AH8/-6-9RRJADSVC)0NB.;N4*+16*CW3(<] MD66;&<-F2CV9F#CM'-^63>^-F'Q6=DV610%XT7F>78TOZCY*! ,?IWU,)ESH MM&W)"MBZ5"IL7P8;U:"99GCT[GX)=FT@42! ^+OW7! M@JX\A$?L>IG4&?!UH:LW/V:@1NY9,.7O2,'4H^HP7?)G<'H6>C_G,?TW2T3B M%9HKS>>HR4P";RKP4VO8"!K:R8:M=N@\_I?20PBJ"JDAPA-A8^R*?O0%T/UJ MYQH[KV4=$]A3%58V0L[D]V#'], C?/0TN38%A\^-MD*W(ZG/)U",U3VKS#62 MLO0.9[/8!QIZJ?RVK@ HO[F0&B\/DE)%82X_5@)A"JK[]=6\0ERXP.C:YDL7 MDV)Q4:AV>?/,C'F1%KJ^?U@M8$;[U_P]=Y"!GM:%,[!G90,%$BO6>6!A;!B- M;:P7ANH=SK7Q_%UVAT_7R[L+7EST]+_UH6Z:DLW.&,M-[^JTB,64 U#W(%C, MR,>JK_FK3A!O?'-^TYH-/Y>-O1,=C,9SO4D@A AIIOZKXWV5&W8!C&+\2^;X/8EW:SB;TKJVC M1;U:&F#3X.^"9)[J4TU8\?B(TV50I/+ MM6U6C!M0WWKMLRV:YFTKOPLK0_&%M,@8+$)<:L,_P"=,C3@-3GY@?4)+: I4 M5<)1S!BRWR?2&&.:.QIE _=Z=/6H8D%;XQ= CQH &V-@\[%9%2ZVPC4UY4/5 M[D_Y3]?W8B=FU1X"^G\R@PU!AZ7(=HQ6MJSQ#[ZBLJ#*@'Y/2]ZT8>%IY M6&1P&F/]"A].S7?=>64X2X_)0>6O[U-7ZU;1[YJD114!;YX?)LZAW<>&\5S9 M]_//UL;S%9JY^F$5#,[2KTZ/"8M?PHE0'0 ZNC+L7\]],"Q']>@-XV7-+1=8 MJ52I>QVKZ#LGYQ72W^:*!-RQ%*9L!6 M=P6F9&YFP96ZTZ@"9,VMCBK &^[B:(+/C6*^W\B!N? WQ).N7/ GAUD M]6>U6+3:X53?@E,-W+H)2'%KU?#KT[_?']DDLOY55>#_-4(NW16-# JYC[]6 MA*DLJ/J],$&H!JGH&0NDB@]DFMGS5$.+%NB]R;3()Z-IP'+JAJ+[6YD4J1&9GR8Z0>XN@#+4_<"]Z\K02UQX!:>9-SK.5FJ:_]7E[XV*UFJ!EO0 M62-0-$+_/+8N>9ZB!S^]+AV7NBY1$O58SZBCGM7/JI)R+!X&X;7Z_ I.GWQ2 MA;;+7+=>]\Q.:M2ZI@F-C@>:YT,\OD I(!Q2C@=^*AJOK62:3SOE+T!EC"\$ M6D3-9A23!2B).&V7JG(=!L5UGMA:=Z>#$===Z1IB8(A]YI72+4K8P:;-/;?# MS=?CD[H_.8>W*,?OYUGZHN8Z;Y;U0=;!UH9.J MF8*;*598W33U/EF9*J\JL.H81EYES5>U5TT;F::B;RVMB]"X%LWT'OZAJH1I M9+Y*G=2P#.J@45C2G04[T[X\1/&37)7CH><'4H-1 M.VDV)I8@%ETCW#9*R\Q>-P!P=8)ZHYK7;H]OV>,IE%!E7F#+85G\-",KF]5Y M=QM_&W,O\W ,Q]]08K]NV6JW_7?1+;--)=/"[S)DUJQ$WIUZ@K.+*HH.QO.E M08+(TQ*<-*:V(F^,;[&!TKYI(8 MQ3@3/VR3BD9ZP?=F"G@[%;R53H1I1JLTYS26UFU^;A5]FP'#2:=0ECIJ606B M2[@;3(>O!7A3A[KG8+9GJEL[\F_O"*AIC\C4576=QI]+#427&9=3-\*5X)X= M'1Z*#E.1LU'DKJ>H4O,UK[/']0S4E"F;U)3JU4?\['>F06YC<=TFDIWMM36? M0^E9)&6^ OQT4*R_I@-A3&+$I,],(4(?TW>KCM"\8@?SO6E%E^:KWI2Q^.Q\ MJ751@G;&T/M-D[-*V1F1DV:M+:N<+"BIFB/BY$/FDP/8Y;&H(UB<6S9DA."?PP M:K[\>9;)G5$:V>7VS MS#X\,3>85F:(0;DA!D8]1PY4Z]>R/+E\ZS:V"L=OJN9TQ5R)\FBI(?R4E35D ML_%0#)PU2NIN41&FDAH+Q!K@CU5%%1['/RH-77]^>Q4:M@I4VF!: UC5 ZP[+G:'P<]F A*F8+A4I,7->[W,+JC9LV2^8C) M--!RQMU 0T/7>]8P(. +?0-J>JT'A)7@QHW2J5N9I%%3R8LUY**LC50<+L(: ME4R7/V&^ >[PNU;8V01V5A;_6"LXXU7$G$M"EGT;56(3*W-MG54=%>J/ZH>7 M,BU&?7[]1SK4)-)?>EG>O#2B."8[. XA__+ZLGE MQP?ZHW^.Y>)G.L48K?S8.2 K/[OIMH0>L,B_TVUO_LP-6;?875JLYZRWH']J MSC7<"P*"HO??+]P7T]RY=F_^<"RB=65UO_K2:.%2.OJ)%R_*Y[Q &5G:C@*. M;JL\OC M>32VM/M@X5N^W(%MPZ+R-7CE]G=\!AM%MB%4^[,='=_@P,M M[7)=0BB5)#>]*T;M5KYI7?&UY===\ WTZQXO#C&:JS&;/L3;?C MT7;BMWGQV-(;-]\TQ^<]_:M&/>I3TXGT,"^-'VWX\C?ID]M$;%XG=;RZ/[SJ M]P+7ZWBUX]4=X%4*S!H$';-VS+H#S$IHCSBM9-:-+>Y$_[,C%G>%UK#T09UHO8IHY 1YG'H(Q+>UX0 M=:1I(6F(UPLV/CBW2)K]#DA]J(;[WN> 7/+&;>8HVO,W5L/+B?J4SL$^4B;J MD3#L*--"RM"PYT:L(TT+24.BGD,WM5VV2)K']A\?;6-/;RND6IGAVR/SBY%- MI;XSBQ]%ZGLLV#10WU'F<633 'I'F<>AC+MQ$7#G>]Z^ MKV?9>)VF[3N67)6-HB[LNLPFV':JRZZ>;>'=_?:CA6()S@9S[Y@\V<:>[$:% M:2<&^RX&;H]T8M")P3,7 X(M!81TL;#().J?V!]6$0 2W%,&\YX+L:P MSQJP;REL>CFULG]M8,LN8'$J7P)JI@?@FJEV<&M8=#^]]>:]^FE6M[S$S<@O'49>PAL7\D,%J=D!STN57PD<%JJ]#;X*4-TI8>L5W?#T/]?*0F8QPFAJ^].]!FAV,SD!R'T_7* M\=0&T(T7&4Y&OZZG:2-9?PRS*X-RI\>B]/![&@0:-Z>\KAQQ6J%8UE.UD:4J M9ADJ'/R$PU.FL)QJ@:U6B!RZ25K,UBCFP>&9- MAM6XYQ%.0H0K$1923[A"U+U>C;T+2RS'L>,(N^RJ9/0*]J\<_U1-A9K"8=^P MCC/S"?GLUI@6I>!-YQ^&[>D0\S?[,'+88'G,!OA MDG);*'^IZM9:L<14[1.YM4$)#Y$XU3HWMJP>UK4#)7G[P=_38%CU*O%,] M'4)D(W4C,J/$U M'.E9'\R9\A;Z8$\0J5=<(_62M*_*LUQ/< 3#LD"#*3-'.3+$VZ-#C1(]- _D MN3'ZRO'&S4-\ B9O#D_I*/_0E"^58&\-4TH/ 1XN, [8*3C[%=;86S4#JJ/B MEJC8F(O:F'J=FBD$LR#V3@O![ -@ QZ MCK*J MP.!Q6ER44W;*04I+1VF53KN?LJ%(_EV?E;#1) MQQA61+ET>$*?PTIV7+ U3U$/4]%":7S&4EO/Z-E>/:T;::J+=AL3S>;#*ZMN M.4"S>)P-&S-/]*01/;>MH^@#R'5IR,X(-:AD33/0V1+'JHA<-2L;YIQJ(>XD==MTU3. 1MJP'EE1.2:%B;7"KR"I MY>R-!1^R"^D\C)C->'Z50,R* 4ZD4D9Q]E$#ZNS/K)(U9ZR6PFY$X;Q_BZ?$LXR"\YW#SN MJZ*:D5F8G&:VRGU;:9%;5]FD+YO3JC 88IY:.XDS2;#+M(ZXZZC#:PE,/ MK+<9@E1P]/.UI,U$U$B_ 6Y:# M0W'$G19X,PQVR87FR6/,\\';QNHZT_Y.IDFA)^F0 M#[5]WIB\92PZ-9..G+'P5PQAQ.0BCN(;8O;PENC:;7G*(\SM-15NI3O[\,K\ MAZH'@UTK7@X@K&@WNZ-SY05KB_2VQ5??YP\])D^L(=#O3+6$?K%#"2*5:N\; MQ_.],=4&Z[S(_"'Q%*JI^29\]DWJN@D]^.BST;I.Y>V:& M;'7?:NRC^JG$!!?4*^4!?NBK<][O-1W8)>M/)D-M/P._KO.6.NEN%J_, ZQ$ MJ<*,1=1>%0I;7:#3LP/AR)KFEAK#QF5%'<-N7\%[%)-?5 M*_HF+^>7 /\%4:PW0UL^]7R])>/75[+WLZQSBW:@SLU_9,5B9K]6\E3V%C?' M%C>F-BY.)S:.+6;SU"W3B0^LU[58@*+(RT(RE:ARAB7XTO/33J?SC,M9LZ(/ M,@2GDOGX_'9MH2>K%E7LWLV:O_A#O>*&X MU&JY9R;L#I62Z!0V-*HN ]/V( ["S;.K\45U#JTUV[<,JX\R#.^DO+_$2+JE M_ M/H:JT,3.]#";![89@XI6#./-4EX'I MD,56)WD_@*N[TCY;F.Q$IY &[X>P^^M:8D]L4397W(.#:;PK!F2%'F$6KDL1 MC;FHG?D4CV5PP\H+ILR&]8H]4[6(C@'X';7Y8JP:$QY C3X5K9DY]_KN.,?< ME*_E:I!.RHBWSIWAG.M=X5=#=^N,_VQT"[><\)_2JA@:?Q@9"Q[TD*X?GYFT MC ?77P>?#L \EEJE9[IB?*PJKD"[N'81JJ'FR$K]K"A,6EK?M3ZW=>DY:"IT M+_%N51@Z4FPP<)K*8=U[6M^+794E2L* 9MK>,DU;*JR?6Z[GVL!J"L MW]=KKX>Z8\Y%EY5S@8IK&^+@ST&F!W\J'/QIS0S]M'!2H;X0)_%95[S0?%/5 M-2\S85+YWR_2.&34)T[B!PS^$7[$0B*#2+K,\X,H2KZ%WHO'%_D;!?RC0@]/ MJ\33RCQ<5]*?6#>]UI5Q:3&U9Q>'W-Y$UUW19\M&I]<#S\WP=#S9L&E,FU]: M@QFG&TVZFJI:#K8YAQQV86>FCGO^@<_"W9F-[;FK'_I<%NLYZ]VV&^3] (.\ M%R]M\::\UD;!_4;FK@N_M,8]=GWX\%I3FN_^\L]Y:]>9!_[$O#ES][V%R#JM MH[65;_/'G4BS]C3".Q%M73C5O5CA=ACP!GPXXK:1$U?UV-\'$6\O\$26O5<+ M<4'NA);6/GS)CKU:REYW02'KV*MCK_5>Z'?: V-U8>[$8W#6EFS+%A_MJ\M[ MGL.<#^+V0N^.N'$MPG_;2]*0GM]-^F@E:6B/DDT1_MLW34(_FWIM5,H&'#M; M\/_O,S[B'BB/+6$[QGITXP$SFP;E=@4_?R_(&01W'+C7D;-UY/R=A>[&-OHC MP(KN8V3X/UE1]DMFBQ41=S \]H'[].&P/@-N].8[9$/N!RGA8.A(N?NDA"/A M7F#4;3D7ECL0[3L7F@7%=\L5;C&-N_?WV/_@X$*!^G.(";ILTQEY7=3I,>BR ML:_8D>51@H'!IN/QNE#@YJ' AB)^WD' S;5S%S)J*RV[Z-_>D'+S4Z"+ -X[ M A@KQ-MN=)3=>5[J\YO]M8/3O7YG;B]BWGX&QCI&W2=&99M5;'6,VC'JDQB@ MWAU#/2VS6G8E/OUAIN'])KME$^MY5VQDA!4E].7.UTGO(VU^W\"LZBCR&!2Y M8YBG\QIOV-.3$A?F2>8E[Y_%LW?SH^_I878CU#L1V'T10-^U$X%.!)ZM" 3^ MID7V+9 !;;/]4^,VO6H[!/I,._U1 Z!NQP#0UX#]NGVR_$K(KYZ>-'(^G:M0 MX>H9)+ *37!M9+#G"*]-G1V UYZKNZ@WK$-NVRTPM)U:;(?W7WTF)8:'6]&:5^-BNOEIL8^U@D$/=^] M(RA,5\'QH)1AO8C=L2N@H\P#JV _#)]/?:[*(-_&A[:@ KU,]1'T=-XVCVUR>? M].17<0^4K!T[W1G9%#:UL[H>@RZDQX(GK&KN*+-:%9.>XY-=1AAOGRK^H/(B M&PY5OQZZ_+N9:(ZU0L4X$S_LF.-0<9$-L!1(Z^<%$NSCP1_V@HTU=&>2/0YE MW YRO)64<<,[UJ1VYO*MYC*:QSF.N+^U6/,Y6,^D%P2;IB'8?"#O0_/&;?^"M)EA)%ZN*60,-L(UU5-=T6$G. MA_!SH7J6S--+-6R0+P8*SMQ.P)HTLU?W*^#V4O>\XFT_?#S\'YL09GVXP"_0 M?[H6OG7]-6N,>Z OO[I(@8VN%'#2$&16Z+6-\)61R2;]<=D7JZQ"B0R>\;\3 MGH\5/">QL.OF9<<\VV">!6E/A[F+SRPUN&7%H U- 9;#(B;93YE770NY79 5HI/+JZE*)W"$%'&?C@QWA M!I,Q>3\[B*'E=&].\=$RC1I]K%N]!YEN]5;8ZFW-M'EKHT$S C:6:JICHCY/ MD6QP*J38]:J*<75?/"M [ 4O+GKZWY;ZWTEZR?OPUN8H@EWYH4I,!R4FN3G. M\)-T> EWTAH,#KU!.AD8>SDM-&]8? G4_I+GTA+&"65__TBC4-&?>(D?L#@ M'^%'+"0RB*3+/#^(HN1;&+ZXA;L>X.!9R5T+/;R:4J]AAT&NBNG!>X(&7K,A M_R8J[0I#KH$; R:L=BW-:32&_PPT(\&V3$=>KL:.61L49A:&I ,=>3@<#S=D M#['8(+S;'CS)8CO0D66@I/,JKL,9!N7O5<+TX:$^KV MD)VOM.OXJYW\%0![,;]CKXZ]'N2%6-2+GK).>/_'PK];F29X#NU;S.^%M ,[ M:"-I7-*+Z!V+_CK2/*Q1R7IAM.F\Y_;U<+5_4OQ"&.!YSXLG@=OSW&[0^-[0 MTPE[_EUA%#IZMHZ>/IP+WAVQR%HVA757(L5Z=GR29X-&*OT^AOON,^'OY2FQ MGQ.KGQLMS0G1T7(/:&E.AY:1N]A1 M6VFYN4KO:-E66FY^#'1!P'L' 6.59+FJ6KC&_.>=$:6>'UC(+N*!D(#V0F]S MS/EVZ,MN-MTSXE0G[+& =9S:<6K+.=5G/3>D+6/4O0U1?\BSR[1 W +L_;W) M<-G$?-X5(QFA2@A]N?.ET_M(F]\WR#AV%'D,BNQ^#7C[].^)&EM]R\#VGF-.AGH9.#9R@"ZQ4&P M4R*P$?CP=C;SSCAT,SWV1PU@X=LP"JFFP%2( M1M3X8DD29_H5'@,!)N/57UE +%E_T\[2@2JL$W5E?V$1CDJ@8LSA(XVRW6I[3#;NNPVV[?DPZ[K<-NVXVM[;#;6N(V'B\ N'=E./N;,D9X MK;LV">Q3$*ACUAU@5D)[Q'G.S+JO+-EZQF,]/^B&?F]_8]^4XXB>0\&,2WM> ML"D@5%>=\2CR[?6"C0^6CC2/0AJ_%P:;(MQUU3-K5"_68P2?0ROJ\&C$+]',$S^#C+KZW7)Y^L="AA57>' MP-JQDQUK\^Z(A=C97 ],F%"<.*F&A=;/"R38Q\/?=7I>](1!K\XN6ZV@2<\+.V^FC:0!9\;9 M?1"A]NGI"K]-IKD2X]M+_YZ#!>WU/')'N.+.3GM@RKC^$P8M.\K<$.I_PFE/ M>VM%&V2WC97RFDG[LA)Z+F__;"LW[K4=;13).\WXV]Z>M+SHHQ."YR $=QI$ MV,E )P-[) -WFI;X]#*P4:]F*_KJ?O.< \>"6_81O2@=BEQQ;'D;KM%2=\4+ M:Y2GV(?7O[;X>)RG\<1TNXTSW4I7=^VMU2Z'K%%2P49Q_,.=[SZT2?C(>X38 M1M2O>?"Q'CR[#X0=:-[XC?@'T5)BE32QJL@U[#^V1:JRJ,Y*I;, MTTLU;! N!MK-WFV4*P$K0C:WN!BGE^DX+5LH/WP\_!_;IZ'F"OT(GO=3A>VJ M_%Q9O"C4N.C-W["Z6QU9+V"Y4M\0[Z%OZOG4^G"!7R#6&/=/=V!>*-X?7UQ; MEUE_,APKE:]]<]B"8C(:9?E8LR)<,TYUR-[*$OT7_51*J?7F^%\?#_]^4]_( M/+ZG7Q$O'/%KS?CP/6[]1AORTD^%WO9$:99_GPW3 E\B'W"A)EI/P'K?#\4! M+O3??#CA^37>!SN(K,DH0\JI7 !A\*]Z/W^*_J0 $EG92*\621F/N>X^!0(C MBQ1Z:=7#X8)DDNN@6"FF^F.1#09X:]!3OZ8O^[(3Q*T((JCK301QL-!*LZ%( MKB-!$6.E!-'8>E-@>S.\/5G"UQO?FI#ZUG.WL]0E[T_,;,?Z4OPN[T96=0(I;9X:76LO0W6C@[8)IP]JHL''X"CFVQW*/A(]?M\GO^N M+E(P4M 6*54\W*I4EH42&=SR?T'KCH%/C-XE]=%5W7G4!VT=9V!&#L#CLO-V]' M"]E^ 40$HDWTB5I=*E'?2 %NQOA@'8*T (2E.0?]<&8.^JTP+"T$_L"C=KG- M>[YRWGOGHCRA9>2L(-?F M=IP:U1Q5UQJ(_R+(&C"OX,@@1>#'@KTYHG<';( M@;_T>WUU7GYAD7XBRT=8S*HJW_%:B^@(_@)KKXA_E>4_=D6CFHJ#][-SBEJN M.YM3[FJC98C *(-, Z,H!$:Q9D!1C%N*Q$(CI*>U)Q:[Y2G2%6R3%$$B5#&N M[HO.-!A2@A<7/?UO2_WO) 6K"=[:.*FP*S]4B8"DQ"0WD03\)!U>PIVT!37* MU2"=#$RD*2VT\%M\ *Y[^DN[[$L8)97__2*-0T9]XB1^P. ?X4]F;T>32"6 MO\0GLUADB?I]=D4P/@'O*LVV^(..L0"G*^N"7^J9,Y,\1P<@/1^F";@90X,L M;/# &@!B!];G\CO#;&Q=J_%LP 7=W.LJI@-:5DX$7 $D3R6H/U"SQB?@>LZ- M=0GV238!4P4]$KVM,R$XC.94OS0BL<:=AJ7+3"\"K1YX"BAC8QJ-T5D#-PP4 MM)ZK78! 9>A*76M. ;84K@$!+#?/UC+IVY',#NS<&>GI$S2 M(;BCRKAZTY'B#7-0([[!/@BE9#EZ7$<*BV+"-8\DL']2J8%67^ =ZM@__@S4 M293A$ZP+UG2HOX_;C-]%?LB&Y17CBSR;G%\8)QA]P+XUFL0@;7 EW J.6Z!F M:8S:\*VY#XV1"S[FA;*-2JT_*JS)$)U,?,WB0O5QT>>E*:P?#[N"W')@O<45 MUDQ?+ZD^ DRZI3H']$YV@(T-%FN /K47L/$AS*4;=T4+6\ZUB?";1YV#L@YQ M:C9:_/P<>!+UD;819D6NF( >!&X=%F@N@H3JF;S:VJ@$43L*!Y9UJ+773?QZ MP>7FU@C<\S="W8-@9N$[I/M.A]8)!IBU&=>KC#=P@[6YAJ86G FPF%/PBJUC MHSX^H98Z!+HH-Z,45JU&PZ, X\_A<9;(5FQ/68 M@W;Z!AP//3!L___VKORI;6Q+_RNJ5%>]I,L(RPO@9.95$2#3[B7P(#WO_38E M6]>@CBRYM(2X__HYR]TDR\: 9OHAYG.P[9TEW///.UO'8?0=^@A^%B5XJY9EEI8&;R*._Z4. 2=-UV M^1"1)H&['Z]L'"@N24A^&PNVOB=TY&/FSTG.1W.GR$H37,<)6#:_PWZKYSU^ M?CVWZVQL:LH.JP[7!PFA+K,3&#GX S#R[J-'[GEN;[-;LY:6>0(OY9XF_R]@ M4B0IF: GJ%H_@:&RKK?RX@JRCD%8ZBRTZV'/IVPMX;:G%/Q0?JTSP8DNIP_^ M 7B!#SW76Y-F]E[LM1VW-SAX JK=[E'O:09[]"-1[=X=SZCGVG66\^PVA+,- MX>P6+JWW."%]6&4&K-9S BJQ0Q9=9V^+C#R"=^H"#, .>?\@X5J;3_%!PK5N MQ>CF1_A,E9//+ 'G' +#6)*&]#VF\NE5H*CKYK6%<.BW7O^@U>G>HW'-]I40 M-K*UI;)U.&@=#%Y&M%[G73NDS.9J3?L:"0\.>ZW.X 5)PAHNBE472+MU<'3_ MYG\[Q$3QS*?\$^47-W#*=ZQLOM]J'S94$]NX,X-!Z^CP!7GT7N=MCIYS("S< M^O+T(D*CTG!,V$;X?*-=)MNKBA>KL99783]O?E6V\,R^/3QH'1W<@\EOXZNR M4_7>S:'X(0Z%AXR#7G<'3\4N=>LU$<'C10MVRS.ZYY7T+*)"DIH()R$LK[%6 M*YICIC,M/2E+K$3I;3QC+)/U*N7T)UTWQYD\),)#9A<;X MR%&1P6@S"YAPHU/G, 9\;AKR(&($&6"]RGHSR2R8*D88N(I, D)5SAK',0&Q M3K (K[AF/#6(++QY C/4EDHDJ] FJ0]&2S'.BU2X#B;*:3 R2U _$K!SB@A_ M;K"4/&QX/R(F)#_XJ:)2XLG$2[]&3QS<@27)=K5:[UHNHAER6./NC,**7 MVHA9\UHJB:;1,#Q=U2"4=B\/I[0Z$^>;B ,8BRSH7A-[L0T(K_7@.U5 7*R2 M/BMWDV M_0.WHR$YY:HI6>"!F_N3=]BQRGO47M,J_W1H@7K03EY_;ZV76=6E M?LGL]L?CM+!VM@6[F"*.-D*8]00>BV?ZIT[7&A_,;$'L:E^UC-WW50N(=Q\! M.1Q8!>\KY*-]Y/;+^"@E)$LVS!NXWN8VC"5Q4"K.WX DEHN?JJ+(X.PQE:UH M=->NU#:98/7N&0&/U(I6 ES>J'6"WW.[98$N2[\E)E,_MR#%M5CC^D,P*]*Q MKORH_=T/IXB6[H?7;R_51-9>$&^+7-9[[@;^=(VMW)4#;N+4/_0!G]2$ZTF@ M^JY7/M_C),Y"LEOQ.K(!P&3D+L.:2UQS!1R,A:^EGY?.>@G9;LIXQ'06)7,A MY =:CF>1'Y=KC6SV(/XRLP:M$.VFI,GN0$G/$]1[KEP4B^^J7(*CR5F6 MG8$:QJS<_TX>8TDS*]U.%78Z9JZ.0?C*/3/OOBIJ,+"AJ8 MZ(ZMH!8?\D#5UY6>ZA M"F'%5I3.?%HI#&$>&9RS("-Q4G T[=]8]@93#)'[ K[E5Y;W%@[AT@6>L%N) MR])0T]SOQ?4D*+9LU973*RG2Q&1,:;DH5"3N8;R,V ^W;9%X,VN8%S>]B96] M0U8#_$G.;#:+^];LP"9V "GUBFK?':3."Y%HPE;:E?V9)3DS4C9;\T1;,_6_ MHL^(S!_78%T9AAV*?8*S5$Q\3/3(5):.>C:KOYG5#V/BZ<5[87AA,G%PUV.!D0=AE^MD\R\6436W-*VE3%^H_5M$9ZJB7 M?%)\BC9.V'DKR1&_U,9/5)YJT4OYZ&[*\ 9J=I# M7DL&X&Z0Z ,>(9.=B B M?YXA'0W\";.O(J6_$Q,(NVF*A@W]!7\$SIHM):!LB#@M"J>AC$Y._%#Q/U., M@B_G[S* '_(_(G(]2OP B&B14N'C&] X0G,..].%',8.[\6L9 )%(LJ Y8- M'^]<$2$VC!=_:U8#0S9Q#$N/<";?LCU30=%].E^XK,FX(-R0(@YD*^D/Y3V? MEKSGLT7O6<%_-/0(\_!(SU:,54\'?" "M>"42KXA>927@+I@R3E*JZD^TB*^ M]>?W%/43F.@H#9>MO[?6^N^.I&!,"]:TB!6),H;RIQS?PN :7,P6F9/:DV7@ MN1:=0<9Q*#)1)&#$7^M=P[07B=I(1"'H;1-)NS_QZ"H&,8['"9Y9D7%CC;A$ M(%B5(34G^F,0DKB5P(%$O47QP3#-\@K/>\]@!'D)*X?S;,PJRX(31-O M4UBU.^.LN&:9!9FS5!R'4&AA%T-;DA2PI77C2,P3SNJ$UE#*%/Q,6]FR@IU, M[@S*\AOEA?C4XBMUCL*Z]/F[YBS3V&T]K6:K;F"4.IQ03)1RE&# H58Z$QAE M1-K'=:Z0:4Z):T8Q"S3_;*K/OXI FALH*59 ^U&O5J]"WJFQ2/&?2AKA!V E MT15RB]!+Y#+C4>%@1R(6$TR'.>=+3P9<1>8 ^7 M33E-PZ<$S5PT:>FHCH1S MFR9$-BT9 M+OMCR"J=8E-O]A?-M2(1O)00F3+,K@3W59*;%#E9A!QP6=38E9FR<9I M,EV17L)S.9&)OY+BMX#'9MCJ296Q\<4A\T&!H#XH"07LP 2""S5);778JK%; MEV>(?DA41V\'4!VD*TI>3J_?>'NVMT?TC&,X*RT\>M?84Z>E7 ^9=7LNW^BY1%SEL@NR UVS6IC:+#U2Y9F9I/,R& M\U;J<+OL_AV[%7\3UD5"]?R[0+:8JE5\8C@G^D9=.AS_RN\EMH/VKNA$Y64T<,FA::U(047=80"QNWC+JGPL X,F-#%XDTM MB1MN"%2@EH&L -<9QCJWV%J:MT*3@IZ% #>5=50/M"V+8CPF2B!*XYJ_2]O$ MBJ!0"FB$P<[4V"C:,-%G2L=$JYT?1_9[$62LTYP3BIN"=)LFC[B@KG,\'B?4 M\R::4R:.AH X VOM["(I.^5:Q %MF)JS38 $O_T+Z\.^[=(1.0Y <*@A6766 MM4EE2@U3XMU*%V,RF9JDJ2::_]8;5=%*N!VLEG+!@*047\CI=PZ^PJM=U;/M M6X(YNPB;QW($# X=X3G@&A58,R8O:ZS0'?'W:&_HG*DR'4(U3G2+O;)9XW>!\I;M,H,Q"CO$2X0-WA;N$(9S?AS/03KH80 MJ.#T)HD($J;/1(C9Q\#$"CEMSWGNK(3SD=EDN&40^H(=:F6H0MD:W,$3D80J M[Z]7T6>KDWP'#BW!&]185(V85;@/)\@L$4W8*N2E")=J%BK72'_,QUX)4TN. M&G891<.ZGG!\:C9(Y@4_AS]3]E=>EJJ*6H7%K.W/J2@$] -B7!S=8Y'ON$QV MO*V@,' 6.)P2;JN4JDZPY=DXHG@>; S6,.,A87M\KM3O0C_56[K'*2S0N)S7"[J5$I2^>J+=@9_3*6,Q4P,C1O;AS"[.!1E;(N;?FRP29S0*J;,(Q'^%-.QC)B@O*S M_I2&56-/P%^O4VJES!F[K *ZL73KQ/\&$S>P&X=7K(PYO&/]C"XJ'\?,*2'2 MY:+8:01X-H&*6WRZR(^!83+<:QE^W)X\03;N0I#KY3!KKI*;ED-;A\Y+*C@; MI:H9@&4P4JQSECP8Y@&*KOY:7K.M>F_;VJJ?H.)'4_28>;CP5%PD(&X*"G!E MH?Q^+8)K$Y,^4XC 72G6/V=O6A9&H+/H'7[(B.FQH,:3;-=J&"GK2U-8@99] MJ-D+E,6,7S,.O TJ9&V+\V6ZM9AH4RF":1ZJ^TQKW<#^%LTC4IQ.9L)(?KW,1; S<8\#J^&<2]$MEE 8G MRF7X%5RE;20(K ,1)6C:$G8Y9;@T:"T;K=7? ;36FLA,^CV.+/%,1.0=E&1:8R?93H2_!(;PAK\EZZW")) .KG5T M4E%6(X8*URG5\M 7OH$UB4!5MM E\%%?<0K\[Y,AXF>)Q.GK3K[C,!T74W13 MQ\K3L'0;ZR0L(:-/8%1A)GUBLG+_,G?"*"EX-<=@5U&P!(TDL>)C\&2H];"E,F'>:E 16H].=%PRUI@&B'1*$R(:C8YZ9K8-XEOP-*05:'['+ MQ1I]ASSM+P3#,)<$1N@D4:>T0EJ_+2B-.YN2KIB=X'9Q,F" T7GB6]O4#A MYH_C&,7E4G#)8>Q\0D'VVGN_(99"I1)QXE=G)_2Y&*4%!L8Z1US<\G!;[W#; M;+U+,>88RI [?MOKG29DRPGR^B3#!ZBHPQ M."S_XGHF&.6B:/Y+!AG,P#FR""J2@U_(LBFH@$@%KNYM:Y*/QZ$UX_P@?FBN M9UHNFJE7D>N=!+ AMNTH#&$=9!&;BYL!IR!GLBH4$OA#I/[WJ38H,N>8;C@9 M5+P,L_7B)UMR4O":!=N!Y)J,=9H%%K?855@6Y[,.,J:F9(,Y8^?\(#2R*D\* ML_+/G PC+81WG2O_!K,=Y 4P_-!Z(^IAZ=&/\Z5ZYE;%4*-!&JG#G M096-J2YQ&@DU"#)WD, VB<5<39!C)?1=_:!*G)9]GLH33B M496G2<12=H%IP #5TKI*Z(4Y(&M,R3,N?)3Q!]0O1MLNF^T.:5Q-;"2-: MXF-&H7B#;H^\57_*Q?MO\0=O[*^]>8>?ET:F[@7.O1CJ$3M43#DI96-)#E3Y3*F V4-6*9R*'UU_Z!UINTT)5 M9.#\0$6?WKFSRC/A-Z(908%RG_/DRWZT50L+WF0Q+=A28*##=%H@CL$B*.:7 M_2.SXJPV; 5?($.3%,D@ +LTNLS?C:Y/)N#V$>P)\R/$39/A?W'VE.Z42":X MFG4]1,;0 G@ M5?!&I0&676N8E((LMV3=?-L$.(J8;*9 M:THRRDLOF?+N1$_*V]HR_C];E$C"8$'S3V#1)W 0E)R>LSS2[/DS$_)0G[WE M=->BD"?6CU<(.V4'9[RYT?Q=2],#< B)QWWRRK&3QO!RPNMD2(===7X-.NQ*]3:)\9] M&L82!R--)^<<@5]F22]5V'E7;"@.==+.Q277E!T&.5NYXPYZ4=9Q,D%VIKT9 M+\;A^;(G:$BJ+LR[@C/\-')RE(NCL2^HT3&7;4?:YW#1?Q4<5UGX0>M^,UDN MDS]D_NM@>?[K/D[?P9NMRYIU>NKT/6R=-^!Y7AQ??G&&0[)Y.Q_.O_QR=ND, M/W\ZO_SC^,OP_//#?>S!73[V$[3^6=/']ESG=[ *(W8W!1J'8-SOBK8\5I ^ M*YMY=ZA98H0P!X2RU QTB0AV@>@17(_),BIW?)J@HR I8,KR7K M6K-9*#'/!K@M'R-SG82=%)(;/174MDK#3!6\T8IB%9D=B*/*V4PRK8H\9T)B M+EEK(< /?BWMJ)(WH9BBC)=2.78J@.Y^6 M3GO-"93/7:MDB)#M]1..5%P5W8(09'-,5'Y MQEZM-\HN7VVJ*#8IQ9['D1\BK-3/^-4 M7./Q1_/O2E4+G#$,\JHXSG$4F10> M/;/Z5GD'P##9^;7DN3;8CP%:>SH^W ;X"XGMO%)I?WT[7*%9WQY\\)RWGS!' M^#EQG6ZWN]?I#=J'O7G M ]7>OO:?2_P?N]_DXHT@UV#(P74"0DV0G87B=.JWZ4XKU%24>FX:^2_)_J:T MZKH&Q='V&A1=USD5$Y\RTG_.\."). 1U\WMZGC; MNUT]U_D#2=FOF)G> OK\>-NT=74I9IOZKG-.#O+0)#UW:(/B%1WM?\BH[>%& MHK:=PRV)VL(ZC/=@;9&A\SW##.8O=%(.7##";L+1VGV #^DT2$B./S2*#/4P+G:?P M?X%ZL_S8I8_V\V#QLX%[V/.6?MIV'_I9KWOXH%^N&NMASSTXZ&_\L9[G'O37 M&^T^+6]:T34>:\ >'>$S>MQV/OJ7>\;)?E1.YZS>=V7?\ ME9TV03Z6JD2R,&[FA [N.J DY_),DC+Y3*R^^G!N=-%J%H U_63%O:=@!GX+1N+77JB"S\Z'%QJ6 Q[M!(0MSV?9^_W]V]M;%T;G7B?? M]H_!-4;XU;X(KOUT'WET]KV#HT&_=[0/H_2\0=?K],'9/>P<'1[N!X/>0:<= MB.]=S[W)X?!U7>^_]OVJ=?'4"J&1A.V3A&.)R)65D4(4L M5<@PSO^1.2>R^J>253K:^\V*&,+<]KH#F,P[F45*[$@MA_O>N8^7\ONK_A_! MD&F.[1,?VW;OH#_H=-KM3N>@O9]/.YT.>%R!]W]P=/>T%N\T6KP1A[U5JOSC M//)OLVU6VK_Z,=4\'W)TOM'9C<[>S4/*_\1#VFX/!OMR(EY;'D^OW1C=C22@ M)'P!E2G+2(\58:##Y?*_%M'BF1[T&U+,]ISO9^W1#/KZ&BSI8_9 M4A/ T!$+5?*V6 !V88&7K&+GWEO?*G:F_W6_8N?C()E)0(Y^_A4C:Q4@I:.P M6%=^.O)!C^^=?X_$7#T*[?V2ZGR6W#$%S9U&6S?:>BN.=F=!6W<:;?VJMG2% MMEXLR6VT=:.M&VV]K4>[4[6M.V!;;XNZ;C;T\1MZ+\N:R9/6T^7>$?&1G;AE MK>MU^^WU]/.@?7!/_=PHRTTKR^>[\3"8-OQ\]?.SH9FV8=)#@C\Z__EX^;LS MC)DTV3E-QL2L]WS8ID:>GT:>KTY^^7'E^8O_/8F3Z1RND1QI.[&"97PCIGXC MX*]&P$^.?V\$W!+P$S]"&EDRI7X/XZ_(NM^(^ZL1]].S3XVX6^)^BJ2B82/M MKU/:?S_^V$B[)>V_^R,1-8+^^@3]XO*L$71+T"^PH6"<-V;,JY3WW@\EZB?$ M?GGA7PLF-/69=.04&U43W.DM$DH$@62M4EPIU@$)I-R_>Y3@[U.)ZS\7*VC+ MW=Z/*E7FS]_U_N=G37;5];OW:.T^$>X,V=!P7Y97(&_=^OW,T>O%_X]-$L=V MM#US)D4:A]D-$[5I0';']6CBR+U#?/ABRISHV(%K.D,VE3689:F]M&KU,]*/ MD=T#"-:G^@,@L]NL2+&;BZ1=9KHX[T@'X-?O!> Z5\BD6)EIS4B887XYFC&, M)7DD,N%@V]BE;$4\BJX]"F)FNN?(6X[XCLTO%6[2;L1=QE'J3L[$OFM- 8G1 M2[/8#KJ&.EJ!9V.$7<+<<+01YH:N:0;ULLP-+\NO>S7\G\_'7_Z\/+O:&>Y\ M.^_'Y.G4-T$V%%M3[? /];&\08HQQ"D3HVK :I()KZ6ZD7T30+EA!X.1N/&C MB:+?(OVB6F2@ BY0 ]'S_"*_2:CCQUI<&/W=HL+HN]UN9^/L$CW/]?H/8]%8 M]=B.>]1[&,/&JL\Z;N=H\P0;O:Y[N.9C7PW!QN9=J2?$^3V?(\(VX%(?8K!] M#E4]^<;%Y?%_AE?.Q>79R?!J>/[9^>/L='@R_'QVU7*>_._">P3#T'/OR'ZV MCVU9QV'B7"7%WWZ=2FONK&;6:_$S;8&4UU_DC80W$KY#JKI>B%?U@#L-4X'] M+9RW*R#-[QI[=?M,HL9>W>+-:>S5;;17OX33)+^9.[^)*)HWUWESG;\^@[41 M\4;$=TE9K[)8:QH]KZBKJS%2E^))=J0+P"8RR(/E&>3]41+,X3\W^33ZY_\# M4$L#!!0 ( -> :554<*Y =PL %US 1 <')A>"TR,#(R,#DS,"YX MJO+P!>1(D4081.CAOO#S?.">-WSZ_>_?I+X[S^^73';IF;C "*M$5!RS!0Z]$#M%W#\0/ MU.=LA+XS_H-,L.-\-D)7;#SC9#"4J-/J=):?\K-6^_2HY9VZ3OO#\8ES]-$[ M.VW*/CCN=WNGIJ?>/P=EQO^/V#MNNTV]YJMDQN YN0(>"3 MSG&G94"GXDRX0QAAI#I&Q=E4G#>&4H[/FLW7U]>#U\,#Q@?-3JO5;OY^?]-FKK'K=/# M5BR@X4B! D*%Q-1-%'B2.W(V!I$OHQXW]6.MI^6TVDZGG=;DR40LK>9#,WS8 M0%A*3GJ!A!O&1]?0QX&O1 +Z,\ ^Z1/PE"OXH,E>:)!Z+#$?@/R&1R#&V(5R M@_'Y'4*:)C(:,RX1S4CWL>@9:P671JR!0DKOF(NE\5/=4L0=R[1O@B^%OG+T MU<%4>(UF>:V!< 88CRMI3LN$VJ,[52Q(^6=;N7USJATNWX)<]S'M'?VCT^XX MA^T*:E?Y87G=ZLJ)Y39APWRR5;,AEGNC#;ES:Y4OV"3-M2AI1OY<+3D(L8#N M_8] V5) MW"2C8-'U]..F$@'_;MZ36%:S?]X0B@ ?PK'9Y8Z/.53MN!(1:I4P1/_?]]_% M?M7^*Q$W\/\@7[7[2H10LD;OM?2S>HZ(=]ZX8FH7^H@'RCI]_^7IMG [ M833/96+@&'INT^>6^:^-G/G>U4%&$FG13\UE@26H0(#W0#^;GY<]/1*.FA0( M+KE(:;G%LU4I31W'35>,+"4\1.$JCHP@>A?CH?:+A[WLZ4P/_B+GJWA D409OE-)% M9"NMA^O1NJ"E]M0F RA8_T'%=&/CYJ:L#=Y*\E$YDN=Z$.NCN:;]+,[GXHJ- M5 ^'J@V9P!T3VV&\0(N5^ _K$+^@$&F->P?(H^:AWY7,_3%DO@=N6%HXLNM413M9:,)0B9#35-#I\PS+@P/K*R2\#H6D2%8C,D[82 M=:JS9B)8SUN^2 25]%6RHO'!=%E!)Z.!1 M^:Y+H HO)0%M5+5;RU1%P)JK%#2:8Z,8O$;TW6/^ R3N^= %-^!$5B,K5]Q* M37N9FCD,FN/4B(4;3/B_L1_ /6 ])";&5Z A7][*0V>9!XV##!!*(]6("14- M> #>E^E8K[]5.%B6M([^X?+H1P@HAJC1L*OD=T2D<39,]=9*QV.@%9>.(A0K M'4?+=*30D()#"W@UXX91DW:H87CDT ?.]9Y7W:A(SDH8*SL?\MAA-,R&##T) M8GBO1@29_EYBDY.,=.@P]E39@)^!JH#7R85 M,XB,J&W4.SGY=0R!0HQ:C7R9HL76JB&EJR*=3.I=OBJ"WL<_U:G(F%?A>-:7 M;RV31"!6QC))>FZQ!+T/\>I$36[5HS(W12A6F:]"&"M3I9/\.C*TE+-7IB9? MWLI)B>)Y!Q_XM[3,^,A9>J^T3\=_XLK@0VUU)A)3[W:Y+"^L:>^Y+<)S$XU>A)=99/P+MA_";0B=2M$('^U;G- M^L1:JJV^4KT6MK!&++2.K4'*'!3:@V*#:NE)^<6O#<6/-<"MWE"^WK:/&%:> MDPEK/@D@KHR#NRO)A,C9IB@OJ\?*?J:R5\!^*@;,U49Q(%:\]X4L1^;QP]A, MU6WY08$.JP]D:H/E?" D/M2YYS^'&W<(7N"#2OB3O'Z!IU?,/<'T[\Q]Y9C* M:RSA1:C-N2[Z^EBM_NY0:1%A:RUO8.^9!_[&_.<7V&CUOTP%L\C_(H--U2)5 MF%AV1V.WKE?HZK8Q'6G;D3$^+'EK\YW(_E@NZ0$R7=A[\XI(DWD<%0RV$]=L MVFP>=I3]=JQ\A,MK%>FOI7LLO4),F%)3C'C$#]0ZH+H7EZ9AZOJ!!YX^FE)Q M/@[";K,^8$[55-0X0N.L\8YLNX98G2I3:LUY*;K@3FG#T-PR%)L6GM^9,DX+ MQ>894!&^::VAUZWZ5'I#B=5:\%8/R11?5W^EO4^N5G[(O0Z;.>)6MC*UTP68 M/SL/GYJ+9T.&UPOG1^K3(Z,#:0U+>OS_^%= 01]>MS!8CSZF]S#J 6\@W%,/ ME)>?-]1S:)@#,,\;5C%*?%^_YHS%S-F]9RH($N8]FS/MO(!'OW@D J6#R$!? M?>4L&)\WPN9$PJB!PB/PDL-\SSPVPH3>JF<::'Y:9J9O%_)Y".$;UX=^'[2) MQ;TJ$-B%_CRQP16CM]0M[D6FV2[8GIPX<4NE4CS*/18^9"J#F(_+9,TSE MI6]^@W#>Z3[V1=+KS2G8XG#)6$N)$7M^59>S\/]?1F.?S0#,CO8QX.Y0;6KM ML[02Q"YXR37T9.K;BXD*V-JD&\:[V(<+UPU&@5F"E5)]Q!8'[)/_@*>W;=\8 MU2^V%=XE*'+A&4]7.LO&]=@'+SS<6<:/>N%1?6J4H$=DR1$-[XP854L9GY48 MSSC=?BCU!L)\ 6B?:6\#W9'9]0C\%I0'V+\T!K)JI%?TO M(UK!'RIV?^,IUO%V9^6JO"1I4K/*!M>$V[@KA'?WZ@@[*C(-.N;.OW+C*W0:F MZ>5LWN01S_0M4WT,STB[I7I_&Y[D)H? GX>8AK5&H3NK=QN/IB_?0?^1#O N M)L!59$BJK4E==G4XW1T+MSAOXS+/%CV3R MYI4@%V@7EH)XF;Z&>+F.3LVE@SM]?4=PC_@D/,MJA;-4PJC2Z5^Y';QAOL]> M'^ACT%,Y3[F54\NPJ&+O0Z[>D,%>_(D_**MG1).G%_&(%>$O? M8KQ0HC_N+O*:,I*[X"MJUA(7NOK/UMS22R8DH_=8".P. P'2ULNRTKO0TS5R MT\UL>2.H#8R!)\^&,YWE!3VS6]KQC>__?%^[O1Q#6R?*IYI?IA(XQ;[V$:R2 MX@OJ7<,$?#;6S2LFGA7!=G7K^98]]M97J7PENSJ4X>:D"_JL' #ZMIU.!9A? M&M;-:ZOP3Z=]?O=?4$L#!!0 ( -> :57N!I;-+!4 ./( 5 <')A M>"TR,#(R,#DS,%]C86PN>&ULY5U9K($A$& 0X:U#&_?K/ 0SS T UT=1&*$"AT4#G\54>55E9/_[C\^%D M[R/.N_%L^M,3_CU[LH?3-,OCZ8>?GOSY_E=P3_[Q\W??_?A? /]Z]O;5WHM9 M.C[$Z6+O^1S# O/>I_'B8.^OC-W?>V4^.]S[:S;_>_PQ /R\_-+SV=&7^?C# MP6)/,"&N?CK_@7&O6/8)N+8.E,D*7)06$DO*"A&]]_E_/OQ@BTA1\@2%9;K- M8H+ D(%$&R4&)ZQ@RQ^=C*=__U!?8NAPCYB;=LNW/STY6"R.?MC?__3IT_>? MXWSR_6S^85\P)O?/[GYR>OOG:_=_DLN[.1&SO_ST_-9NO.I&^EF^_Z_?7[U+ M!W@88#SM%F&:Z@.Z\0_=\N*K60J+IHEX (D__YSEY_\ M_-W>WHDXYK,)OL6R5__^^?;E^2./YN'SN#O$/$[C*7;?I]GA?KUG__ELFG': M8:;_=+/).%=-/PN3RL2[ \1%]^EL]8?#G"GYYTX\.C"9Y=.YAC M^>E)?0I4Y3,O6:7LO]?Y^?VO;*0P2<>3I=1>T?O3AU2">^0(/R^0OGHBSC-* M)K-TZ:9)5>9L?O;-28@X65X='7?P(82CT:MQB./)>#'&[OGQ?$X#:!2M<"IQ M#=I$"TJ+ EX* 3$)4PP+A2ES69*5R8ZX7(*@A"XND7#ZB/TJXGV<++JS*TNA M+P5^,Q4G\MV!S>/;]:@R;8F Q:R[Z$RT3'PU@,#_&O()#XPS#A!R8D0Q4(0Z=*@J8 M*IY%5I(+K#T25A-S'S"(1PN&!@IHAH?71S@G*4P_O$+R3&=4?3FC*)C(:J:&-)".L5]:]NP?'(;^L]$R+0WKJ@,!@M2;,HIA/6D(ILP1*-* MBJDUFB\1,"0?MX%FKYFRC87;#)]OYC,:-8LO;R@^7#R=YE_^?3P^JEG/'T@C M!CT7VEN@_".""A1QQR@,%"Y2B)GR&<,;J_LV>H;DU!IHOYGH>_)E;ZL87Y<_ M.UPR.^+D2R46RD1K.JJ!DM:1!&F&E43:F7EW9%8*&Y,D:P*&=\-OA87& M\Q/6_IA-T[F=8C;QR$!'3W;*2PZN%$-$H7'.>)=XZXQG)2'WT;]Z1/K?6MC- M]/YN,4M_'\PF),*N6J7%EY'BR##&#!A<(NSZ?)W_S=,CG%DA54ND:JX4KQ&FQ*2!# MKECRX#,&*)*'8(MD$5M[NQ5D#"G6:0R&;87>+E7/>5S9#Y,W89Q?3I^'H_$B M3$;D9E-)Y'TE.H*B3P4\EPZBBI$),EW,-9_76TW*D"*>QBAH(?R6<[QG]F@9 ME9$C.YKC 4Z[\4=\.4VS0WPUZSK*TUZ7]^'SR#%IM9$68JBAF5$&8E$(T?!@ M.<5^5K<.CM8D\3[(T8\4.3TJJQFB+LQT4J:_0@)&A((Q*3"&@GUE4H+@$\$^ M>BE55 8Y-H;0730UY'GDC5-"4.8:2<2@A(P05/3@LLJ2^122=/VQ-Z08NRD2 MKHZ%347>#.[Y;%HG-'":*D')16ULKI4,SH-**.K\>P9* Y0/ M03GA10_)U@WD#"F\[A43K532Y^R"]\7Z6 2Y=48Q?F04[Y6HR!TH9SW7/F+K M=86[[-U@5L;:(V)+!31>&SM?O95!">TY>!/(+R,B..TS*)TQ19F+,@^XMK11 M\GA$H>LOGX]J]0UI[<*$WAF//%"0D:0'YCGQF"TCK?D(W#@,-G*G60_)Y%UD M#?$\S.=?R#:?I,"!XN&4T %W MF8.2F"GQH?^A9YEA,%ZJUL/A7H0-R6^V TM[G;2SDA_#>%++GGZ=S=\17>\P M'<^7GN$%QL77=R-C@L_26&:_""9;#H0O'6:Z-;Q]CWI6U(KK4=:'K1 M3!\I)\5Y2K-"^;63E.FJB ;HL1R"0RNTI(]%ZPF*&].O9B56%U;)T),8+6-@ M'..U\@O!*R=!F%"R$YEBV=83^'<2-22ONBD6[EEAM:$F^H#Z>6UH=$@Y+H6Q M7A,=Z) \.W<@1;;&Y:2RM@]<T?O6]?SO%O2Z MS(!GY13"]&G[POZ[GM-GA?]:/#8J]:=Q/SNS""W4S0DQ],&(2M+9=IHI)D/^@,77Q<;1K+(9+6.4$*DL%()!\Z6 DEJ+4,1 M(8?6 =Z2%QQ,R F4R!I"5A&$E=*4+(F] MT)BO&TA9$^70+\PW5OY5:+<0?#-,?^7I5V+Y9.KXF(;;5__R#,MLCN=$8_?+ MY\4\D/C'TS#_\I*$MBQFHV^2/"?+D;K .7:+D:9(40?+(,L@:S5^ B?J_'.M M>]4Q68RMI\)Z9&=(D5YK,.Y>_^T+G$]'%X7"2B9D69#?\9IBU\ H%)8)K.2I M*$:>Q+9>E+I&Q/85;AV2<.H$U@O\B)/9LHK\S!LZP56P)4'Q2);#"%8G'R04 M3)XKH8,TK#KN%I7?C^>A MDI'9)(J[0*=(41AE[A#)KT#.0=C@4M&V=6W3'20-R9*VA4=+7;2WB!=5IV5F-M9MA3[0"'3*@J<4 406 MT13MLM?--R[<;NMW'+9NJ_P;IP4$$%,.;30*)'.,\A5R=)'L&Y 9"[X$I0QOO;/B44R(# 6;5X=N M&TWVZI8$LQCHT93$L*4M(?;J[A%/P5-!CA%EZZ%WIUO:;7PR5#!MJ[V=+Q)< MJB&NY/>[5G#+XQYJR>"^'#=:.5A1I'U>H%V$%X7773]>8]WHF,"5C""=\LI& M975IG9/<0DZ3U8,5O__G=(YA,OX/YG_.)K4'V6]A/*V"?SW]6CGP=#[NZ*,7 M]';ZX0W.Q[-\+J8L20Z:"=#,TJA*'"%(2B^CJU4+/CFG>UEWZ(&7(3GH5LA< MN6:Q:QSTM=IA=-%&U+6<3+["10H1M# @K:0PGT=AL?5B^RVK';OUR7WA9W.) M[]Z;AN[@U\GL4]]>]/IC'LQ[WL%A*Z])C[E2HOB68K7Y.-$33TL8+U^X<.>) MV2 ,S6OMS@L\^4OO)\=YF;*G@S#]@&^)JU]*P;08U85878(#DU*@$% D""(& ML,A%*E[(E%I[F(?EL($5K"2\F<\^CDF[S[[\21AY.7TY_4@DTA.?IL7XXVG) MC=4Y8V3$3!!?JTL]ERG2B^RG;I3L5Y^%I:A\F&=/UZ"MG:XZ\YQM-Q^^/IH.3\Y*LJE M4+-7KYVI]>(<@J%L1NHHE;+)F=):=+TR-*10JB<$K^AC.!" M.R*N8*E"_VL M1K8H+7-*@-[6KD3:@4_<@'"))<.MC.EA<'N!J"'%23O%WJ:*:H>?\&4Y,T## MH!)Q1MGS6;?H1I0*I&@4@LF"^)7+K=M6@/8*)>/)Z-BZU<=M]*P9OO1>2/L@ ML&FEG^:(>8O+3C;O9^_#Y[_&BX.#DTGANL-PI>4@G5.J M<*Z#;MW1?-.4;-OE#6M-U$&207"Y=J,S&KPQE(UH2CV2+=$ZO>OEC1W'E-LB MY/;5CG44T&PLO,"C.:;QR6CD%EV1]/#$=025:^%"0DVL$36,B$'5&NT7G_\( M(KO6"-A8_.WZ%-U@F!5SJA 8A?<$1E]2W3>;(:"3H:!E1;9>[-SH^ M=-T'1>;_ 8JV4=?60*KE,BO(6MTCIE*7A54Z.$%^.0904A-US-&+3'0!C8OQ M2A!]O0IHW8?>!RGVVT!*K_IH>Z;,"I;/2JC.RZI&1ED95?+ 8N2@@@H0M*[G MWCAFLI#"8_-Z__L2=Q]8N6\#5OTJKNFYG+C4P.%LOAC_9RFYU^7%N#OQM12R M42QW.#X^[$X*=);3VR>CH#;V939PY47K*:5U:;S7 MQ"/[QLQZ)^5>FA3);'X#*@]:*>(.;!U[,E&>98+!=HFK?LV;3R=/-E ML_>SI^G?Q^,YWMZ3DY#!BHJ4GRL4#%2-DJ/D!4(I02MIDPRMA;$FB8/:(-X3 MS&Y:).M#B\U7:,^)O/'\SA&7%%F+8( GE&02M*7 VAM0D<)M*SSGL:\UV;NI M6W,MX=L$6!O=]5)O5/%.%/T>%A7R7UZ7W\/\;US4T7"AI; .C%R<)C*#K2T\ M;9URM!R*$<9[FY&IUGLSUB;R$2Q0- =:KXILVH)^XS+AD;"U14@4D%0F&RP* M@F];"W68-_M?18<,#2B\R/'(LL,@R!Z;(%BB'E$\4C,!DL/29EF20 M&N/H,@5#*C;8'6"VT$K?&VY7^9&O\Q_D@LIX@B_J&:N3[C)-]]MIN];O-]IB MNSE/C?;67CZRX6H"QJBDMZY78*ZB:E ;01X#,K=6;6]GA%WAZ%8.OI*N9=WBP@V4L&PJ MPP3$H#+8N@'<4RAMF_>V;$+X<,:US$+;NMY(^8 C?YD<.$HV@*LLG%3,"6<' M.:X?['C'!P=J?R-]'67OW@=]/:/K*P>I,$^/X&!Y(CDBB^"4S!"RYHD;S8R, MO<-U!6%#"I$>,6*W5?E#N:>+SOQ9Z,;=2&HI$RH!B9?:A-IIBNP8!UVK_+UQ MQF'K;DGKTKC]]J)[!S@7CM<+2EN*'M:B/XFQ.]LNI9&UN'B%N.^,U M:.^Q,^QMHM"'/]%8BV3KZ2A0?(VPI#/@D*A+SCFOO-56M=XKM=F)QOW)X(*1 M<)+'Z(L$=(0/Y7P!)[@#$202.+T-H7FIZMI4#MGP-\'9IE.J&RKRP0?=F67@ M,7"#F@%RGT!%4P_&+B0BJR/Z$FUIWORSAWG\7=GYG4)M$Q7N(JJX>&PTH_0C M4!YB,M&K KT$Y G0RE(0LV.[#"QN,F\/N+:Q*I>3-A>MR'D[XR,)+7MPMC;) MLEH*'B7/^4J6U,/RQH;I^P 7V#:$8[-%CFU5_."NXH+ N*#TQ9D,F,.R18X" M%YR%D!*E-<('HUHW1>@G-AG@RMN6N'P@K0YSAE,SY=VRW9NH1]D81XFU3PB< MY9A*LDD'W:N)W&*&M1@[?K"673,:M9[#/0MKKAM M#M3^JC[64?;NRY%6V2JK59:!^J7N9?9N6T]V68G+0U.KTGA\7YUV;3 M\+:*IAY#M9ROWJ+*N#=:&E4D/XRL&E4OGU!Q_NRZ0WXRJQ2-@G3:)A%!R&4- M?.;@63+ 5% \,J_2U:8KVX<8-Q&S?CM%@XH#FB#D>E>B9AIINKGM^E:?E>09R4U@!7*AQ$5IP\"G MY &5S)X&I7>E-6#N3=R@/'(OV.E'3WV[T-.N6VO(F8K?*)TU]] M@_-N-IWBY+0M^)ETSU=N-*=DAH+7*!52HH-(@!;MKK?\P;E MIYJ X%)$WX/0V[9#NYGG5)RA'$&"935YX+65%L^4SX@D%=?)NN;]2FZG:%!N MJ2E4>M!(FSF(1:N!R6*K8_;@ M<]1UYD0R9HA8*]>Q(&L]?4B-'_JS)_TIY)XQS.GU^A)#AS]_]W]02P,$% M @ UX!I5=(&UZB7+@ 1 " !4 !PRYGO_"HWG==#"OG2T^X8L6;Z:D"V%)-^^]XF!)2%QS.)1/;D^03\#-*3 M/X>S3T_^F6#ZQY,\Z4Z>_+.;_#'\X@GY1_^/GG>?OTV&'S_-GG#*^>6_3OY& MF9,TN4B8,I9(G22Q01@2:92&\^"<2__GX]],YC$(%DFF"3]F(!)/@1(!)@CP MEAM.^X>.AN,__E:^!#^%)SBX\;3_\<^?R?HO\T0S!/^[^>?70Z7/5!?"Q[^M^_OGX?/\&))\/Q M=.;'\?P%^/HT._N'%]&HIXL_XD>GP[]-^W__NHM^UJOGQB$\6?N)\A,Y_1@I MOR*,$\'^^G6:?OC'7YX\64C.3^*D&\$[R$^6W_[^[M55I,/Q[&D:GCQ=?N:I M'XT0[HSI$P*9Q'D M@K^%<2%X18RKGKX[YK-GD039ST>SBHBO/KLJWN[$#VL*^,JC*Z#M'T1.X"3 MI";4[YY[ >AOBQFP=47DO*,DR=H#WR MG=YW8:#(J.%X6!:IU_CC\J5E1/L<,GR= 3X+?SM,/_XPS."3C#P(RH4$*RQ- M03+O&.XDG,4PV.G-9>RGHQ]U\3L@H[)@=V<,&_D H_ZW@_F4?/3^\^#L+2@N M>(7?3@="Q<0UU21;_"(!=T,+,1)'!>GX* MH]GT]#>]YGNMKT>QT.GMQ_5J'-$LF,(+6/SWU?BJ#-]UH]'+;O*GGZ0!]TH) MPRQA)G@BF>'$TLP)=U['Y*1$]54>])80OY?(.<^?34YELUQ=;KG\%)NI*C=F MW?Y4LJ %CN^')]T$'_?C#W17!CWO3DZZ!<3WG_P$IF_FLV(]%8-TP$P6001- M$"!BRUJ1 $:@&:,XSFX5C%>5Z7(=GOUSHZDRNT::N,H2MBM+KHYZ8$%K(Q1Z M#IDJ(GW .1*3)MP89R&I+$W]]?,RBOO-B!VE?I4'?%<>/$O_;SZ=]=OUA^Y9 M2KVP_>BM'Z97X^?^\W#F1SUYB]>#^_S)9]SP>V?J'> IKB5OX?)EV&$MS 9 M=ND=Q.[C0F7_Y4=S&/"$ZZQ#BAO+ BF>*O'14&(E,"NU98;:RJQJ/:;[S=&C M8L15QHLJ*]^KZ70.Z<5\@DOQ N9BA?X-_NS_-!V ##:)J A+D16+01*+2S+Q M!K+3+BOE0XO5\$9D]YM]#;1SE4.R$8=Z?I^#M$Y)3[DC24HT.M&)(A;W=1*, MM=HQXT/@^Z'0]\ >)(-VT,U5 JFFB]#/)Y]'W3> _D-OYY/X"47V=N3'TP$' MKEST0'*@@LC$$7%2GG >4A*@; *ZSU5I/=0'2;*J^KM*.]URW5J+>L"T4AS_ M1R(@<@E.D!",(Z H9;%LV')%X*_9.K86Z(.D7$7=726<:;K.O8/I;#*,?EP1R]TYY'_M.MW_\8Q"'" M'RB$B@\"XA1(A)P%<8^^PR/-*NML!9%S+!]*BU^-Q8"Q''!C50*PTC&B(*$+#HF"UC;Q68[G?G#T*!JR@]LZ' M#PAD,9(">J"E%5DS7,X32D?ZQ(@3SA$;HX@R@E#5DS>^ W"_271[6:_0_,Y' M!MDPMV2#K[X,,(!L%H&X0()/6'4-DF$L!K(H!ZECA- M(M0_(KR(H.+\O9!_W#RA:@;+()OU;''5HO?SXPVPRA_-?=N,9?)W] M/.I?^.,/4_A8OJG&A 6QRE;5C8OO^.SK<#K(*0F>52( %E M&V&XKQY,N@Y019YAUG-E9X V2J2YA>M'OA1N!&ES*4J_$AI6 M:N[VZ[+LK^' [HKK6DE];Y3P5&=6/"O<#G&?5R&08)4B$#GZ6D()KFLG0^V1 M"M\5,!R>"=L(NP$#+AA8O_96\ MN )B_R9_!>6LSZN]A60;I%ROR9);@DO35]: M/\I_#:#[0(%Z$F\P\]_!#,<'Z6<_&:,W-5VB"E)[EY(G&=#3DTF@"Y1QT#ZY MC.B\3K)V*'0UDOM @ HR;I%-'>/\9-Z?'JT+82V!ZIA-5"D1SFV)L7)+/'/% M]P^@-06)5*V]*&P*[C[PHXTFUJ8C__WI)5FAI_Q'NS+&+C_WTT\O1]V?TY;5 MBRM?LY>BQ9L'>*E64:*ZF%"*,AIEB& -#USQK"F5F7IW4ZWBRA=6+U'4)@K. M>"3<*4>D5I2XX"PQ5,ED@W2*-XL8O:Y5HO@;S(JLWDZZ+T-4P$_??D>IOAJ_ M^0P3/\.U^%F<#;\L(O%A.IOX.!N 5!%4'\$%G%F2*9S)41.+AEODCHE@:^=S M;8_R* H5MV'(BH!W2\4T,)R_#]$[9T*B7)(L TU(Z" M'_@XI+7&KCT1V4;<#:SD[^J,2I'0. Y'\!W$#]VVT@G9>A\T(Q:\PC'%3"R/ MMN2&94;1A(BB=GUKBW'<>R8>7/D-C/\7@!9F'"Y2PK0#92@ T:'8DFAD$F?* MN3-7ENE(LXRUU[*+[]\_@0ZOT:Z2.EI46Z_.&\Q6R2"S(I1J'%X*C#@>*8G4 M*I]8M!!J1X:.);7SZ.A2044-UI2ST;XNV1+O2ANP-QD%\6PZA=FSDVXR&_Z[ M!_KSUX(9!IEK:IRGA$=GB+0!O5DK(J$N&JL@"Q^KISAMB?&1;&W5VJ!F^EF, M$^AU= ';F_QB.(W=O)S@C-/;"9P,YR?35^,OL)3U(&5GI986[4K&B%2X_EI: MFJ9Q2\MZ+**N;HW="NDC)?>AX@:%V%?SR<[DLSP2.!..B=H:+3))00LB<+,^.R'Z05DF$P@+5=MG#)][+E? MU:>#D+2%OA33HDAD $&\SA%E9;@6CHO$?',";H+T&-)"Z^C^1HI55UP#Y^$J M:ERK^S7YK?^V2*RB*NI,(P&(JB3C491)2D18M%P#A\!\;,ZL2Z >$(EV44<# MGV$EP,DE5+3RRR'==7+HG92+.)UP,G"7B:+!H='G-;%&B]N>GH<=N7 MWCMF-)5Z U.[WQ%7&'^GYZ9GAUF#P!(PK1T!RU$:D- GR"G@EX@[* V,F]J& MSL;@[AV-VJJG@?6\^4G#P,L(+(M :&)H>$6*2$-TA(J@:%:12UT[/KHYNGM_ M1M-(40W"4VN0+N(4:P23<;T4W)!$2R4UIY38!*4GH1;&,A#UD_&V1WE?,Q)J M*::!LX4V_&GKR_BO^7 "B!T)/_M6NBG-T#$LJ6J?^W54F9T0H1US:A-T=W-*M3-5UW>U'4/BCU[(L?CHJG6#J*^!&<#I$$B$E&1D%X*8UKZZ'^/#(55%E#3Q^%$L$2-.7*+>" M#MG_JY\5@-_>Y%_]Y ^8%>SGH ?:O0IZ%!0#!*YMKM2+='>5]-]UJ* M:;P+EGY'Y<*X-_E"L> J5P:45H"3):ZL&R(XXX2K[3CQJ!(4G6+_2901[,6 M5=/L-;O<[FII:)\OKZLZQ?B\FY:S/VFCHC&3X"5.H8P+<%!:$\-Y2I0IK53M M6.9U>.X_6VHIH\4"L\2V=7](EH-P5&KBF,^XE2>&#JBG)"5+-7516UZ[S]-M ML3X8@C558@/;>_4RNFC=]/L8W_$*?S%&414W8O40^A;T^+'1O(ST8N^_@8XN M*O\9,??X1WN*'\G#.@4"WG.,)H2KXV3J#>OW9, M$NH$EPP4J%@[(VN_([SS_NT1$Z*!];#3: <6$DT,@/AR/:%,&2UP;LLIBN&* M.QT#KWYKZ"Z 'S8YMU)7@]U[-_ N9"45-3@S'! I ^X3DF:"^U!B3%AKY1%S M;<_2.MO$-0?'LH_$LM*.TR=T4X *8ASXG"DP4[VS=17@#WNFWDI]#:X%6^*\ MC YMN\GD&^YGBWL[+5IXR=% HBGM.ZDTQ-) "0=-(]?)@:[>OFX38/OGT &4 MOH)V=376I _:11$, @63J0&B&<1E](Y*6RIK4\K.1XF)WW\YHP?'BT\PS-.ZMO!NW.;^\M5-#@ MFL5+%>1OPJ(YXJOQJ2?ZLINL+BSX-C F<\_0UHX^I5*M)$B(D9* @[!:&LE$ M[1.N'> >@%$M*'!YE=Z3_AIL\B7_[;M3NE?C."^UE(O[5W[KQA&%]F;RUD]F M0S]:_OQAXL=3E%HY6,$U'27F)5&JS$]PB01F+1HMR?H(3.90V^/;&?3]I.%^ M==G$ON@+:OHRWC26 M(J=KFU;'\S,-TF(9^\JWDYB[S4?JK"A(Z'+8$5$/00"0* MA5@G-0&>K TV\&AK=Q)9"^9(KG;92L%7;.P:@F[1M>T&VMZ*USWE@/8F)55TK609\4.USVP9[,/GV!1 MR',)E6\G71Z.X$6YPF0T_1[<9OYPZ10YS".'1]RR6&Z/]JXERYIRP* MK4/F"O]8>]O>!F"-4-Z%:Y0OO7#9%[+DD$YGSXOG/IX-6%0)/$X\RD'AZHH; M=-#:$*9U%$9&%ECM.,KV* ^P%#;CU:J074.=-;CS80O$)<"X!&UQK_ V!L(# M#>7LCZ)AZ V)(8+7N'%X53O!Y59 '[FVB^9:7#-Q">:E05P$_9.?HN/AJ,L( M4A'%4#B2\X!XR]T8/ 79Y(UU5?%(X?>++UA1IS?0?;+I)M. M?Q]/P(\*^E]0YLOE^"?(W00^X,.TGG>.IIMY%RYR\6* M#6BX M@C$QLHL$'Z]PT+^+7#.1^$=)PG*-TO.,-! ,<%/?I !/.*"F.<3;7/ M6*H OX\L/9QF*Q:"[3352C?\*XM^R,(; 99D4^8999(X#Y)02S477&BEVRZ4 MJU#=1_X=5G45\^UW'LBJY3Y0M'&S*)>=4X=BA40L*"!":)FC=QHNMR%L0,/' M_7H_"FR0.WK;5;T,YWP0:%0$RS00+U2I;^2,!"4#L2(*F5D&6KT.NPKP^\C2 MPVGV*CUM;7I^WWGQ_*?3Z*;D.1@9(XF^9*(XG8GU01,EF7!>>M".)-%'G6,@:AL<+4V2A!'2_>$E%D$W%'%Y2C-WOCU,*+0 MC76V(@2]\Y''II 'BFH/P2=<89,A,F9.G%6<*"%3TIPQ[UKOHNNP/5)J2_VL M(%*58HOUIN\;-[C1Z_&4WQ?>62?D.>I0W%(0<#DXC,G0.Y3'!IX1KUS@)9@95ZM M@7*HG.?J&N_J2[[!"6J?QI5A4JX ?0^3+R4SZ..;O +M] ,^SU4QQ[ZLW#3Y^ MIMZ0UGWT1-U&J0T(^KR;?.XF?G8I)+-,:;7.*)987SJI2MN.0 *@CQPH31&< M9A*J-_.Y#M#^3?_#Z?IRV6(U137(I"L]M-%ZP4&_]6C&+$%1EZF.-),H2P&E ML8GX1 WQRM$(6E">:M?SKP3RH%FSJV(:K#F_O_^E^P*3<;\8?P0<]F7W=HDS MER:O5%DB><]J3TFY>K)TZK29>I8MU+YU;U-L#YA33=37H 2_OX=R)3#/I0% M8$'STN8_2N)=L*6B"[05. VJ=_9;"^8!$ZF.@M9FL=4NI7GIAY.^F]FOX*?S M21_KF+Z?GYSXR;?N7$:+J]J7GTE^=O;/NK%_5P9:2H;ZA-$=RFZ:8:E3HK,? M45TJYP%GO>)2<^J]#$);HZP"*[)W,4AM!\U0[1CF.GW^XL4X*R_0[).>!Q(P3TB9T;+1B!O=VGHGS7)%D.23!J BA=M"UZ@#:=) \ M@_AB."TA3$0TH$%+8!%7%5-NI 6%5A#-BN@81>;2:U/]B&-CSWDIX$ITX*(UP6:2A40;2'-!+->:9,7 FM(LD=9N$G@]HH=,JHJZ M:E$:U(MG)<4YZ,BS)2I%CH9T1ON*X>@CTEX8DU5DU9-(UH%YR/RIHZ$&7DX- M$2T.C$*4U+@@2=2.%J.;$<\@$2I<#EE[877M]:H:^'T=ZAX/(0^C]Z,Y&CX= M_4_?^O$_'_GIM _L@Y "F"J5Q H=4A0J\4HD8G R K6>.U/[OI.U8 YU/'P@ M;JQCZ$XZ:K#;7A+/"H'T$OA]W(4I3+X40;P:?Y[/\,\=>HBC8=^,\.*HEL&0 M3<;5Z$BYU9@.=+QA M]D'.W>+S38?0=XS.6ZB[ 8U_[<;P;=%ZY^5\G$YCPC%E*4Q@Q&2-H@J,$@LH MKV0,3P9P@V*UZS!7(SFX&W0@37?5U=3D)/JZ8_)(G4_*)\)%:>472LO@Q"WA M42L15<#96/M \D[.9H^6L$B.E]KAC%Y_3,0!*.VE M3DE!=28=16[#D3)H5R4U",UL?%!N@T\V*T-*F)%(32,)R93;$P*U3$4K;6W[ MZGCS'(Z27TU4V:!I_/HC=:V9,LP$(KG'?7EQ>1$*@TDC M)%4=935HG'+!7[EP5/YR O^:(_6_]9X+4UG@IAR) (&[5ZP"N)Q3FT!L'49;#^_@$;$ZJEU'G8W6?A0$;;4,RAAO14,CZ!ID MCW909>TU\-56SH.K>)S2*U@(]N'E43>.;+%M5U;6OG6\M:.%TS#E) M$B151,:DB$>7EB0NC/2,:J[WL@7NEUN;VT_'0:UMM-224GV 9-I+@)W&+:2( M8)PH;>/*KATHL<$KPGRF0:3( J]]"<,U<([#=*JDR'64V5$++6VG"]#X:>4A M@HD6!ZSXT:[ZM><7@/GH1'D-EI8&R2L77]7SOB&BQ1^/T[/NW&Y M@GQQ%/,LI?X-I4+Q[+;@']P, O#H MHZ',!1C<]J6[+05]3^2+[WI]EAS-F&+6,4U2D(#, T<"D@]W,2$]CY2#JWW" MOA[-3GV6WZ+_7*ZT_HA3+4YP7N-_GXW'(A#^=DVAGD(<*1=8@2'<(156TN#<%OK@E]13QTKC]/<5U;J:^US5L$&+IQ M?VTXNL!O4=DPF4#J?W'6)N;"A]Y!R16$]+*;O)S/YA-X-9W._3CNY,7OK[0\#MS M$,$08R4CTN&7D'%!EEE"L,*PK-A&Z\XM =0HBUB^[+G_/)SYT?M/?@+3M6\> M2,5]DC02"!G7%)$5<4[ACY(Q8#+9&&L?#FT-O/B4A)T5QF1A M(O><9A>A^ATH%P'L.W*R'U5?;JQS M:Y$W.)GL5\(20$XX^,\H)[^0]\2//RZ.XG[Z=OZ9M_Y;7P]41G ^##1(1KZW MJD]3@3884Z/,K1;C.4R"UPXTZ8Y4QW>%OX;IX 4(XF-$7\T)1KRQF@1.07MG MN,VUN^7>'=[>D#QVY+3=1K4-Z/HS>L3=-X!^CWG31ZQ.4YA4%,8S2T2FI7]T M\L3%)/IK[!4#%T6J??B[%LP![AL[N*Z[%HIJ<,BZ<&,N"*D,>@DM6<>94IR M08-$.D/1;=&)Q-)6)5-J1*R=:W8-G$<655-6@Y4(#=S99!AGRR#2$I21:,]& MHPF-+!-)#2^]3!(R'"#YB!9O]6S%E4 >N5-!00V*64_'UV_NV6;*)>[KD3-- MI D91R3.,(G)E6.MY&FK5/B3_\ MB1O7M\77[ZS<5^.27SC\ A>,E&R,5*5?K^ESAQ2EQ/.,RZ3B#/TX!YJW[W_QW44^W#]G6/F18"_3M?!(_H85S 2Z M])H2N+6)RY<:;\N!JR^]AQ384;)KEX':.0$]V*N&<.5Z@UN\I?'7#@U0Q?#:L\(RUXLW!8G MP\C;SN((W3$Z_)WZZAS4QHT"!B>;4+]Q7>P>GR_ M=?UM,; (9DP_=#,_NOCWY]UT]ELW^Q_H^\-]'/<#"RCE7)K 9:L=0>V%N8#+L2XUG^JGR.#9+73 7:=P.R M.%J>2 AHPWFAHV).,>#NKDR"E2-\G!G'0Z &0;UFH[UPB?IV04"M@X(XG, MGI-R3RNQ05G-C;?>5G0!WH'9L!U)WW;:*+]X<\F:![*2=]6FKG^%.@V8FVO M;)^=C.7.B)R])C*X2%R2C%@?A"J7-X&^[R=]%76\C33KG_1U'SYU\]+=9L,C M*6%PNV3!D](@ATACH&27"**I5+AZ.4N\[=:(([P0+C1^K"CC!L$ MA+Y/X'>!^62M)ERDDL"?# D>RN)] IP]\Z",,J]'MUN5BAT=;;=1;6W#[/=E /U2$<#OJ)73AC(I\\0D<**T*-?.4H7P$B,< MG(E.:6-5W,@4N_E=1WC*T5RA73MMM$SRN%*NAN9C$.A4$B]2 18BL2X[@K,- M<@IAD=U%77@9-"SCD.7)L2SB+[ME[HIB]LF2)ZJT%? MRA:55E#OHJ-,:2FES5&G<[[M:B_'O7#)S]>GH.?G:._ZT:C ME]VD_*-!B1 :31D1"FBI/V;$0D(9>Z< 7 ;-S+'(^%8C/,)=HB[SJZ6N.(9-(3!S83D:C-WN5$Y1V<*8O!W:%)L@>6[G]" MW8)BM7W$=J,LY6H"%;CN778AUG67 MVQ/BQ\FQ8G(<+V<.$:N^]3C_JU?&V3@#""4,[OO1E7N$8RGNX"X3RI4*E@>F M[I U]OW8'F?10;:8'0C6(A6VV3A1"QF&%X1JNL MQ;5#&%:[-.E _L]1:N&?,/SXJ11!?(&)_PB_X*-G+_P,SJXAO#AY<,I$ ]01 MS5G$R8,NA)WNCAUQ*Q'Q#' ">)"C(# M"6AS$1F $2>T(..X[-/>.@?Q'.)&W8NY=C43=+ 6?K4TY M.H*+YR;;D\%V,R,TG,+U9"E+D M%%%CQ-- B?2EJW'TGIB$JI196PU'D^I1=>2/T_@XIW$S]M[-&.#-,C#!><.L M1"M$!"*5T,0"5R11P/\$*J*IW;[K&,9]/,U!+"10%@2)(- J3!Q=-BBA\\2% M94)F9FOW3W^(S4%VBM$=1-G'TASD^P*-G$24Q@?"Y9*>!6'+BV%' ;7=R54JI-QO18"KA5*>!6--E'3=5M='Q7^!L\==[F MG@L!D:D M[8]1B\4N<^#,P79&A&?3Z?QD$8EY-YS^\7("\ I=T@FNB^^0 M!@,'+@O00%0LQ:TQRA)YDR1:GECT *YZ4[GF@SK"?:\NOZO%;IO0I%5I6KAY M@&&3 ?[\]3,4B^ #3$[8(";T]*T4)!N.MH!+Y=Y&4;I;R,"]E3G%)KG-34;S M,)E_>&(<4];==2/[KVZ$CQD-9]_Z69$)S<$J M$VC2L?9%",T']3@3#DJ38\HQ69[&]O[?=/.4FD1!! L>Y[G6)> 7B*,Q$<.4 M%R&QY/315'[=;HB/<^2(*-0BHZ/:(6'65@1G-0$H_8"5S"0(R4GD*CFI%-9 :E$8JCQ&?!B8"8 MC*&&)JH?+&^WR@HX.MINH]J6%YU>:25J7:3""T^L%&C;&%:NE BZM)SGR81D M:8B5.7??>[YNI>N->[YNHZA#9PB<]B!=_><2Q1A/H5WGUXU>NY?^K]L+X-+Y MNY?T MW-MR+&D1I28QE(,]!8ZXS T!:B!S7,!E;+8BU1G"SE[3XDV05@-9:F^@F=<^ M:D^$*NV>**XXWAE-J)),2QO!R=H-"#9#MO]U_) B_/K,Y^TCNP6 M_FD4(;F8!8FLM+9G5A$/RA)@/GDPCDM>_GA''$K5Z-<;] M'4TPG,3E<:^7X^P]"^HBT%+_1FVIR["\I!I+0= 4L\:ZG+6IO3M= ^?P$:V# M<:5KH[,&SM<::*?>P@;@&@6MK@5VF.A3-35N1H\==+!WHDAM-)7"%K?2E3:Y MF?BD&(E:I^RE 2IK1\\/0) ;PCR'X<#4J:BYY(8'DH#1^>(]Q((I3XXX Y_73MQ:@-8^_<$*BKR:N%&52TT,.I_ M@3%,_ @1/DLG*.KI;.++%;+?@V0,(-#$B- NEH+25(*CFB0:F%1&9OQ;9:IL M!.P^D:6^)O9VC]-O@(*83M$:[(VYLU"2'\^&:3B:EV%,(>K$$2"H;CXAD!L$L%Q)E/@M?OBUL*^<\1P-QS/3KKY>#9P7 ME<;O2KMPF M[1A' TKU*0;42*5P]+7O_ZL"?/\;QT$X>R70N'>E-XU#[CB<10A!*QMB1A\@ MI9!* Q=%K#.*X$[*6:G:Q5\W"T#6&,&^(H]'P> #*O]88HT[#ORG;ZL?T#O$ M7%&OG-($[4Q/I&*16*,MX4PXGU%Q3A[9>G[=< X?Z]P_2>NN^-7(TB#&L1K9 MA:R*3? UBI/>A.U B7K'0H:-2+JC)@_!.&>M19R)& @&<09+0G],:S,+)MF< MJ]?A'H9I-Z76W56B;:/ O2;=9>6553X0:FDDLG0$]IY'$E0&E<"%8&JWMCZB MI+NZ>MLX@6X;H3=P=%;W_>%*.1:9(Q+G 9'1VU*\IQ!45#QGT-S69L*1-&9J MRH+=A=UZ/5A"\M0P204E)3>42&D8<8IK=*94B#H)$,!;K@3W4ON["GIMM7CM M4/L[&)5$L;=^,OOV8>+'4Q_[@L9G*?6/]Z-7X]Q-3A:G$KU?>4KSX,D:,QJ].\4 4'1 MZ=.T7.H1*4%[)W.=I0FNMB=^$Z9=5[,7<_C077@)3M_G\\FDY,>/TV_=."Y^ M&"3A54@L$%U"BS*ATVUI5D0I%IAAN.BZVD4M&T+;_ZI7E2>75[T6"FD:\%TW M47_Z]MU?^JA)R)0E@]Z!8*IT>\(UW%+M2::<25=$YJKWA;D-T'V%;YLRJ;V* MCB7ZNMGX>D]51VVC0VN1:UG:<#M.T&,(.#QILPT)]Z7ZEOJFZ X?&VW&E"N6 M?1.--S-&HW0=0HAGD5S6&BEJWT=PU-=A#^?FAA<3:H@!X.@,6UVB1/ MG'$1D04?=13"AMHFTK[H<$-H\7!LV$;FM>_ ?-=]?-Z-7XWCJ6_JM41WUQ/E M(:)O*DK5AG2$JZP2RUXPN=E-E)<>?%@#]S:"[BI):6\%L'V@:1YG\\EP_'$G M#WW%95 '&['#'(%)K38+AN#M+YI().4)J^3$$:X$#(CU/AR MS8U7Q(H42/+@RO%K!%J[/\!>B7"CN[LW'FPAZ-KN[?^=CZ&HX0JVI2.G=?+4 MHLDD ?"+-8DXF@WNL,ED2 8BRS?Y2YN\Z,!6Z6VUT34290/K\[IJ7%,.&B1H MDJ24B"^B"<6X(4PEX;7VI52R\E0_ZD8);0,^N(+\Z9R]*(S#3-M/9M6W>K_4$[?FPC^@.U M/W"0%?"HB4$EH@W%)0F _KM2GFII3.;5.Z'?P?8'6RGR%NT/MM'"P=H?] MO*&E5DTR_,)0"$HIXI-PV5F0WM9NFW.21 !^2P8 %0 '!R87@M,C R,C Y,S!? M;&%B+GAM;.2]>Y/;.)8O^/]\"F[WC9FJB$0508(DV#TS-]*O6F^XG X[W7UG M'1L*/-/:5DHYI.1RWD^_ !\2]08H@*)[9Z)==B9)G/,[Y \'P'G\^__\_C@+ MOHFBG"[F__$G^$OXIT#,V8)/YP__\:?/]V\ _M/__,]_^9=__S\ ^%\O/KX+ M7BW8ZE',E\'+0I"EX,$?T^77X.]+I^=B M^O!U&41A%.W^MOA+"',4\IP!F&08H)0C@&F< 18RE$41S?.?HW",/ZUO?I/S>7?]Z[_(ZZNADJ87ZO?KB\MIX;DDQF(F/0@;ZOY\_OCTZ9/ZKON+7N7C0EOT@BNF" M?UJ28OF.4#%3TE=/6SX_B?_X4SE]?)J)]F=?"R$//W96%%M/U5+F6DJ8:BG_ M?&RP7R\0WY&\RWU9'0A7J?O>E8RG,'WO3-Q[Q0_"O\"=82X6N7ZA7L_Y4._N M>JB+1?B\TP'9%G^@?OU-^:8?2#3I!I-4Y#W1U1Q?>EF'-1 ML^76HX,I_X\_J;]-RF(Y^2C([+4B\:6XG?-;IJ; U4R+]DH\%8)-*R9_3Q[% MG?Q0+)Y$L7Q^M7@DT_D$AXS+$".0YX0"A&4&\HBE@.(L#V68,)C(R7+]WD_$ M''S^U(I8R7&Y$'^R0&AYY$LO1+E8%6PS1S[.#DU\:L[3LR3^=:[D*)]("0I::6?>OZOVE'\5Y]NBU9G4K S M1FNN^)4ME!?WM 1;]M->KSMPE@MWKV)M3"7\GX)%P46A_/L#0*P_K%4)'@AY MFMSR_W=5+K637]XO/@JM]'0FE#?Q5BT,'L6[1:E^_I*47]6HWZ:*/%\\?RX% M?SN_4S(HH>8/MVPY_39=3D5Y2\ME0=AR$E/%=51$@"8A 2B16/TM4O^4@E(1 M(Y0F\42M0^CB'!7Z%-/F(^X*Z^];[F@9+!=!T>H9*&-?S.C5ZUMPFG['8EG/]+QCTK6"@=(PJ%4,?M)*_JQ_K?4, M6D4#^AS\]+DV\L_!6MU@HV_PI=78 =L/89!3LT$S?F=&:'ZRF16\BCC(K#$$ MR.VL,LA8_68=-7(A2"E>B?J_;^>?E@OVCZ^+F7I&^?J_5]/E\\?%;/9F4?Q! M"CX1<813BG*0QB@#B$(""$XY8!PQ3F02IB0W\:Q[CC\VI[H5/_BI5>!G/1%T M=?BWH-8B^*+U"!I%#+WNOF8R8WR/X'LF7/*!/.L?W>I! M:RG>SA4;5SOTY=WRJRCNOQ)%VOH1Y=NR7&D.K_>K)KF@6=)4..EIKA[M[7:-Y4*E^TQ)[1_N@4C]8*OV#!H";H'E+U$M2@S#&=X0W M!WO5\W^\=V5+_/]?O3/&[L)5;%<[&7KHRG,(\SBLO(=AA1G$Y[@*OJVGT$))KL8AX8S^B;, BY!NK^;@*$/OR9Q2 M]<#>R\G+^U'#!P6H* K!JXT<14!WQ2=]TLK_1F8KH=R4[IC'#N@ M'!&0X:"#\I$=$+OT9'EWCQWA5X(N/PFV*NKCMF]DJGXU$V\6Q2"S*;_6_V33.?O%00K)9U:^@DUS6L:G6 L22BA!) Q 1"+0I"S) &2 M(<[C).)ICHPW?AT+-S;F6RL$E("@5"K=! ]:DV"U5B5X4+KIY956L6;%2["0Y9LJ-@4&D8;%0,?JNL^G[?JO=7M:K% M/NT5K3O0=NR5K&RWY>K)#"=W5EV/.=P&JB>TMO9)?8UQR2Y%Y314&[+K7="4 M1!A%":!YF@'$20@(2P1@4$W>8<)%QJ!EA,NA<<8VY3;K[;6:[HY9K^I741W!.K1%([(UX>$@Q*W M1XAW2=_G4#VVAN[_6-Q_7:Q*,N?W?ZBAGE\_/LT6ST+4FU'J@_NJ!/F@OI[? MQ2,5Q21,T@3+# +(D0 H3'. 68)!DI$$BC#'*!/&>S^VHX_-TU1?0ABT,M>[ MKT$K=:#%MECF6UO"8'?&)[Z>*5J)'K2R![7P)Y$.OM0J&+KX_2"WV#KQ"?U M>R.V)G"TV]$7N9/;&=8/'6Z_HJ^^6QL2O1]B-V=P,9V\GB^GR^=;SM6[5GY8 ME$LR^[^G3R\77$P0AEDF(@$(DAB@F#. XR0#64AYRJ'Z092:3 ZGAQG;+%!+ M&C2BW@2UL(&2-M#BFA'2&61/D[T[O#RS>E^HC!G$#(D#?F\IV"\/BV^_J@?4 M+J_ZR\;3/?/80I>G@S2^8D3!$A M$G &F7(1DP3D<00!#@F'"#L/&GEMLZ=/06RV MB'<&G&=6V,5LNL;LO%?7(Q79 !1G.<6GQAHX.=A [?TL7Y.;[%V(M@;P;];-R(CC)<0PAR"F- $HB"3"4RJ%(4L(2&D8H- KG$#E^T"^#TI6CL-9%'KY#<>?.IC;<%:QKM=P_N+K M'$R\_BX*-BW%>O.K*NOU=KXLIO-RRJIHJ0F.H@2',0$HS15_Z$*0-$MR0$,1 M9Y&B%BF-0I.&%'IL='3[\%!44>3!M)6SB=44C3:&^8>#6GZ8KI:[=J\LAJ]DU%&E*N*Z0$ /$U0>+#:2WP2\UJG_4;JMK&&QN_=*2UC7$^ MB:H9@[C#RC.!= 2]";2H37;D1EB7@<\FH#B+?SXYV,!AT":*[T=#&]UUP=XC M/;^8I+N+R;4HMV6Y>FQ7ED^"U346'N$D$R)EB?)D)"82H#S*0"XI!33#,&6* ME4C(K7<+N2YS+>9L*LIWT[EX MNQ2/Y40D249"D0$(<^VFZK,IS%,U<82AS-,,96%H,UT<'VIL=*\E#;9$#;YH M88-*6LO4O!,(F[&V&]P\LVY?R*S)\CP:CLCNQ$"#DM5YA7?)QN".'OD7;Q:S MV>*/N_F'%9U-V9U4ZVJW#V*N%K168P^[1NT#R]ZRL]=#^M'OK7/\,T_&LF>_8W(\Q+ MK.J9$QN#-@>XE71MKP)W]'=,?T<,M_?X04GLF'*[/'7T.J=)7Y,P3C@5602( M) (@2C$@- Q!2@07:0(CAHF#=*^Q$5,G:>FI25IB#A.]+DOQ&M'WOI/<%4S/ M)\2YRNER_-4?&V4,>5S'..#)IZB9*]+O* [J3=2>0210E M1"1" )XJ0D H8P"'&02<)1Q%F(@PM.JN>'[(L1%$*W&@C5AY"EIF79BY6F$I M!T%4. 3,% M8#\,S/C.?O13-?J0ZA.^G?-/HO@V9HN(7L9HT]GVO7&66=I^E&4 M2B3!WRR*-ZOEJA#ME+'9)$:4X)#'5'&RKF,^*Q^RXU7XJD0:C*L M/AV*$Z;^+P%)*B1 4$J0,YB",$)QQBB!60CM2F%W'V_S$0U3P[HK72#J!FIV MCOX6?&:.>E](O!_G;L1RYU8?4M:16[SUZ$'=VD-*[;JE!Z_I&0VBB: ^1'JU MTC$F=2IQF#$@6;,EE3[LXEFZ^ MG%:E-J;?.L$LK[^SV8HK#TLIKS,M5K7C?B=?DV*N9"S;)H7WXOORA0+G'Y,H M4[P:1@E@,,P!BD@*,(01H!!3+F2,4VR5[N]>Q+&Q[J?5XR,IGC7K=E7LA(\% MK9*!UC+HJ%D=@#2*&G3Z'.HE,&3MJYIVJ,T!$[-*([,&7^YUR%F@U0TJ??W$ M#3HVAOO@0E<"7BL"T3' )\(478_DP4FO?KE3NHM/HI#F/$P8R*C.@)$P S@C M$/!80I32C&32J-M(?Q'&-DULSK[ENEY6Y0:NGJH%>BVV_FW]XT6MCR>/_;#5 M8B$RD>C%5(R9LEH8 Q()".(<<@0921C/)_.JQ"2_JMWRVFY=4?Q9;BW:H+9P ML'*Z^+OP/M=1)@*S64:>?Y/U@LW+?-EXR%C1, MLQ""2&84(!1Q0)BB3)IGB$@N24;,LSPOD61L4UUG161\>N/M*&W':,Y/-ON; M8IS'F^9K%,>6\7;2V=]"8S[NO,H9YV$H'1YT[@PPUM/.PSA<<.1YY($#%\W: MGEJU2-MEE^%$A$1F,J(@3_)$K1!R#+!($.!)#K,X#^.06!7K\R?JV";%L\7Y MM0X#5= Z;V?#U<HH&4,N+,*6N8C7IYA MI#,';N?\=[+4.Y?/=_)W4OQ#+/6@F]W,B6"9Q(APW>H% @13!' V;U[<2D*AE) M)X.W\FOD-QIT#GW\)"I9H>Y!/:,.U[5O*]=_3+;CM9'3_L2RNX95+3A48SX\OA3#&@2]S3"O;1ED[ 9DP MPT9T.@%N+P;4S5-[[-GKVDP;LMZMY'/+V.IQ5"S'1)F:H.Y*HH MM',LY*(0]^IA0I"<,)@!+E!5U94 &JD_!,^C'%.9LU2T)Y[WAEOY+@7L<1IZ M/\1FQE[AL9O@06L3K-;J!.KU4$M>5FMT$]!*IV!)OEOL*#LUML'>_^"V&T4] ML]J '>WJH-1@HU_PKC+FRQUCWE_/F!;'!=<8BI /()$"1H !',0,LBB*>)FI=1*R* M4YT>;FS+G+VN8YO*>&Z;CG40-]WS<86C]PV>PRW'-L+Z[3BV#XK'AF.=P:[> M;VQ?<9-V8P?NZA//T[?W;%W>IE,TX6[Y513W7\F\V3"O0Y+:EK0[+1I_4\]? MOE*\N>Y/,6%AEL6I((!'"=*AE Q@&L8@D1'! L=Q2(UVM<>EUMAXLLFXTI3( M%[,9*NB0MD9GJQ1/A4^P5 !M MCG";5Z[32GVO(V^%5*"AZO1.^B'?1IN8K+$(/<(5V@_\=EI&DXWM)3@=FC8: M:0>,#YD8G7<_J[Z3\JO^GQ?JF5M9*H$T.L/[%[9QO_Z!SY40D,DO2 M%(%05)3D@Z>:KCXI>D6)JM@"^2R894=R7SQZM:R)N MJ3^KDJR-K-5!?J< JNNHN)A.I\WY1&>3B>(>+!I%M$$Y9R *(D80+K!L>(B M#B E8:3&2V%(&YN^GALF5PULT5:N<=A3Z-+]U["DS,,T2]5Z+D(B!(BF&-"$ M9B#,(6-)"B,ATLERL22SD5EQ(Y,_"][K,1H+F=AQ2,.9;7 -9@[/*Z+Z6])_ M!AT!M\J0U)=HJ^S\L'N'P]X.+I!UU0CB(EF&[1KA K:]%A-.'MJ_-[);]]BQH+.QC2IS=T??/E*6"#C>S!%R_U._KAYK MCL7@@S?-L0?F4$N= M'D_IV45Z2NAT5AVQ-H>FZT#!$"8XDB@"DE($$$DAH#3GZF],IA&2J<")717* MXX/9?%S#U*1L! QF&YG_8MD^^CBT9OSD!B[/7-01:Q]]_HZ+.P361Z#U%M4DD3EG B.0)RD!*",1P(S'(!=YG""1$PBC MGHT"N^.,T;'9] N<;@[V>L4Z' /7W(FY$+(!O)5-,[ZVQ*3';GR'<'#?E&]K ME&OUYCNDZHD6?0[E0;&_&M M#^A(?5TC]65VU@.G"BO(8JZ& 5:+#&D]/NWOXCR8%WJ-@/E3/OWJ"N M<^P]2-C/K7@OEF_G;/$H=!CWA.:(92F- &,A!TB7><[SB &8B"2,,4TB$MJ< M7VT]?6SG44JX*@_);G;,PLJN]:@_:H&5578!FYCOV?GL\NV\:@5JP MX" 32&T_B=$;FPW")G; M6^3'8/*;H-9L-"2^#?0X&+R1Z4>B[VT8'7/WSL/[YF<\39=DIC?FYGRJ"S&7 M:FV@C_?YB]7R_6+Y7V+Y@4SY1&0DS*7B9IDHKQS%40AR227(\I D2$">AJG5 M8;SAP&.CWP_J05])69>D?"H63Z)8/M?G4/^]FCY5)PK3>?/U*THFC!7Z +]I M/&L;F6AJ'L/C? ^@^S[?KT4.NC('K= !72T#)7;P+):!%MQEC+8=5,["L0V' M'3CRV@Z,_2!KR_O[D5F]J_%)$69U*O%.&UE1YZN%/DV8B!3Q.-=!1+&4 #$B M0,Z2!"0)S'F215$<6977/3G:V&BKV5U;2QNTX@9?:H$M-P%.0VW&1LX ]$Q! M%V!G33M&F#CBFM-C#4HP1FKOLHK93?VH9)W_>EN6H@J5[H0__BZ(CI+F=_./ MVFW3S9G4!>\7\Z+]YPM23LONYF:81$)"0$.4 I1S7>,[B8'Z'\J21$@)8QOJ M<2K=V*AJDXNOED65?I5[U=$P:%4,U#>X5K*ZJJMF4.EYP4ZGVY? C!2O9EK/ M)'H5JUK3KQ?T'=&U6]D&I7UR@A\6Y53/6^]7CU04 M=[+]=SG),,.090G@*=*AIS '),%4>:P1S-(T%$D26E5 =R'5V*:+6L"J76S/ MKA!NC&5&[X.;P#.MGRFY^JDJN;I38#5H%;D)-L9;*^>P4+I+K%W52WG#AR/K"^ZD M'D;4C+U37 Y^I6LO_\K#X]JNZI_Y"U5\V'^;^DP;Y&(\J MT'Z QR_HG:^D*TY]*!;?IESP%\^?2UVZ\^U.C$#TM #F2%V#ZA9ZQPM3V_WJW?5)V:Q!!%DJ$(,!E#M8S !&"$](*" MYIPG#-*4VW#8T9'&1EFUH)9ANT=A-",=)^#X]D J&6\ZY=D[]><@\)5 M .S1<88-:CVG[EZ@ZMD;^C%!55=SQ70+XOG#!V7YV^]3Y9D%:1I@='&=M:8TO(0$L9?-%R6FXF'$;4C! NQLDS&=A# M9$T$)R%P1 *'QQB4 $ZJN?OQG[ZX9WDG72ZJ+A3UJGYN5;R\8I?7CT^SQ;,0 MU35MM+4>=Q(1RO.HK%,Y+EC-E3T"T>C1_/"IT21X4@^Q+)34RV9FU./=$IZIJ9*M;3GSJB&H MINU,$_/4JE%7J@M:12H>4_E C^A M%^:GB<8#DI[)I@-B*ZWZ2U#+JZ.Y==U$UR!:]&MT"^9 C10-0?W%43M#,QP#0#-==KJS&=Q6]]^\ LF!"]U GB[NKN3=7'ESWI1I\95HZBIX';. M#_<)U!ZFSK"12QC0C=A1@#QD *:,PE8RGB6Q"E*(FE7 MDLZKO#:?WC E[EIUZ](.XKMZ':9EM?Q>U"+7R> GUMUU-6/M5IV,=[["RV'F MXX[&X+XGKD;/NIQ\N\G2EI@_6$IX4Q+U)EBKUY06#EXW[XK#+/5!3.'( _ 0$H!$B@"E6 "FOKN4 MAKE(A>4QSNX08ULM-!(&E8@]HT$/ &EZ>G,)/-Z/;JR0Z7%NP,, M?&)S3,']XYJC5_9T1Y4EWRO;5B>)"/(8BI@!$><10%#F +.$@1!'"<.0I^K+ MMOFHNP\?V^=.J8H3?BD59;G)"?E/,\$+(12'TYC9.*8JKR3J3 MB5H5)A#@*)0 ,LJS+($Y(U;1HTZD&MOI0MW2F6SE5I5*N4[B\4WPH!7J9K\] M*)5L0[NV,LJ%ZZ@55'IUL^.T9CG#[7-M7JL5W/*Y:;#X43PMBF6U5"/+53D)<9['442 I^B>3%$-"<4)ST]2;4P.-S16K95TW %U+&]3BFJ?FG$3W-&&ZQ,PS M!_:%RRJ3QP2+7HD])Q\\6)Z/B7K=M!^CZ_NY>'?+KZ*H8W#?+^JRB?/E!&&4 MBQ +D(4X!2B4(< B3@$3>2*%9 MZ/J!.-+[JTBMVQ#57:;B- $1HRF)8RQ(;K4I8SKPV,CA=U+\0]2A2GU+01EC MGJ4H)UQ0$#*" <)1 G*42Q#QE&LW#(70*LC."^9C61/K!++':K'5M_:+L5WZ M+7I=H'W]=:V_A>HY?#RM18\.>]7EYCDPSJTHS]Y_0[$&\4[J9!E\*75W?*8PN];8\;&HWD7/%.XRR;5_5^#?@VG M?9O'90]I;[(.WQ;:-^P'.SU['_0Z$UP3?J5GXKJ"Y"1*<)X*BD$F,Z$63HB" M7- 0D A'4N:88FP5HN)C<@:=B\SU \TU M'3W;BKWCF5V.&F$D,\J^?#_4+'(47MI;.6E2%:P2O\M>G3/VMBG>L MXR6;8C;/]WJ\>_%]^4*!]H\)35%*A"0@5_\!2, <4+7P41-"'.60P20D5CMI M?808&^=_6CT^DN)9D_Y&BR:+N=7 LGY6'].84;IOP#VS]EK\?:AK#=:(!U\J M)0*M15"IX=#COP1%5W6V^H@P;,6M"T#:J[UUR;-Z>M.KIZ=91XE@PNWPAPY%M/LMA M,G^Z@@>\L^I6U%@=2>IJ>)NB@G^Q]((-#6+HV[H'V;?'VD6W*BRH90XZ0OO9 MW; #RI57:3CJL+ZB'11['J#E[9YV B?!]4:"ZW?#T3[#%2T^@FV(TG0? MH@.#KL+0%EAJH0@:+-9YED&%QH!;%9[L.-1.AFOQQ[71XIY,RCUS5MWAFT_#X3K9N]N;$'49YRF&8@C#. M,$"I0%\1&G +:T/5S!)]O M-ZT_[IFV!TR[EZ@B09G4;C@B2C(P\>.,GHM'K[249GKN_G5:RK^[^= M/ZV6Y3OQ3Z@=O\Y.<9&+Q=4[[\@WJZG#4V7/-XMXWTU=+R:?UO][U0Y?X=]SBX$ MTV]%_[-2C*&FORE4AE7]C1_7L[UR]\&-LQ BPBF,8B"83O3.$064$O4W%,)$ MI 1'H57JS8$QQD:+'Q9+7AL"-QDWKO/TVF9SBZ6.@:IB';C@+YX_*X)X.[]37@S1=59OUUEWRE/C2* H M C!,X2GB&8\%3FA-E4YC,?VNH3'Z VGV[D6N4DKO3$K1RO12MS M)TO1,G7;W YFG. '7<^$H8&MHB1;L;63]-/G&N6?@[7PP>UYF.V3LZT1TL)$\T*+;QF.>QOTT M5WE T_=AH ,@>\1I&L%S0;CFZ>$]4ZWI7TW)70Z MVQ2EGX01E9SB#.2,$8!X% +,"051E.49I6$2XP\XSE6Q@JR2]"=:RWK0-)AR6EC="Q56-^=.##5MLWDCQO:KS M9G?U(Y,7I)R6=_*6,\DBFQ(94S(8=&[E44NL@S@_JJ:+I_FY'*X9XF]&+>Q0]T\P:P(W(-T$M M;O"E^:^76E=V2#FB'L-!!Z4@.R!VJP5@^ZTC+Y>VD(\S#E (5<9E&81!))J]3U$X.-C7Y:6>O6\ZV@ M-\%<')^<[1$VHQY7N'DFG%;,FRID>UDA]WJ#W/L3R/7ITGX6$G=-UH\/-72/ M]+-*'VAQ?OZ>GL$>[*O@JYFXD^O035%\FS)QY$QJ5IE5_>U.?A1L\3#73?[J M&/"7BW)95L7X)DC(,&4H!C&2NO5.A!7IH!"(-,-,T#SC4%@%4/J08,4!<YQ! E5JMEF\%'-PUL"DN_K@^L#FB4ZNA!V7)/J#LDE^O9USJ+-^JQ3R?SE;+Z;=. MX[+7W]ELQ05_HQ35A+M:-BS[FA0Z@K=4'%M1LI#V]:WBWP%LU[@-+M$W[FW[$2X*[G)+H$][A\['<5!+GL=P-OD M6XLL(3 E,9"40("(3CL-*08A2T.>9I)!;%5E].A(HZ/V.IM=GQ$5W_1GOBC: M%EH5+W020IN2'XLZ\/F"'/AF]C\;3%3C]$Q"1_)4DR@HA\OT8 MB*F4*8]3K/X>O5.;)0/M/8CR+^S-]6U,_(L)/XQ L:Z_'T-?)Y#_0)) MBB(05U1_/U>U] M#G7WN4K:]R'+>IZ>+K36#S,=G>[+,X+)Y[PAKCW9G)#PQYA*@F.UQ"<:V M*CE>QO9)_;6[PW7!OHN]G0R)WB?ZOFG\1*G:IB9W?4FCP[HWFDM^[HN?W^JT M)\8?0UW:\_ 85J0U>-# 3K6.VM2);N6R6%4=S^Z67T5Q_Y7,MSEF91CD42(!8RF2(<,0BK!UMN\'V""R5Z&')WX_ #._N:(+WN,] M\.R:>S+K#^.RU_H''0"""H%@J2#8<^CKHA&C<>?[&^_:;GX/R7\,][^_29PM M"RX0H6>2M7[^^\5\74Q%9W0_BB; >4)CEH4I2P F1'?02A$@<1B"C"00XRP3 M&VA4#-)M-*Q![I1V>P-9L=W"'FF=!KL+J2!K6HP4^-L,=G:OO4 M:B-47*56GQYLV-1J(\7W4JO-[NI'(1^%9BNVK+SXVSG_*&;:']R4F7DU+=EL M4:Z*3M RA93F"FF (R0!"J,8T(SG0$ 9"I02E!.KP],^0HR-;K9TL*.:7C8P M(R#?R'JFI2WQJWR=1H%..:M@HT+PQ4L8^24@.F*Q7B(,RFV7@+3+>!<]JQ\/ MOJRV"JN]BSHR[G:U_+HH=)+.A.120I)F(.%0T9VD&. 8)8#&",$L%1#%5C'C M)\8:&ZN][.R@W@1D+6?_)?PIH,TXS1%\GJFK0>Y3C5P3;;F1U!T[&<#AB(1. MC30HUQBHO$LI)K=]C(<*6DCAXP'<_=Z/.P?C3Z;E,#;X)1 MB).80""B3!]J)RD@B>1 H$RD42Z3.,(V=9,[S[:BO $*(]_K,?H7 .RB9L9, M/;'PS#?O# "PIHX#JCHBA.Z3!_W,#ZBT^_$>NJ1O-(KZPO5&]IVLMYS44DQO MB1?BJYB7TV^B^2DMJU9(QC$.5D\=T4NZEES/BELBMYNE7UJI74Z _?!R%M%@ M-_K \0R]H-F/9NCWF(%C&=Y-Y^*M$K2<1!$F<12G("=( 2A7CQ$#&0",IEB MP6*4#I*\LA9I="N)3EVG\P?4=/^ .OBB=0LJY6S7%9<;V'/L02^SC3VDP,QB MP\4([(%\[:/_C4 _QHG^'H#.#NKWGWQAD?/F+$ZM7$0>*7:F@(1,%U6"D:[\ MF0&&.(L2F&01#VU6+GLCC'/]LCDU%HVN8KX$T/%^_!![?1^IK3%Z?PZ1_ MF4>QC#,&$I)*@"*8 M YQA#EB>)!CGJ8R(M"MC8"^$S5L_3'V#JB61G"W^*.OZ,=-6^$Z[I[\XZ?=T MRC9F).(7;\\LEQ5V[U5+-*!M?&[15DJN>[D/?D^H2BF>2@S$-.,*TJ,!<"I8 +C!@,":=Y M;M6\TF[\L:U%.^('BRK.CFWM'XS\1\+_ZH?E-.",,X M19P $O$8()8B0!-, .37;D'@TU&Y?[-?5M^[D5!=>K03=(DS<*024"1=MM2 MM9S-,T1!&$8)BO)8L,2H:XW9<&-CL:9/Y<&PO8[8MLT^3R)^FH7;3Q-D+NCR>?+Q S?Y-%%UO\>GT5W]7*1U2:7?!=&AV%7*V_J'_^=4%.J1 M7Y]?+1[)=#XA. TI5(M"&!,&$%+^$F52 LR@\I,H1BB$-JZ2U>AC(YM.^;2U MI)7G\_[V;\&76F;+4T<[:YCY/]XP]DQ$E\%K[?_T@LF1'V0W]J#^4"]8=OVB M?@_QT3[E]G%1+'6\N&[7TG;811AE,LH@R'(N ,KC$. ,18!1CE@2IVF$,IOS M/GL1QG8@N-WBHU12WU3+./7GF1:]KFQBQFU^D?9,< :-5:IN5K4.PQJ2T>9CB)49KH3H,Y0%+H MN@(8 9EFA$&8AQF/K7>]#H\U-L>M&R_VU$0?D4W 28^MJB,86VQ078Z<[VVI MTQ7!/.U4CW(9G^B]C(;5E!PPAQLP6$ 0ZKFWL&*I:E6);M/B#/DBSF$0,$YPE "8$ 2XP!2EFN M_A+)F%IED6\]?6S;KG4>1L/M :E$M0PJW +/C#YZ0^*9)FJY/&QY'E3851#? MUK.'#=$[I-9> -[!BWI^J3M>R\:?V?9NVM>19#"-1):#!-$4H$Q D,; 1*OR^7TL5H22'W4^:V.[2*'CE[Z'+K86L>0+/QA/H;C M%O=#$=TW3J1/$%11F( M0T8!0HP#M:*10/TK#%D6(0:-SEMW'SPV+FAE"[1PYH&V6UB=_L8O0<"WCV&D MO%6(["%->P7#;CUHL+#70^)W UP/_OXZ33L[0;5_%].'K[I8\3=1D ?1=D#Z M4$R9^+B8S93#J&^[P@9M[*N,WNF3-==@[M '$3''V5 M@OHM\E+G[6J6O'9AHOX*_!B%C"XVD.O&I1=(TC?S[-,CFK,KI7)3E)(YS MD>4(@TP71U+3'04T@PBD2QV^;&PM-]\OJDHE@FM^>=-X M.YQ+C&.)02RXWN"' JA_JM5N(@2E,,NS=!AWN)?X8R.<>A=B++TU#QKG87UV.H=E._*+!"1ITQN#K7F36:_NY_83_,7S;8IJ2.I,%:5(>YSKN0F\TOCH'T/"GTQ-!)0O,15#RF,>^.>/7DY2,0F*0L M'[OU@N2\KXN9NJ.L*>_]8BD.=8G,:)Y'2<8 Q(RKA;;( >4Y!RS+PQCF),.9 MG5MM.O+8Z*=;E*0*(-TY0>V1N6=D $,WUP>LOCW4CLS_UCJ;6FS_#3FMX7*9 M[&CG^^@SP_4N[6Z+GNO*[ MZ?#7*0QO"<[1NO&VS[F@R?J4J66G3G^8$,RC1(8,8)W+C&B& $EP!GA,2>K1&WR!G1D#]\?!,+QTH7IZ"HE^'\CV-7?8>WSQ\ M^*[B>XH=[!>^?]5H#SYV#EU_4X]>OB)+L5XY3I!($\9E!C(I(H $"T&>00X@ MR>(OQS_CH=Y>+%L%4: Q"C:%,G^H MLSUCF_\X)W[G5?IG.PQHZG5+,\@/=C"\X2V@?=F#WTU MK>V@'7RYU\F6@99EN Y70?0,U%^ M4 _ZJB;"4E-EW82G^@;+M=R6Z;66)C&C0!\P#Y2(VT@>+!=!(WM@4"[ 889N M/^AU:CCYL+F\_:/82?'L^IN?VX_1A/I53ICS.6\86J[D^IOBPF$V9>O[& MM0@5TT6*[$!*4@@0HQ00W8669C%,TRA,HMSJ#,%LV!&[@1T%@HT&0:N"Y1:+ MF1$,-T&<0^M[F^(TE+Z".JQ@K?[]8_I=8*N]QH:3^WX)/(.51GC($HAPK M7B/*>\.A(""$" H8(H;SS(;7O$DZ-BJL"\#INLZMA%6;V?46H^[!$12B+B2K MG)55NT-=; XEZ[:-J_G4MG:4!-X\/5-'O[/FV>\5:(1V1%SR+ M9;#1J8I@6;FL5.4=?D=L[T_.02<([W#OSBG^!^R=5OQ5S*I1R/QYDF."2((8 M")E4R_\4AH!R*4"*<$1YC'&21Y99Q9W'CXWPVPQ:+6+0R&B=4]R%[S357@Z* M9WZTPJ-/0O$!M2_))^X^;NATX@.J',@F/G15/W_Q[9P5.M+NE:C_^W:N?--B M)?B[*:'36;5VGB0BY)00 C!,$4!9DH.<4 @PS3"-$XZS$$Z^B8(N3)T_DV%M MWN#NX/Y>Y$;&-J;7TA4S@MK,JW(-GV<":,4-?FH%_CF8SH,6SH[0[CP?&X@< M.3%&0P[JC]B L.M:6-U[]>)>;^=JJ30OIZP.@H$02T533.=Q"H B2 !)F/H# MXRS&,HHIM.IIZTW2L?DNMP\/177\H3[01LZZB'&PL&VU[=_*AKM\8[#=@$M0 MI_6VUAJ/)AC)U"K7CC Z*^>/$39D"K?'2EA'!NS1 ._^#S7*<_WG>NFLM];4 M9*=^-OTF.HT>40YYF.0(4*1<7\1C!+ @# C!4,3S/$L@-9E#K$<>VYS0E!Q1 M_Q/%-UW9?E$$!3J*0'T_89/+6QNR2NE=*QEH+2VZG%D9 M[/1TX-4,GNF]%CAH_M,*WN"\#>[YGIT7HFS1*,X7V@-U@;- W5%+MSZ G>S7 M9O7 X9JQ]=%SJ]-:KP?TC AMHQ@WX:FWWZ?E)!8HY%'$0AKI< M(HU(E$L>2JO. $?&&=MDL GJW,@9?-&2VI:*.8*KF5/O "W/G-T'*/O8RM,P MN JA/#+*L)&2IU7="X@\<[G]N4833/0,(WH_7<[$1-(D3YE 0,A^B=/]2X!!/?#IDE M'%:G&L?T[G6FL?>PP4XTCJG1/<\X>DV/Q=WM\OZK^+T*I+V34NB8Y\9E%5!D MH2[REE/.Z[1^*E(,8"RR5(@P8YE1C[+3PXSMD[U= K4B W5H<=#*:K$L. ZH MP4K+"4R>O^+#"/5901V'RF*YY 2R@=9&EB^7W3+H+! GUSS'[QYN@7-6@ZW5 MS/FK^_LLN4D>XPCB4"B7!2N71>I #!(F(!4R%)Q*EL5&5>>.CC V M$EPW[ZFE#)2858*M?1.C;2#/>R\7P^.9_*R1Z=7AZ*#V%[4ZVG[BX#V/#BIT MJ/G1X0M[^#5MQ8)-+95JI^.S#@9M'9P\D5%,&, HS@"*9:0^ZS0%&.G"P*TV]MOYBT6Y7,Q_ M)V5)V-=5*9:;MSI/4XY$"N)80H#2. 5CNJML/H M)%T;/FHXRK;3;8NV+6_M7:U )P67MW->Q3"26=FV"9S$F @B.01"5UQ#:G$, MQ,SQ%TGFFY-VI]"@B< MP\-=L8"C(PU=&."* )R]Y8+P9'H^A(T>"6%;YUW5W9ON9!U(];'3:RL4 M,45IDH(H55F4_-FMQJ.FAY7 MCZNJSL!OQ:(L/\\+068ZV_@0/2I&;@-6JW 2T M4B98DN\6*W>GYC78,KF6T7R??)VN E8;L*-=4*D7;/0+?JN,^7+'F/?7,Z;% M9LVUC#K0ELXUC&NW$^3# "?WBYP..-RND@^O S0;ZEY6I2J..M$9@+E M4,W'/$IR-1_+!! 10Y"GF: (DP0BJTK#!F..;:8U^+B;4K:6FUMVI\),)H-;+)PN('*U_3$8<= %C <'N"L3FUGYD]/G3;XMOHIA7:Y<',6=- M_)2UMZO8&T[+4 M=2WH<_#YET^_! ]KI0+2:&7'3L8&,:,H'S![YJG/GX*-S$$K]&X]W_.GH=9< M98N5(\(R'G90UK(%8Y>ZK._OQU]U"?1)G"80"QZ#D'.=GA-!@$7,0!ZB#,<\ MAS1&DZ4NAF;&3O5CK;AG_7!_7T9=79)4LMFQ2@.3&6?8*^^9$6Y/:VS]H6\K MZ.@S;AXZZ$>ZK)RN'LNW MU79G5:5[$L811^JC!&&:4H HER"'0@(<$H018NK78=L$X-[<:^@GC=&KO-T0 MX'Z(O<1N"]N%#)X:R:O39MZJI%MX'&P9Z M+#^(HCH>6L?1I"Q$NH\*8#3D .E( 2J52Y/2/!(PQ"F#5EM QP8:VP*KE5/G MJM2'N[W#E(YB:T9H+A#S3%G]P+(O+7T&"5>5H8\-,VQAYS/*[M5E/G=]WVJM M:XK1ZR9%/G7GO,Y^D-WK;/[ $;W@':%OZBT /?\V_3>[NP$>WGI[P)P5%S4> M>. 2H[: [!<:M7Y"[UK'BT?Q::E\>3W:.VUL/;/KJC.2XS##<0@HI#% (L* M,L1!DA&!F$PDE=QF9CTQUM@FUUK48"UKT K;JZS/*9!-.;8:*2MYOW4B@W:GC9VY=)M M8#]-*)[ '&#'0>.XECAH1 Y:F=O8%/=XVA0K<8[K4)5+SN*[#O[YQ54]$RNL M3AKY5"I E(0Q(!E/ 0T%A$($8IR?(0P2Q. M[/HBF0YMPPK#]$;J2%YMQY4=V?_USSB"V5\#4>E@1^[&QC!C:A\ >Z;=762; MC4X?NYNVZ#BB4>-A!^5$6S!V"<[Z_O[!&-M=F=K5G(AAS/,P!2R))$"IP !G M60(8(420C! :&56C.3O2Z)S+B_JT'0>4B80Q';&2I.H/A+#R]^,P KD0A&98 MHA!E5A%E3@ =+LC,$ZR&/K8+L ;:N^D(>7-VMZ97*,A))!Q&>QP>9_" CI/J M'HK9.'U#SWH0[*O@JYFXDU61L15;KG2I5D7NS,E?%#2Q&'K9*@3TD>^4&>CS"4R_.\DS#MM_4E_MW,7WXJEN.J]4G>1"OOXN"34OQH9@R,9&2J9<9,A!22@&"20Z(3&(0(A)1 M2"%)3JJ_YI.@_X8C8C1:E/X()2J_NSXT:=#E\!0QX>IV%] M\[A!>9S2M#Y.C8 N;EACA"A9^%X'?SCWKON9F5WR_F1?M/)?^T M\3JS+&%48 XDSB5 >A.&8*EF/89A#K$(.;9:#3B3;&S3F5:L[C1\$ZREK]S7 MKOS]E@GNS&DV>5W%2)ZG)D?VL>]SYQI+5YWQG,DU;"\]UW#N==]S/D#/S?&= M\@@[Q1/JG)YZ%56-.1$AHE%,$\ $)0#E5"<-YS& 24;C.,MY9IDT;"G 2'=^ M]\NL=',.F9+>\0>T?;,K :56-3/6@VJ71R'.\H]<7.UT6P[_+#[ MSSW!V=N6[ON<*VWHM*ZTV8(>*7+,LRP%>9QQ@!1= LQ8!/(P9 G)(XI8-.B> MCI7X8_.#6^%&LK%C]RH,M+?CS< _TO;.&H0?GEPW'LLEC)_R/M<_3RS#. MMWKZ2=%OOGPOEB])^?5#L?@VY8*_>/ZL9'H[;_J(JR4*6TZ_55/U!"=JD2!3 M710Y90!EN9KK>)P"GC%!<))AD88VBP3SH<>V/%"2!TR)'CPULFO>DJW< 5D+ M;C=A6=C";++Q@[#GB4*#JZ4./G3 _4E+KLC^YV M?'!['F9K:K='S!$M6PP\ M**7: [)+ASV>T#LD4!&2HL;G4&TF#5M3>141. &RX4>$$-L_\TQ.Q/O%L9\!P%]!V;*"A M(]K.*'P@I.W<'3UW"?;"DM\OEINB.))$)$JR# A&,N7N)$(QAD>)[BS.SNR[R0,JF.5L;Z8UB?7["0UVZC (D803RF$N0TI#'))8,(M3# M^]@99FPTTDH9/-5B]O(U=J&T\C,N &@8'Z,,&@G]A,N?P,"M:[$[R#7&BI=:G3VDG/\8UH[.1F,PS)S:EI7[2>OX< MZ.\\V*@:;'1M+=I<7ZE;-43LJ!>T^KFN1^75"$[K6?F1] KUL+Q"?KB>EM\A M72U9U^LGA#/*TI M6K% (61+L.50K5PC2GD$ J<$;N$_!\I!?_3T93[OURZ M2KUXA?JCK$YOE\MB2E=U7?7E0KFEVBL::+TZV%IU+.M4^S6JH_7IAT(\D6E; M:NIVSN^67T51!RNV*RP",YPQA(&$- .(X1#04',+%I0D(0H1->I_:C'FV%:N MCAQ6X[F?;J/&*"OAG1.,;4,^.T<#;B5FA6 @>UQ!X6OQ8 .6(; MDQ$'I1T+"';YQ^963U%Z9R(D_E8UD]8UDY6,3#@?W:V6Y5*]7OI4\>&A MJ/J7*/>KF,[+*:L"LW7S-I9$(@99&.< B30"%"84Y%DF\YC1.,N9TX ]7YJ, MC3378JJE=B-G\$T+&M2=OZO/7C1*:A_CVZGEV&D/_[T=X%WR[EP9A?J91 M?G_;O#BO.R^._K&Z:H/*3;!Y^=; U/DZ P;]^3;N4/%_WO085RB@;W-91P5Z M%\A-5YY[\7WY0B']CPGD&4ZQ%""/:0I0!-7?DAR#5+(01PPCB:SJP!X=:6Q3 MG8Y0J_:6G]I6,Y3;C7+4E MSYZZYWKR[-]P:5FHP[15;6*TW*5XJ*:[LEP]UC^K\APW;WX8;9*3];\JO1H7JG:HJK:):@%7U\0( M7FDOZ7.I#TGT#U_,"/L'4,]3HI?M?6M @M\77,SZUJ5R\F(8NMY7,[=O?[IC MZ1,^<]?LVG->&["C8Y.?'GBA83\&<%XKRXEP5RJGY1+8XQ6WG([2,R>%+%>% M$F5SZ#9)PH01DB!=>30!**&A^AN+ 1$D#M-4S1")L#OBVA]D?$=;M8SZTZ^H M>J586Y2V227[8)I1ZF4 >:;%#3*=P _#N9Q'%RE?NP/,&R*QU$%]U(YCE_9 MO\G4Z^_*8YJ3V4=1"O6 KVJ)^TI\$[/%DV:?W5X],*<\940 CN-8^8D1 C@A M"&0D9%&<<8YY8MMRRDJ"L;F"FZK/M1)!T6A1]\[>Z'%!0RH[$YVFET& ]\P^ M+>:M_$&K0* T"#HJ.&A>98>]?2LK;S88N+&5N2U\-;KJA:1)VRN[!P_>!*N7 MWH=:8O5[D-W,P\5T\GJ^G"Z?WTQGHGBI5L,/B^)Y0G*(",E2$$6, 123'.0Z M^2>#/$6<29&$L)KV'>#B>\?2"A)CACBC M^ $?LA3LEX?%MU_5G;7[J/ZR\1J//6^0S_Z,,NU'?>ZR?LO"IO;S!U(LG^\+ M,B]UGOUB_DXMBJJPRPEF+,D)(KH8CUHD1C$!F$;Z;%^(!$(>26*UAWANP+%] MU&VM\TK@H"-Q\$7+'%1"6Z;NG07=;#'I$DK//' ABM;K2U-H'*TVSPXWZ-K3 M5/G=E:CQ?7T#)1=,"%X%@;\MRQ51RMS)EXO'Q\6\V@J;1").N% T T-=$26# M"< ,*JXA<2Z3D&598E7;]NR(8R.;1N Z4:-J>Q8LI!2ZCJ5U7.0YL,TXQBF$ MGDFFE;6&KY56[V?5\M8;^BX#(@VQ<18.>6Z\@8,A#=7?#X4TO;$?T>Q4=GJ_ M>J2B:#;ARTYLARZ-R"8BRU.!=!,NICM(A-JW800!13F4$"E#$G$;TK$:?6P$ MM"[W1IIR;ZS^^.QWJAYHC3[,8>E-]ZP;++=?T>,G29UNJ/>S7J[9Q_4&_F>_6N MOEH\DNE\(C.>)!') (4< Y0P#O(T%"#A-$^C-&4LMXLA\2#DV%BTDC30H@9? M:@EM:[OXL*09A5[;/KY/&2Q,,V -T_/87;U2Z0D1QQ6$? '([JJ.&HS5,W3X M\6FV>!;BDRB^39DX+.'[Q;Q.$*F#U:K*^]W?Z\+@[Q?+_Q++CX(M'N:Z6'A= M%?7-HFA^I*^#$\1)%M$4 0QI E L0Y"KA3@@1"!).:$<664N#BO^V":&UAL MK7O]5$E=.='/@A2V/O3 +X/9##)>$WN>6PZ&$FZXHJJGT>1M-1&&6DM=Q4P9 M?QEL%+UIRF\'@)6ZW.=,T272I@16;WHGB$$XEY3'/& ,,\ @@3H59%, 41 MCB21">=Y2JU71J!$>0S$1MT>"ZN!WQ6+===XWX ! MI\Y+,UP[2!SH7[%&(^C $6@\'*\#KV-+E\O$@348?A5Y'1,=7&1>292^02.= M!N)Z==OL,(584#WU@20-JV;<:J&3\!S$E(51GH0\2JT6BT?&&=O,M25FH.7L MN>UW#%?3<)"+T?(>!6(/5(_0CY,P.(OX.#S*P($>)U7=C^\X?7G/^LRSRB:" M'UXE-!&F$Y9E!(=)"&(20H!HE :T11 0<,X33',2&95K]EHV+%1176\#2HF MUT>K&S^GR2.PK.=L!KT9?;@']-K;+:_/8&I?_MD*(E?EH,T&';8\M!40>^6B M[>[N1TLZG&2ZK/;H;^>\+CKZ(.:ZW\4D$6F6AQ$'"68I0$*F:O6.$,@$3)'" M(\WM6E&<&&ML!-01M[+3G=L8P! M&(ZHY=1(@_*)@F:2R'!A@;1[0R!JV0@9;2/)'E((BGB< %-+[=#3M4K')9 M3JG>*YGEX ,'RV8YI4XWG>7D=7U3T#Z*AZDN[#M?5N]="+,\(S(#60YS@)", M 9:4@Y0E&$8LERFSS$';'F!L'V^3<;41TO+C/0CB^8_W4F@\?[R6J/1(1#NL M^@69:#L/'#@5[; Z^[EH1ZZ[3@7;3CSER:[BJ8RS-"$,9$SGM#$N MQX)3%M%$3.K0C$]+4BPMSO#\2V_S5>WJX.\#>Z'>@WEUK$+)K$J[&*3;O*,7 M@LL0LQC&0/=U BF&% 1,Q!',A(A$HE,>?-"O)[S'_QU:#7PR;;\1WT3+ YK MQV7;'^B =BN78>^ MD4@J" 83ZUA2YN-I+*PJ=3C"N%U:PK758-MA[^@-Y%. MCQ/\57UB4T_F5>;(>_%']:MRPAE#D.48Q'DH=YE8% M@\V&'=NJIYOLV::L5>FS52HH68+E5P$>2?$/L0R>5G0V99O$VIM@KGZJ;IRV M#ZE:DS2_5H\KEV7_-#=#,QK..\Z-XWO:J(Q02QR\:LY]*YEOFLRVFT#)75_A M< _5#BB7S9'.#SI\HR1C( XV33*_NT>]NDV-S$[^KZY55'P3.D[TS4I7QVL_ M[ZHBY@1RR7*((Q!F.=-EC07 B'.0H3R)<$I#&1D=)?<58&SDMRYG>[>=Z1ZT M:@1*CZ!69),67Q>N-8Q0Z6VKT[PVA 5\,]R(P;MGC/N3<<1V M9>LNP/%DU;H^SQVN:-T%6F_5K+OD.3V][!4MQ7^O="F\;_HL<5,CG1$H1"A" M(*6$ ,4I!#C$ L1"DCA#/$RP53&:HR.-;CI9"QK4DEHZO$<1-?1Q7>#DF_1W M(?)4)ODL%JX\UZ/C#.NLGE-WSS\]>T/OGIYJ]5>(ND1[W:XL90D,,2<@IY(" MA&,$L,@(B!+"F,""Y2RR[.&Y.\;8F& M8KV8O@G^1_A+&(8P>")%W8?NKP$, M;]2/]/_:(C%DM?RZ*'2V5[60GB_:7TSK9:":@3MU9 )25F5.U.LA=&V,?_TS M3,._QN%-H-_2Z@FO!.O^"E:_@M9]0OZ-,'1SSV,J'FCF>?32@8\^=:>:2H!.XXBVF]FKZ;&QNNVR7R1LC@>2IFQ[^Q M*]G9\PF6#^N-_^RJTP^JH_?-IH5FJWJ@=1_!H96MF:Y]7&4L[X]Q4&4+O[,C M*NN!+\@ G.J'5C/@[Y5_-DDBFB4XHB!".L )HQA@@$0]#G&(>A:EUQN4E> \Q$7]NJZCXP]5L$KT8+<\3WT:^9AOT M2RVBZVS+8Q"XS+7<&V/X3,MC:A[,LSQZ<3_"_4W,14%FMW-^RQ^G\RKF:U#7F*4I$* *G( (H2"G"82P!9E.:$PYQG(,P1!E,0J-P*)$?4;C;FH%1O!<,N]=O=W#?%Y99S];:5+]5?[XK[ MQ1_S":,2(:)<;9I3#%!.)"!9E@(<0RAYG @AC8J8GQAC;'S3I'0TB; 'SR+FR"&( \47]7H![0*(#$$Y M&2QT[AG#!089:K,5!&1Z3_^Z($U@T4OR-%V26;UY=S3*:!)%L8Q$F@(9Z5U- MC%- )), B43(!(6$A%:!0-82C(V&7W8#[+?V/&4=6;<.I.\=-6]O);.%H%?L M/3-Y-Z!1.7.U^&U_F(]=,^P$.+HM3=(+/H<%2^S&'[R,22]X#A4WZ?>@?J38 M])Z?/[3]@&]I616,G. D%0B3&$A!0H"@X"#G4OTS(R1E4"8YMRK;=G2DL9'< M6M!UB_>_V%'8<4S-J,H)4IXI:0/2NB?[EU9,ASM39Z%P1"_'QQF41LZJNTL7 MYV_H1POOIH1.9]/E5)3OE>AUC_#U:TSC*)%$K3\1YLHORK((D%Q(0)F *,^0 M%%%N0PTG1QL;/;Q;S!] 58M\MA';DB%.PVO&$LY \\P4'3FK/AB-I%[HP@@3 M1Y1Q>JQ!:<-([5WJ,+O)?J/ZY>*;*-;O-"=X5X.V?-:XQ2&3*9<,!$HA;Z,14)-*HH]&AAX^-"&KQU!O.?K$X^=A%S."8Z ("!2 MI$B= 1:H]F6V<#PN'[=G!H-^2/#:SMUTIBTH.J,6JS5%N +CMJGH#-!)RXKN3XK08NM^J3[JA?NT[^5V M_JV4%+A/Z/V\"7U8+W,L7"YLK75R4'N0#<1@L(9H*M4J]W9MIGS@:&T\Y?6 M;A_-Z_E&+E:;IW5%(+.OFZOEN8:TFY.RN09!"<7"0*1M.)%J#K!=!(&"%RG0 MB@GE\F@U\>**CZ3/U *,JGG5:1UM6!#1=Y#\_-V(T _L!:^TN1J(>282?I$< M8U]M1G67D: [=J*Q'MMS2_E^L]';S9\U=YJH1RO>!3S6KUNQ\\U?EBOA4E1< MJ%3N5[D^WTLY7\Q+77]^+F]_M>";3=W;$F>93"'* 5=4 RPY!X(@ E !".^ T':F#7'31&W;?/!P(P]MY[;#5O MLW$_$-@7=_V'DM>5E-S.-6YB>31OYTMN)?'%A]5F7K)3[%:D/-.%S!@#F7!; M4:#RF%]A$[-/>]U=OP/>ZV3G=K!*0)! ^#G@&/#.G0< MW!_1#C3B_A!%(Q'W$#DRA;@_"*<$X@'W=BV'??-%KW^S'O%/Z]7OV\\N-N;+ MYYE6F"&3I<"HE #,(0%<4D<53C7,!*90!Y;$GI4S-<=3%WWN=$TJ99-:V]#" MV//0MON7B( -[%(Z8M6A1+85B1YELN>?.W*I;*MQI^6R[9?WKNKZP->/Z]+O MJ#* ^J#7Y;)XEC%N.)<9,#)#;HN/ :8E P9"Q2C.L31!!(@>,J?F')J56W<' M%M,@5;IJDQKD$*L:Q#%+[VZ*/%6 MQ5;7(&@IK[IZ:]3C.[=)]U"=$)8_SU2JJ412 YDK#G#..!#NV $JE I*"1,D M*!O34^[4_-)'[=:F;@I>OSCS*WLO=>!S\T"^U[%I'SQO=FCJ%'5IG97:Y5\' M/S*]!-2P!Z8G4J=P7'H)"L_#THNW3X!O^N-\\]]OUUH_+*VSL.J7/,2"24QE M"D&10@QPIFRX96@*I-&4XD)0D;*;\4V?TWAR3M'J"(Q5,IG76B;K-G+A&XVS MYV;3E$9OQ!/;R'S3SO+$F9[L;)\RX73;.$V1)4 M\J"FJ$'2IS:/-)0OX\$7ZB<'_3N?282-C?\>P""(C[ ;$ OL3KL"P:!%W!_P MESWZ3D$P+.?V#,(?TC/9YO#D1@)U@1U2 ["&I@-E#7J!$CNOY*RLVR2' MM)E],<.C]::._>OJ[+]Z[^#3ZA/__K?Y]O/GU<+U7'-%#&?CO9D61@I4*)"3 MM' ,=P)PK1$0!FM!))(T-[.E_JU\:D"ONX[Z>'U'1?4=G6@UW#>U,\=E(FSY M]^3W@RFN"4BUW;9=Q6X!TGE4_3S:H(,T4C>\RH2[Q*J>-'2_.[_6/JQN(C;* MZXEBK&YZ7=48M^5>3[!.^O+U?5YOGBP;&Y;G2DZB]41O_O$TWS[/A)"9R" ' MQA!MW:I(@6O- [)<"JB93!6U(=MJRQ=^_O2:P*"H;2]VN._RDY/19,HJUT:; MAM[_]J\,0?K'1)?Z=^;1.@^_G_^+">K ?N[=$9)OVE'KPZ#5"D5\$JWSXF[% MH]5J? N55OM]X7ENG];<^:]?GK^(U6*6LE3;Q5X&$&*N,WE* 9-4@()33!5$ MN)!>5!TG3Y[:8J]6+JFT\\]=>PE7^]??"X2!/W-/^X/RT<[:VBD#[>631LLY M.VM ,\OL_ 5=DTO?SA?Z_5-)1>[=!. M*N&#T>X*AH=XZ!G[]U6R4SZIM&\'NPOY5CCJ ?1<@Z(_$H%7\"A$HOGJC%TK M$5CX4\>C"NML\0LRL>Y/Z;9?\VE='AT]5PT6JF3@LK_"C#&-B\Q.#@IGFG>[TP_>A;F*1:3ME\MR1MUWN6KN\8;+]1NZ)N^7N\3RPV7 M95K3S\_-?[G_/M_,,B6%* @#,*,YP&DA $,( 8DU85#D"M/ _NN^HJ?F0'99 MYJ6"R:].Q< TH@#8_7S),& .[%R"<.R0IA\*2;1,?6_!(R?KAP)RFJ\?_(3. M-47:WO3Y?JE>.Q+HU5<72M2]5!]<%\=Z6=Y@:MBS M-S3ZP>4(<2DI@-R1+1MBW8QDTN58IRH5DNDBJ!EF%*VFYHZ:1KGE0<.L\GMK M&O:2S>1@6^=L[#CC[.?M1A^]@;WB6 ,7W@$O)M"QNN5%T6G387)UM26E!*QFBLL0R>"@9"/-*D$%N[ M4:>'@: ]GBB&$A.O61S:'9TCK0A$$D"H,H 1*@ GF0*9'7959 @;VHV<]U36 MU%QYHUDNVX'Q 2]MV0!=!:Y#8\9!)P:010I##&*(@8\MH-:!,R M-<=0ZYE4BB9.T^2-VT3SYN9HA;3=0\0":F#7T FCL(:P5T#HUAOVTD/':Q-[ MQ:P7'6.O7=NQ%YN4+GK=V)C7L4K;Q:O]S?I)JT9^^Z%DL5&6+)4AB"" :&%C M!44E8#250$*J,DS-7=1*[U8+@25_70?#+\X8 >*!'=-KYVA(6;'6'D MZ_GB::O5#(LB5SDM0&$R"C#3*6".VU%E>292E!F$O+*-K\B9FIM[K[>)!;A! M'YOP[78]%T_;\KO.YD]0=Z8&>WT_! *'N7 MU%I&W%YJAR'6-M$%*>-N][2;>K)M<^7RD8D8'RNNK;_JC6NEMU0NP)!ET;/[ MU:-=_6WM9&@5KHMPLJS(B9 :(&4PP)QC4&"$04ZXR%'*J<1!>SEC*3XU3U?I M708:NM9\Q_70/6UVM+? SQ=.<6Q'W.[O2-KXN&-I;+PB;QJOB/NUO>H PEVT M@K);#=RM61Q#U?XQR!P[#D8T3L>N\KO-@'_9Z$>S:UZ^F>5"2>)H&S7$.SO0CZ:1 M$%TWAS0D1X;G"&BE!<"0$\!@3MRY8H'2@E FPYK#714YM4_>:>S>\ZH0L5OO M3@^@/2.]J/ -':.%(1<>/7F#$2ONN2YPW(C%&X"36,/_SHX$T'SCTJ+='XY. MYYN5M]QNSI HSG)6* PI I"E!N",<,"%*XQ ',&<$T%U4.,!;\E3JW%]A?7HK?B ?O&YPNW_^V8!ZW(^R^K]=;E<;D,KO>KJIW+ MC+J9U/OK Q'L^7H! M&Z^O-A^?A5K[EC2W[G_MXXNIVE M B.6X1PH+B7 2N: %\+^)'GNZLUP3L7LFUZ+E1>#4X#HD,^SJU63A M=&U2J@80"(6@W^[]AD1T8(>WTSKY::?W'Y+Y,CD@7.K>3"(9".$ ?M]=MO72L.P:/4>D_R8;-YXM:BLG)JINRB&D+* "D, M 1@IZUP$Q@"FO$ $"OMO056M;<*FMBG8[%U2<;W-:W6[=%MNA5EDF"J!.( B MXP!G&%D?[C9B18J%H,QHIG;-9$8"^F6OF'&@=DB_Q#BQ*^J$;\'VLP9?^/J_ MM;O&Z'69W.>V&^=+.\OR1?+U22SFK$']OK-=[JF]]SA_:KU MG>[5M6T=76MNZ#<"YYE+--8IAI0(C* !<2 MI]I.#R(G%*HTS_*@3,FA%9[:%%..>,V"()NI=/H*M]1MAMO/%4YI$ =VI_8Z RSC!D J.20Y(Y*$)=E?$#0YE[_7,ZD4 M[4Q?=A%:/S<= ["!W6LGK,)SF:X $2N#Z9*8?0#KXNQ9 M1G!!$$P!$=BN@8TB0&0* IKE/"<$RL*PCIW_7DWSV+[J]5>?$88?4+5@Z>17[Z/RRZ?$;];VZQ:'W90-;FO$=7]GUR,)5>)41RUJ MDS$&,IZI/(5(H9R'A Q#*3JUD.-@4R-M)?2$9* Q]3U8N?U(#7X>LS?1G<.4 M249N@[,Q>)6=C3%,?BHS+BM;DUT/Q,K:/PQ/Y##TJ$0["!I(S9'/CX8%^_38 M:6!Y';-&G_2G5:-=P&'6LBHT4A%ECK7"A (M30&P(@5@L#!VZD %HI@)%L:^ M[2EW:J[?JNWJ:==UJXROE>:!N:">D/NY\@& '-@SUQ@VVXVT81B>QAF&2*S$ M34^IXZ9JAD%QDIP9>'OG[B+;]9/;:Q_NVA&LO^EW>TY@(9A!0AH@ M3<8 IDH#KBBU46LN%19I1F&0__$1.C7G\T+G:M_;Q2NUVCT(G+U&P,\=Q<9U M8%\4 ](N?4F\,8K7GN2ZR+&[E'B#<*99B?^]<4BV?N:;N9Q)KA%A.0&,J!Q@ M*0006"G7[XA#DU-5F""&@+-2IN9VNA)L"6?,(/1:U6#X.:3>$ _L@L]0*"@6BU*ADW)=5Z8>8U2JV7%W*:H+@#E MD@/,608X9A@(F3(%"XDR$L12VBIM:CYDKVRBW$;,IN.V63O"?@XA&FX#.X8# M9$<%<@-0G'MA$JO.MU76N+6]/F:?U/-ZW=3-@]@UU6I7^/"PM+.JKLE[]V?1 M!+4/,GC]K.=*.>EJO\[S'M< M1]?/@T3%;& OTM0UJ91-?JK5_<,@Q__>Z$3R)]?EC>I3O,T_]BO^-X:W47BS MW,ZWS_=*V5=K4__A5DIHQC-L5RY( :EQ!C"C-B 1)K7QB4P59[G)L!=E2:N4 MJ?F02M&D5O%N]T-2KO8__;[R;Z9P&=AV5Q(-KJ%7)UV1"FJI"Z5,!H#6BCJ4LT)$%1P '.98:HI5)+V_?#A#_7A M/RX#NJA!"I !F.4F%EB1E M7KX@5/#4W$.Y$[1)UM56LBK+"\S3UF5\<,=.NTF>EA;^Q"Y!$OO&IE#EP]@@14-!4P9TIIA=DZ ,,)DQ0&!F&">*6,<5DL-\*B+(!8V6P]P\ M2/FW?V4(TC^6=(K;Y\"2AE-("42YY-;7%T:[;6A> *9R ;"6.L]4RHJ,S;Z6 MI2N_;/EZ.P:PQ^*&@_=G_=M\Z3;^$\$7KBRT-YX02<-H1H')\L+5W4"W-2= M;B0VF2:Z(+K&\\W2L]@\!IH[84.&B"HFD'Y[;_V@&7@*:RKW[[OTTONCL](/ M/&[J_65$8A7:G H8M\3FHH$GQ367KQRY14XE_6'I\A2J:G2W;?WI,U_6'0[> MKM9&SUUHN?F;GO_VV;4[^*;7_#?])_OPK>NFN*<(M3ZF@%01#+A4$.#"&%!0 MR4".*3,X95@6XS30B6K6U*+_AN[GLQ9&:ZT3]^WQ=*R34'9*SKQ_6YYZ!FA@ MDU3'5UN+SJ%I3P.@NV0'45)CE)0@E?UK&\S/$^C;,\BXW[JK3URC?HR>/X,, M9+2.0,-HURT<.$/:?:@2+Y3 IF Y0(Q1@"%V%1(I 3DJ*$;4:*2"3N;;A$UN MZCQ'2=^]$K\59[_I+!9Z T\RW8$+=O0^B$1ROZVB1G6*/D8?NRJO>[H>Q3TL M[??HFI-\T]8S\5V!N5"<9JGB(-6&6^=!"\?>40#*%!&,(*8RKU+<:X*FYCCJ M8Z:&LB[2X5<+U,/0]3V2ZX_9.*=RP7!U.)1KQZ+'N=R%!X]\--=NWNGIW)7K MN\4392CCXJ&U_FQ#(OOL*O'G+\NUY@O'>_^?JX7;9/L3GR_?K3:;QV6C1'0] MW]A_>ET6051<0^_U]M%\XM]GB!L.TUP#I!D$F.898)JD0!@BN4)$*R1"8I&A M%)V:.WKUV86CKE[\:6]96?M@YV2[\OMRJ!W?-/I5+$L6S63+OX>%.8,-/Y%: M46@G$E9H#3 J4L 4%(!11@OJ#G6I#*.PGL(+, [S]<57X$=Z ?QBY"D,ZL 3 MYN.KA[OC_/GS#68.1B>UU8DS._G)&?Z'NT1H>ZU.#O1P=PDWUBN>%JT_H>&PK/VOUY-K"WDNY?M*J MP7# 8MU[N8O M>-RSL6! 3LZOPI_0O=OT4:_8DNYB+K=:U;UD7_ZB<>4^*D ZS8A1"&A,6DW-XSEJ[J6T@UB=Z]L/55K%[\K_-[M7E\'< M>F]=^>^! 5V<4?5SEZ./U<">]%4Y**=]L \V)-4E-7-/\Y?-.P8)$Z."';&3 M=G^=1N^R'0W&8=[T IA^[K$_1 /[NPJ=2L.D M5'$ QH]V%"(YH@M"1O4L[88>NXHK5W"4@B4LF\(A0IE861BY\5,[=NWX?/3EZ>*^O.U-G,Y]SSEOX*FW\??'Z.! M/_Z=@LF>%RS^M]\.0C3&P;-"1N88;#/TE%6P]>J./(*[DKFJ)]#Y-,CWJY(< M6JLRXW%3UH U_]U1'+Y?;?^NMW4WH?_1JJQUJ%,@9P7,=,9$!C@B!F"22L 8 MU@ ;G66:08-Y4%O14;2>FF=RQS [/<]VC]O3/F]7R5-M>]W)M&HY5Q4)!W(; MCO*"^'G'R0W[T'MTUQK-[6W=9?17-MQ53+'6RN19[YO/63OODOLOKI5P1.[& M,82W4OQS=JF^A*O[+8;6(%;D>#[GE.-*6!_&K$+LCO6LCQB7]_4%;.W,QE-0$_ ME?L0 DO%A)! 4TH I@4"!<\U2 L(19X)FJE 0L4+DJ:V?*IK$ZRVR4MUDTK? MT%J.2P"WSP5181O8>7=&K$,YQQ4T>M1S7'KRR 4=5PP\K>BX=L/(<7 E_=%4 M'&3W3]O/J[6+T6+)JX*Z]@AQG7+*C9?ZX(ICF6:NLUE.K6O'2DM09)R[9MTIS4V:Z2*H M"^^)A*GYYTK!BN$QM/W',7B>&5%](!DZNZF!QB"=/2Z8'JV;Q_'S1^[@<<&\ MTZX=ER[LFV+NM3M[ORB'RO[T: [[K]52U.W,;@XYT2@OA#(" X)2X4[P!. P M-P *EMI@3U&2AI%]#:7IU/Q*(X&]'.=S44:=T=XUH3WV6'O&@U,8P5L?Q=4C MI\HLS[I-TK7'PCNR]G]0PGLS.#^B_YF_]!Z^8)\ M^<'BN'1D% UF<)S#G&19#C17F>.020'G]J^2.=H'3?(L]PHDNPB?VER 4DCK MF&JO;3=6=G_\VYWYT*@.[)\KS9.]ZL=,[2]1'H:J/1@W#[IV_V>.3=D>;.T9 MVO;P9W2E;N?;/<7@TU'#>*HEI*+YKER3Q>B5+ M%?[O$U_;Z6GQ_%%_7:VW,TV-C>P9 BJU_\.%$(!E)@?*Y IRQA"27H0I+3*F M-G/NU$SV>B:5HOXI39?0O)[,% &C@6>2<'B"\I>N - I<^G2,T?+6;IB5#-; MZ=JE/18 FP]\KMZNUI_X][_-MY\_5^QS]A?G'=@,0:+MNIZ"@D,),&4:%%C: MGZ"F7+(BIR;?Y=Y_"@S9 W7Q>O]?)M-_&F,OH,I(^=U9H!=5!\DM_VY_Y7YR M!1J.MVQEFG0B5079TW*^W?1,Q0\=SX#H>8CAFYV M)/Z#T!2U8A#)F9R7,:JW:#7SV!VT7]R1T7]':/G.$5SN..*>WUOUZUX4&AIE M"H:!RC&VWSXV@#/. 4N14M(H@6@>1,U_3>+4_(#5#-2J)2Z0K:G7#@RZBY+S MM4&>&TBJ?G4(_-Q&5& '=B$'2MQ2V;L]T^1S6<,N8[4'"<8F%M_X57GC$H?[ MFG_" .Y]8S?WXYCN'S:;)]>0MTQ$>:@>K"K:<">';SX_KC_8I>2<+^J_?[+! M\,;U-K%+ D4HASDR(,]3#7"10\!<\0E6S' A84IQ4/9A;XVFYKX>C=%.\T0Z M:Y+Y4BZ>5+6]S6N:5]V)-K?_V/GYM5%'9.BM)]?986=,2?V_$D(ZF;D5@W;P_2?"(','A+XC?;#'=81]X:HG%.GQ7GWHG9[I9W"5[ M+)(=&(E#(ZG@F A-<>=AG *?<;CR/P[Q<>>!B@9EK%.4(XD MD<05'!2.O!HIH#.,A1;4HIV%47%%PGE4$JTQD/:;J^.^I0//KZ=$MS^=H0:^ M? K:F_7V,CH#,>">$7A3-MS+ %QCQFVYLTLZX'>*)WO-(W?W# $K9KM.+[GC]]\,@>-L0\V@ M!W0G[=!K.>>+#]Q*VQ%W0)&2HD *N)Z=T %.$L9@#HO "%# HR#PK96IQ MY4')Y*O3,IS XQ1(SYV(OO ,O6%P0*94<" RCXL01"3T.)4Q.JG'13//$7M< MOK@KN^,KZS36?/&P5/K[_]'/,TX5R[!) Z +" 6F:H4 B'9>)=$3BUS[RI;W)0^"YQ*B>_5DH'%C1?!=UOOH\)Y< N MH2>*X=E\GM#$2NR[)F[<'#]/XT_2_7SOZTF!4-5PN1SBU=)MC]]_GV]FM-"$ MYUD&I$%VK: H!$+K#,!<86.7"E"&K15:I4W-R=1UH@EWW_J:M% MZ1]7B\7;U=H]=492AFB:YR WM$PRED# '($AV75RN?7WN5Z0F93#+@>*D )@@!0I4"*!(RD6> M,2H%ZK2N:1$ZM1GYX-=<:G&M:L<531O6@4N:2 @./$N=!6^ <]<06&(O:]I$ MWF9=XP'"Q86-S[UA'F>SWLX^:KYXLW&[-/=+]2(Y[>M:RWGI25_KC5S/OU:D MW1_6KMQX6ZWVN<@TU20%&40$8,TUX(H@4!BE6(Z)0-!K#=);DZGYIO+T8F62 MG8Y!^RW]QZ7=98V*]L!^+!1H;P<6#:0VKV:%-#R:_=O!F_67/XJ+BP;3SN_% M>V#'UE2ZF?5KZD4%F1F5QF!4"YVVW6A0("2P2,5*1 FK L8QU( MOGJHY/6E_G!<7X&'ZCU&U/.\?> !F@C;U[Z2-(WX\6\/6_Z _6N>A9D6.[EC8,()AFUF^G'#!N MI&LKJ&"1%D6>D5&VTL/TGEK0VU#[MESI@<,_\([W<(,Z_9WL_5YUP_HSN]4[ M!)(2@@GL37<;LUOO.0=J_6/L)7<;BFA[Q!W%]VV->57?S26%JUXX--4Y*[@" MD.4IP!@3P(3.0P6@SGT9'4RCNT3UZ9UYAJ@!5-LS*/WO>RKUXWZ7$:"\W)?RU@"NE)V ME$LN1ZWUWVKR>;^1BY4X$#CUQ4YEG%%I7+Z40=AU#,N>FENO52]YZYZ;;'6!FT80+80[(!:- MA\)?\LB$%,&0G#)3A#^B!T7%?<7P^>[ 3?QJ1^NL&98X1T! B8#]H0!,:0$* M@3EGG."$'RO?6#CF YCXQ=R#(OWT E'>ELQ7>W4=_M(/SD+DOGR#V>I ML09)N^\.8J2PI8,"HX8RW0$Z#F]Z/"D\Y'DUWS[?KS5_M5)Z9E= >:K2%' - M*< ,I-%IB<4[\9C9S]]Y[L$^_F2_U@?]S,("&FR!4!6"K'@0PQ M*$Q*@<0ZM8;8%09).U%.[$5,[0/<:YC\ZG1,2B6[LDP<@/0\CNH%S]#G2F'( M=&>3.#$^-H7$0"-.#+Q(%G%Z9;=/^T]Z::?HA4LB5E_FR[F;G!V'S9NJ MR]!,_"81()'&F0$HY!AC9UZ&00H-4()[E62YYSNHWXF2,%>N1? MN1ZN!^[>FMI$Z11#&Z< NU1A !<2 Y8)#%*2TB)C5*6"!:=>G9,TM95,Y3F4 MZX&\V:O:(?OJ+*I^TT 4K 9VVQ5,9:OH0WWO9@":F*M@Q,RU.BMG_#2K-G// M9EBUWM Q_V*UW&<*/"SEZLMA;S1%-,U4!AS-M@UGW=$C$0PHI;@V&@E9J) F MR!*AJ8-G$14C^_$ 6H@?U"4\>D4C+YJ58S8M_! MJU#$2F6X*&?>1Z*/YQ;%NN#)_.RE78@T,A&,(QG@&&1 @09IK0PVG#=D?N_1>S4'%2#_7>O;'ER M^?[^KWV[ +2A[^>8XF,ZL&?J V>?E@ >Z,3O"M F]%:- 3R :.D-X'-WQYCI M26SF:L[7S[_PLFK8>;_R2RCRHBAR1$'!J0189MCZ(8T 8UP+3',A=- FRT5) M4W,]3KW]!-ZM<=%%4#WCGAA0#1WKA* 4'M-<0R!6''-1SKBQRS5S3^*5JS=T MJHM6UOYTMN99RO;>.0& PU@(*EUCUP:!T%Q8!JF*8%9$B+/$IM6XL2(5_$ M;6K;S$[YZ+5M;6/CN7L[*-Y#;^NVU[;MC;A1;9L'B,/6MK4I,(7:-@^ /&O; M?)[4,8'V&Y\OG'=UI+$VY'IYJ-4@^_[3VCKEORS7FB_F_Z.5<]$_:[-:ZT_\ M^TRG4B)CUU14IL0Z2F$CJEQIP!$4UG6RM"C$GFG;_Y JBG)>'_01Y_9HYUI\ M9R&PVH(-=W2]-KF9?]-5IL.^ M$1XLJ&.+PVD& 4:, 4&9 BR3A G&4RR"DA"\)4_-R33#@RIM[X7J9800&-%Y M#X)GU#8$M -[G_O'5P_)_7:[GHNG;=G88+MR')AE/7CT+,A@A&+%4]YRQXV9 M0N$XB8N"'] [(:'T?J\6=E8OCZF(AC@M% $I0QK@O,@!,UP!H@BQRU2,\S2H M2?=%29-S1TZ[I%2O;Y;!$:1^SB8*4$,[%W^,^J0.G+<_?K; D9Q;)0B<-[[4P^8Y#1+-<2Y$I2&X-(Y/;*(4AY1JE2D!4TC,UJ7/VG%MGLFU?Q MNGG5;TYEH*S.B7'9@=_*[,!]T[-)M$(+?6?Z.-1)O DC>NJ^K=$J%!+[EE0X MG.F/5EZ2.#"20P+J! J;^XWCKWR^5 MB[-D>3[K?O7XM-UL>MRGGZN4G,=7V?'G&F7G'>R5^H(FX\6:]:;Q9[M?VJ@,T M/U #TSCC/)&)NJV@GF6,C49L!]JY.#HDFE:7@KF!- V^>?6# - M/"MT0*A3,YA+$/3J!G/RT-';P5PRZUP_F(O7AG_D[RSFBP^?5TM=\ZDI60A6 MD!QD)-< HP(!)D4.-)0<%:P0$GM5RYQ[^-0^ZE*_I%3P&G'9=>"N?\1]X!CX MXPU (NBCO61RIX_UY&&C?:27S&A^G!>OZ;:>KB.!S:?5O?S'TWQMIW/'.[)] M_F ';NO" ?O;K^Z2&=(ZDQ0SH)4Q %.5 I8;!016&N9I4609W"5F^ZU^_85[ MO<,O$Z\'_J@_V =]MK'4QA5X?JWUKI:N.Z7#%J8J>T6YW5 M:B<[O>^24O.[:AEW%>7@%5DX8)%63P&"1UWIA -RO"KI\(2.^X)7>GJ79]7U M4J:D :0?IZO)SP#N[)#_<>.9](I&)%D MLL7\V)4>#0FWJ>\X-?%B5<>92[M]X1_U1CNF)1O'O79<2ZLRDJLSV.H" L@A M1$9*P N< 4P$!O93M__+,P,I5ESK0-X##ZG3RY7<*5VN7=1![3!/X .X:U)$ M.<(@T^Z(FB,$A. VJK41+8&%-BKWVC8?".XQXM078#>4OIIHD@D *)(#]Y$XJD,/@.#8P8?UT(]BR^=+QZKSYKO\[/9@WJ[6+ZNGW\VY MF"_LVGJ6R MJ75M86)6Z]VR>G_SHK8RN.U+G\'U# #'&;*A \,3FH;DL3$X;YJ#<\3QD.SM MB1@T]@V-6.U+KC A=0:B!2(@!VS<%9;CA N9$&$\9EIL..L[LI,L&C M[4KK71GGIEP 5EUSY-.Z)$CH0FW3<9S\/.N V(_C5'<&)#_M3/A#63=4C\5N MS>V&HN( N=*Q.=B-]D,PD@?MJ,2HSK,?4,=^L^?3NKG,5ZLO7^H3H/)P:--( M\YW13!9,Y#E@3-@XE5,"."TPP$;)7*N\$#"(V*)-V-0"T4K79..4O4M6!T6[ M]ZAMQ9H;F6&F9?97_8K!9S1P:@:@YEOGA8VD7NE_)0_WB+56JB*"T8((5+=: I B)3 MUK]+46A4$)USKPSWJ%I-;;[=VY74AB5[RY*F:MJ1AG)^_BCNL[8[M9H,U ML ?L-TY!^^P#CIVJ"ULJ9J')C>$+]<88RWD]EG(_EK(YEF8_EG./;\Y[JAL$ MWVI.=(\N)[JTR-)RLHLK;)19<1!\=M/G, ^_-,\V7Y9W]J?_^)?=;^S_'''8 M?_S+_P-02P,$% @ UX!I51VY39Y<5 %^<# !4 !POR(FYW50X?M2UE5M"H64+9M(22,INKKF MA>8+7.(D1:I(7D6H?OW >?>=BQ\>OS?7V4_? M<;F:+N;_\A?^3^PO/^$\+?)T_OE?_O+[I]?@_O(__O6__;?__G\ _.]?/OSV MTZ^+=/(5Y^N?7BXQK#'_],=T_>6G?\NX^OM/9;GX^M._+99_GWX/ /^Z^4?OZQ_$DR(F[]=_C/C7K'L$W!M'2B3%;@H+226E!4B>N_S__7YGVT1 M*4J>H+!,'[.8(#!D(-%&B<$)*]CFH;/I_.__7/^(884_$7/SU>;;?_G+E_7Z MVS___/,??_SQ3W_&Y>R?%LO//PO&Y,_GG_[+VRW_^WW_[[6/Z@E\#3.>K=9BG^H+5])]7FQ_^MDAAO9'YHW3]=.\G MZG=P_C&H/P(N0/)_^G.5__*O_^VGGT[%L5S,\ .6G^K?OW]X<_'*;\OPYW3U M%?,T3>>X^J>T^/IS_$B/?A=BF<_NL]7 MX2?Z[$1Z5)ZC!Y%L <6$!<>E >:53B4;(;4XB.RK;[M.]56UOEBFGQ;+C$LR M(^>O"\MT3<6W(7SVB9^_A24]"-*7Z2R?_^MJ3UKH:KUH(+E3M1"Y?_F)N"ZX M7&+^[50K]S*WX6Q-QA4WGVRA\?_G)"SIB;,?'_#;8KF>,*68J3;1BT!R2-&! M\T:#CD:QF)T,UC91_HT7;X4#T3\.#I%G)Y!XC\OI(K^:YU]I0Y[H3+NII9T M4\B@V1 M,4 4)8+214*TW(+@G!7C.!->M=D=;KQY*TBH_B%QD$1'1L6K^7JZ_O%Z.L.W M)U\C+B?.ENP,2J _."B)!IQ3A&T1D;Z1P:,\" TWW[@5"G2_*#A(@EUH_P-^ MGE8AS-=OPU><*.8#YR5#0$:15,!"Z'6)Y.*CCB0);T(#!%Q_ZU8H,+VCX !) M=H&$-Q38+\F$;03_D>2/+QV=YRTDW,7L/D4_GR327S3,CW-69Q9PER"IXTO@V;9@[)1 M4?1D(B07?!$I.!T/"YWK(V$VH/2'C)7WY;OEI\<=\@MY8)X2&3-8/ ME!%D]604H(7G1AH,-K?P36^]>#M4=)S5;"'0GC"Q<9K>+=\O%]^G\X23I"V3 M*1:@_VWE(T',%D'&XB,QHIUM"(P;;]\.'1WG.IN)MB>(O%^LUF'V_TZ_;9QJ M+%HHIA%20/*7I.$U4R>!LVB-QVAB.BS+=?^[MX-'Q[G/1F(=&1S5ZKU88MC0 MK9@(BMPA8"I( K67$*254(P-,@3I'#\L"7[U;=L!H.-,Y]ZB&UGE]0Q]]O[+ M8GZ>F_,I1F&, *<2JQD9 X&[2*JS*3JI5%:'68&;;]Q.]1VG-P\2X#F&[=3?\=YS8-$ M.++Z/RU#K5+Z^.-K7,PF25FE78I@@J2=RI '$SQ1KUFPJABAG=8'Z?[:Z[93 M?,>)ROV%U\FB?_5G^A+FGW&3B4_:VY"X@E"D!L62(RE$"\)EVK9*M,A3DX5_ M]:W;8:#C#.3!HNPB''AYLJSB.CV;K9 F'9RL)EY(*YQV@"+0/B8R0=I1;&.L ML$Y'Z:QJD6*Z^^W;0:/[_&,#T78!D3=S>AJ)8_H=?PWK<,;61"8FC=*;R+<> MQ/ ,C@D#D5P=FS 5+TJ3 Z^[WKY=_53WB<@&HNT"(O6 ?_DRK/'S8OECXHN6 M3$H+7(5(3K .X!QA79)@2%R&F]SB9.O:2[<#1/OON+R M,VUY?UTN_EA_>;GX^BW,?TP,VLB=YN"M)S\Y) $Q"=H#$^$X"HY9MBB1N//E MV^&B^S3CX8+M A\?O^!L=DX]EX(I5-5)]HX1_O[Q"\EM]>YD73M]:F0]J5U,4J !D:I@,K>U MS"=!41:E+8K$=E@*^G$:M@-)Q]G)QF(>&30OON(\UXKBU[/P>9(][851U=,V M\HY5C E8*U6[#\CZ.9E%#LXZ[5OX$M=?NQTB^L]B'B#,L6L: M3M-IEY;NO#'-1O7[/)SD*?WT M.C?;-O=O__AV[?][LG3@@("3%7P.X=MD4S%7=Y9WY?5T3F^=TO:R.&T)O, C M#*--$P*OW=&>D=_-G 4;90JBCKVP#[DG^W!YG8)Q MQ@\,AH1SR]1 W"-N5=>I/[.PEY::'"Y&KCG8%&IQ@:?]-AL-&",O.6%)U@V" MF1N$C N=0S1[)T@.$7,'6'D95E]>S'/]Z]5_G$R_AQDQLWJQ?AF6RQ_3^>?_ M%68G.$DVEY)*H$C.D:_FM 2G#8,2C$(F? KVH8.X?;"S%6$]8.D@ "R&UD8' M$'OQ/4SIQS-\O5A^)([.ZEVFN/H5X_KRNXDR(M36*;!:V.KZ)?#!(V0?A'96 M&^YC:PNU)6WCC%D9#FB#Z*0#K+U?XK[>WVJ$\A;7$RFSE8)X,QGE=K$YR1,M@YBJLP4 MY. <_2&%=8S^KY7!C8'T($'CC),9#DGMI-\#E"[WV[>+>3JSJT9Q1$X;+7,N M@=(,(;H@ 0,F9F10UCQTW+D7A.XB9)P),P-"YV!I=P"94_HG*3H>G9$$=,7) M4M(?,1#I) ?/=$K*Y-8YU-,WCS-+9FB79B=Y=N#+_#8-<3K;A'^TFV[J?;XL M9B3[5=U9US\N1*-3B,)F!TE+XDM; TX+!2Q*8YW,6NG6MF1;VL:-UP?/3P^B MHKVA]QV7<='(!%WA[.9*U,IC$;3^-!,%E(PDL,(S9,2(6DGOPT.G[P?"K:LL M]C#ZOQ]DAZBB"UB]2*F.?EN]#S]JUNLBRO2HH^4<$J*K@Z=K^8$V=DE%MP'.,$>5!< W*2@\.HP.N M)7*KF8RL=2+Q7F+&W?"& U #T7> H>N!Y3D_YXV=$^U$\)@5D$- KH!-$IQ/ M!<@\8_$REH2M=[:'*1HW&3T0FAHJH0-(W;$H HL6!84JLM21,5PP\)@01)9> M6$=?YM8G_'L:HL'2T@-!YT!A]Q747>8G+H/<'%PQ24'45H!"#!#J33[>Y-9"NO+X;Q^@HAFDG87>PR=4.Q>GZZZ9F:E[+E.LBP'FJK-C )2](&[2O MJ7BF!44,14+(7%IC:9GIATKU]RIANY^<;KRDX7#42AD=V)\')$0^96#2)/#. M&5#&(02F)##E,O(HO6&M?>X#L]Z#G>P?!56-5-%%4O+]^9LW3)W6=E($BNAJ M'.%K\WVF4-0S(X!C\$47B2R:QGBZ@XRQR_O;Z/AV1=I!XN[ $%UIP3^EWQDI M136?6=*>N[21G7 MDQX(-BW$W@-Z4CKY>C*K_7V;NI8Z&6:)7W"^FG['>JO25_QML5J]Q?6[\BG\ M.3&A%H/+ L**6AFE/7B;%12?2IT8HY@;X!AM%Q+'];>'0MN :NH A1]P':9S MS*_"A(-L]8Q#E%7CM*F),\'8"4);I*GQ=7ZX.1QJL;U MP@?"6F-E= "OVX*:<)YYCK$V5B4-BM>,F-<12DX1M726'HMN)ZBYP$P[NPO1UDKS!$XP#U&8Q%56+(;6U0"/T30NE(Z=K3Q< M+C;.QD56/D/)RV:J*>#KROZUR=SI-\<;+^LEA._Q/S M)#(5&48&I51?@V$FK\,S$+%8*9+TV-RQ?YBBL;-<1P790>KH%%QO5JL3XH2G M@&AB ;[I9S.&^[=X+U";2Q' M,(5%4%9[<(5QT#9S'XN.UK>V7%N0-7:R:V"T@9M]_\^%C:0P$]XNCJGLX9XS%) SXYXL4H S&S !P5 M1;I&.C^\<=K5PQJL6?WXB-I7%4]M2.^%9%>+0TJS-HBSJ6=7 MYHQ*BR)H"2+4NQH#1;[!,PT,4\S)&,M4ZY/%>XD9-U_: @7W-CP<)/<.]K\/ MI LBH,X _16_XVRQF6-UQM4D%=JZ+=E:XT0 Y5V$:'4&+:4S(OKB;/MJAP<( M&A=(C91^J\ZAE08Z@--?<4XRFA$O+_+7Z7Q:Y5.O"#UG1X<40[*<(M>42%"\ M7M_C'%C&:>FE*KG6;7^/D#1NFGT82+740@>@NB6DB4BI>*XRN7^%W,S($D2, M"5+D3G 99"ZM6VMN$3%N*GT8X!PFZ0YJ9BX8N"Q&G,3HO':V@"^\EL*Z0$%$ M5""*,:B82T*W/D:^@XQQ[LNX +F\7\\5U+LZG!U]TQ<:4K:?]EUE; M[S'.E@04+03GT"6CL33W@!XE:ES+,P24VNJAARVK5D??R]4D"3*GN6104AA0 M=C/B+R<0M#XT1D$_;3Y^Y4&*QG6L&ZO_KD&9;731 ;+N9X3Y@C9Q5X>9D^V- MDK9J8VBK)F<@\2!TL*V=HL/P--AN-RR>VFB@@]WOD5>;:1HR@>I'*UF44+KQNA[2!FWY&$X^!TF\]VAXT^A,\?/ M]43B4[L]&==78B *E#EZBKTI$">OPD5#VTH=%QC02.DT!4*M3=\U L8M8A@D M/-A;OAV8E_/^M?/JG5_":IHF#!/3M@@P(M>\+OK:Y.2A<&[0:RUR:@V2.PD9 MMTIA"+ <+N\.O/R;3/PZG9VL:Q6KJZ-K! ,M5&VHC1J\K?D5*3PO,7BF],"P M.2-EW&*$8P!G'YEW )U_PWJ+".87W\F3^XQO3[Y&7+XKMTHJ3M<%QX0H2JVK MJ,8438; /$6_,B2>O.#%M+9#.Q&X%HK7T5!P M#%J7>M=%B1!#RA"SXM($$J1I/.AZCL;4Y.AX. M*7>1>P>[['VS=WZ?+S',:CG__US,JNG^:YC.*X/OYI<7[+Y83E?TJU_IV_EG M\G6GBWPQKX>[Y+QC 8P*) =DG$+K%,'E>C6Y5]+$YD?E _'23?OLX%#N @T= MK(H[1'#!2HI%I42>DO5U4I!!PGOQDB5HC2BU;5_P^0$XW7;B#8[.53I[: MG)1+'XLBNULC8H;T*Q]^WY$"HH,S-29FK65)#"#0+&U MU=ES)TIK_VHKP@Z?+';VDD_UVJM)M,9%*2/DG'BMPJ)8#8,!B2SP+%B6L765 M[74*NO$C&V'A]G"QO>7=P49Y0?VI1*J-7LPW4]-IL4]*SE(4G0'1!5!DZB%8 MYJ$P;8*QTHKFQYX/$M0)EO;0]'V@.5CL'6#H!@^_+KZ241QL-0[@,Z5/L^_84T]3D(]TLTV M@$ZEWFSE*,9(W&SN11.9UE5N?AG4+2+&A4P#Q=[?3;N'E#N R3V3K<^8R<+) MF**$S#C%ILY88D8AT*9=> P^1M8Z,_@@0>.F&]K#IYWT.X#2S5'"9UQ$98+/ M.4#!>DMZE@%\(2&%[ MQ$TQN/BOB;DK&S0>T!T\#>7> FBV&G9\Q9E*Q2><, M0CA%LA(. O>;YBLTAJ$JS>U$ZI2% M80:*HS\46@<.4P+/)$6OT0>K!QO_>D%%)XGTAO'7?@+N "($[V6]8/%7//W[ MS?QV?N/#8C9[O5C^$99Y(H+6TG('W$8*-;@5X%@1('PP*7M5+]IK7\&\"XF= M!&I[(N)V4?-@ZND ?0_/Y[%%QGK#,3%$O!2C:S)?;@;_L!QUM*%U8>+!HY*& MG#@R'!!VFIJT@U;V1MBWS:DAK:7E>JAK,AQMV%9J"ZDP73=P6I4I&Q#6>H=9 M%]5\8,^>=QL,V<%]-$P=J(%ND/0B_W\GJ],+03\M[HEH-XLFALU1UM?:B[+1 MZ 1F\N/QK*NT)'!_O[1M*G4QROEH.<[BIO\8_-KU835-%EF33P MC0N.5H&C;02"Q>*-+UJ']H>+VU V>I/F<>US6TWUB[_-6KIDRGFM A,>LE+D MH M)3)$? ]$Z9SRW(<;6#0M;$39ZC^;8Z#M 3_V"[W1)O?KZ;;;X@7@ZE?MD MF;Z0B-_/PGPU$2BT3P&A1"9!94$<9AU B)AK'9/+V+IB+B?<:"WH/TA(G"KT$F*T'E SQE-U2A0>T7[>2^CHC:ECP[6A'OL% MZ^F:_("K]7*:UF>7:[RH(OWKLA;F.YDSVD)Q9DD%E%*,O!>2:^9)UU8GYYL7 MI.]'Z>CML&/#M:4F>\#KAIT:"Y+,/H4__VVZ_O+EM(R>?G#>6'X]+)Q(E\C; MT0:LKL-:,R,>15' F$\.K;?$?VNT[D'GZ#VUQ\/JT%KL9P;)E6S&!]PHB-$BP>>00:6@/!,V)G:DC, #5&X' MVF=Q(C6P"GMP#A[PV.]F4%ARR&O%2S:JUJ+P -X2ET9(Q70(Q&C[QI,=B=P. MHL_G@&LP!7: T,%Z0I6C^#*0''BIUX35AAFGZB1Y3"1QRY/DK5W<43N$^;,X MZNH"#GLOB^^XC(M!1O49Y60QG/:=3.)4(7/PTGMP*1ZJ]BEHEW@H"%:8VFLAR/.06D$H.K@D?(R^]:SX/6N?^/,Y/=I?!4V!U->T M@O<;77W!]32%V75^AQ]=$ <1QUJ$!!Y,"(!4V3<%+,9?"'$\.5BM5Y-;'':*H\098F@HN'@I/'U"BN; MD6$R635F^B%Z.JEC;X:3FT:QF2Z>]'S L/KR>K;X8^BY@+=?<[QY@(^PV-ZP M7;SQ J=(3IOAB8..@7!*.W:]EJ->T,&-(ERAD ,.:;E%3^/9+,9I]"5:<+F0 M4YIU787$K$MHM1".)1RLIZNOV2R':?Z1D2R[B+F#?-W'D[B:YFE8_O@89GAF M93?C(G)4T@E7($:#H'RD(+E>7(,B.Q==%,FU+C&_EYA.H+.'AF^"I8FX>\#- M)?EOPU?Z\M,RS%>TED@G9\VV105IN+3 9+V42"0!L=@")G!75/1&^^8E-(]2 M-3*2VJC_)JC:ZF)$=%7_8?*:XNG%'^_F[T_B;)K>%:)@.O]\UENMM7?ZX' M-2YLT=DIF2&(>A-H,@Z"E104U.DS2M@0@]L*(?>^8N3&] 'AT4:J/6Q/MQNL MC4U2<(I"A==UF#Q!G*QLO7M:J^PBQ:)BL-F$OW4YT^ @1^8P 7< D;>XKH' M^^7B^Y0"RU]^_$[AZ9OYQ>7"+VA%?3\]A[P,$W1"O4GLDEE4BFN(+IEZ 51) MPG,976N/9GT"GJ?I#*\Q]6FQJSQC<2%L4JD8 M-$DA%7 4?=2BY,*9TC')U@,UAN!CY(N CXOCT8'0Q7+X%>G=:7I:A6P\:LL0 MP<0Z>LL0]=[6>B&A'3>)0IKF]QQ>??^X9G1\/"P:J:8+8-U3Z%Z<5E$530&R M(8'DR,&+Q" QIT/FR6'[\\_]&Q,&LW7=@:V!NKJ W85\?JNE)Q_JW6GO"HGN MQ6J%ZQ=?%\OU]#\WK)U? U^$8;;>D"&2M_6"6E-MO(^_#C="@ST\D4E@ QZ3IGC)$4 M%L:S=:V32MO0U=OHS.-A[A %C0J[S7'[ Y+;Q(-7.?/2 MJRA\ /64-.[RTM\&637$UJ :Z,&F;W?\. M-_F\_O7BK'82>49NC =T]494S!2 E1SICT3> HM(O) Y-1LZ*34*9U0GU[ZL;=9(]_,#Z$TIK= MIMP=LKFFX+UVT7W;V'PEA,E6.DC<&5"6%PB. M6>!,!6Z-)AY;AQW;4]=EP5 SI-S3CMA8:5WD6V[Q]N)[F,YJ-%]GO8497DYF M^17C>B*5]$8Y3M*K_DX@S\>;F.H]UEDESA"%'1J5#Y/890W0T:#94'U]X'.Y M2(AY]9HD7?FAU?:WL*XL_7A73HO6*[>7;$Z$4\G39D,\2559%!2Q"016O.26 M2:YMZ_/PG8GLTJT<#*.#JK"#\^[MY3E!SZ*/%,BY8NL$*^DAZJ3)7<+,-4;I MFH-S>^K&S?P<&94#*:W?8.?U=![FZ6Y!^LRE(39 6%TON@P:?'":HD86)4:K M56D]IG]W*L&!O/EQ%'>S%#XZ.B-.K4NMCPNA^.:]L9)A8[! M\=27SL1A9IDC0JBWT:M<*%BIH[N"LT(+;U(4K;N3#B)X7'O?$[!W4MV! [6) M[^6Z [3Z6+32S-):] A*1=K5%"M NV;F7#KGU--#ZV #W[M"ZRZJZ^0>@8,8 MOG#XC$#/2TC@.#/U @6*J9%)L!Y#*0RY;7[93Q/"Q[T[N"?L[J7*#I+&9WS= MY(9BB.7R!_D^FYNZ)HXBB>Q9A&13G6BN+#@6&0@T+ F3/9K6L^2V(FS< XL1 M ','9-MJKP-(7A?9)#*TA5D$PS&=)U8Q/L@. MT$<':#K,(U'.NV** R],39%X"[[0]A*5%(:GP'3SFK_AGQ74@@>4W\_/$V.O%\NXVPA\3:XL( MG**Y%'*N?=$28DH,(K'MC+**R]9U!P>0._:T_ $ =',S/Y(N.]CY:]7WM5J+ M-_-T4NDXO6#U[6*>2,COEN_#NT R&>-MYLQ)WFZ/B&=GK/\R\GZ[6+][[A^ M'Z9Y(K2W%DL S;P$Q37Y+U%S",)ZJ4LV1;4/T[>C;>0*UB/ [I:VNQ[3ZA:V1TEL=,O:N^7G,#^;_G9YX5L%UF;^ MVP4#[\K9,7R87=X%=P$^EF5":4>N%Y!)XB+1&OR,EPW$$)/D6*PI25S:\+OT7%N,[@\3%U MJY+D,+TT#%W:&Z^/)U^_AN6/1?DX_3R?EFFJW:RG(YW(A7A/PDZU<&@/>[;E MDUN9N'T8:63U;K_FC;.31[&U0RD>&Y,DJWQH)G4PC6/RY?>]DF*7S66AK( MA1/$K!#@L7Z;$_>^3FO!UJ-,MJ?N\!%^%V]Z,S][UZ42;KUUGE_BLJ9[*!2N M96VG6J84E)1RX""/2FUB=KJ&VE8#P:J30ZFUN7(PS%R]@3 M4@=!ZNU1@1T H6/S^3I,EYNC\+]AJ R>CC+?PW[>_:!6!G0+,AM9T(LW72K] M$HE"*BFLH\TX^%*GDWN(DJ('8[P3K%:&J]:WOCU$SZ%6\JYG7R+<]EX&Y M^8A6IN5!TAH9E;-1R'5_V;PNS"ZQDTR.IE[R'-QF(U$%XF9\7N%%ZI@==\TG MT]Q/3H-;/JX.?SY_P[71O'=MITD*4X2U4%PF*=3,V)KF1#;OR MOA(K8+@0++<3A2.7"P^&K5M'D\=<+L88H.SM[?^?2[EH'DBH*-A!!4"*".+//2>/=3VIVLK@%H8UL MTJ6Z-P.X+EYV-I%F4^2U&;<1*SGG\VHN"\:MX9%*A=8;O M0)+'M7]'Q.>M8L<@&MC-'%F"PH'DOM6*DY6>%!Y_5RIQL1VPCNW+?RRZW+JP%--F#EK1A*9DE:-EZ M.O)C-!W>7GSW\^^*.2A\01^Y!X$IU2,O#AY3 "U*O1W-).=:-X#L0-ZXMJ@I M=F[W' ^CI*ZM%,GM)*TW32S[F::K#VAGC^XEJYD1NO*&37_N1O=WS,4KL28! M2J2M*" H41@XY3QARQE)FUY2S0_KMR:NR=2#AUYT%_0]9\(Q*Z#8XLX.PUQV MX'2V@1FM<_.QB_O0.;:A&@)?=TY)&%)_'9NNCR=QA?]Q0D][]7W?TJI;SVA7 M(?\0<:VRZC=><@$IJ:-S7!IP21*0'!/@I.8@Z ^!%F/6K0.T^V@Y?-S ]>=> MPCB[Z#2C.$$'P2D$$0QJS0X($T4,H;;1-S\TN(^8L5NX&^#@]F"!%H+OVGYL MT\0R?%?.2-TY8W7IB!1U3%(""E=/:[2 ()P$&4*4DO$HFE^S.%R7SB]A-5V] M*S=>\./TSRNG2*%$QVF+-<'0.F2^@+>:8@>CBQ0\6MV\LW [RKKMTMD%)3,VM-*1IWIV#>-F3[ZUT$'[\)-GBN=1(&*!H,9X>#1CM0 MD3N&M(=ITSH'<;PFV/KX*T^]<0?T1@%7',W,HQ1) X^A.IH<(9AB:TU&5LHP M2[%XZ\*7'>A[,LVJNR#JKO%=@RBL8V-V9V?G_M;LH<<-VHPZH#U[L/4P,NM$ MMA%R=+IFYR/$PA 09=0V24MIY?2;A_&[^H:Z+>H"P"9RO+ /' ME&!H(.98:SQ XN%,ZD@\IH7,8D#132$?<^T"4%'$9M/EMZ:NGY[6'?! MRZW#H&&TT[$I>JA%:G^[M,53C]'C-:#%>J1KQ\@28O6E7;!(Z& ! LNT-2:% M=3A@G>_R)#J]-JG>RV5Q1=H?2&G+[Y@IMGA]4H<9GH\-OK%0G(L!,0A(OBX4 M6[O+K2S 6.4^DXW. M3J^K/JL[^W%C15EG>4$?:$75>; RU\0-$R!*Y#$56LOM[VG>@\XGW>ZU"Q)O M9?N'5FH'1T^76\+=5ZA?O33]'HX3#-4'?R7!.U]/\W1V0A[1E9J25W^FV0F)\C4MY;H\ M3L[O 7F@CUOJVEN$H%7MD$S>0%1U"K[VP@;EBU.M:[?:<]%IY_TNR'L@ES^& MJGNV?+=O;GJ1\[0^^5JA[J^X#M-9JXNG'GS%@)=2;<]:5Q=6:8J\N- >O/&1 M=EF6P45F@;^9D6;#Z M7Q.9R>8+)L$$2UN1<@&\5D0\24G9(G0TK=,$UP@8-\$U/K[VU\;N4/*G4)KC MYQJEM;GF&4_O CYW+EZD=/+U9!,%_HJ%MK'UQ">EA;0&4A8"E"P10J;@SZ$C MIT,G%F+K24R/4S5N'1H!.DM$&66N*T" DI013Q1A,K0\0N^HEF*#TR R%55QPK)-!$CB3 M G"O::DB=Y:U;B#>@JPGTSFP"W[VZ!S823T=.'!7FD_K^)C-N0 9B4E@7DM; MO05;#.T'&<$[1EQAX"QX3]0VOX/I;E)&/HIOK?*;Y=T-Y-\!C#8CTNC-M=KT M-(=.CL 5C^.2N]4G>N3J[E_]NOA*CL3$HREU)BT(J50=*F(A:DS@2W&&:Q%" M;FWB6](_3F[=/])*:5T@\.M77%8AO0_?<'G&!/.% MF<0*.2XU452OQ0N9 K:@/4MH)!.Y=TK/;;BLT*"@SJI%.P*KO" B\.6]>Z;DO;N,F8;O XB"H[ M@.B[]1= E9[]-Y_AFC5]7)#)TTFXJH64=Y2H,>.]#K0 R)A9!?OB 38F/ M$SAR'?# $?5PNNH B \+[\77Q7)=:])J-=K+DV55QX0GG2G&0V"B7HYEE:%% M9RQP8Q(%A(G'YI=7[$[ER+UGPT%FIPSBP?K;'Z&+=9@=&Z%O%_-TQJ032027 M(HC(8IWGPB#&8"'%A($,@0ZZ=1R]%Z'CFLXN<;JG%CN ZDVV;C!]E;U'2XA(_&GRA42.Z$+DK/G&OBN-XX8_QP/HH+H;$9N;GN5'5M_E M\?I?EXO5ZO?Y$L.L,&2,/#=%PUCCVB^!#&+[>32]XQVAH/, C.A59J?QG4U*O]W[4Z142A0I %; M6+UW"S,XU A2&E52\ 9O7DDR )+W=37 \^*$]@/MHVPZ.S^ <;1!E-4L='*<]KO7M-"'\R[7:[8'"W M(H0A5-S!]KX/TY,D4PJ*-B:GG0&E.0>'R8 5(GL>?>*B]4K?A\YQJV1T9,&[(>0U:DQN[N9OX]I M4\<%;+W#D$CAF8]"46$Z0S U^;M3_Q'=^GM0O>'KE/ZTC*[<"Q MN&#\EQ\;UE_.PFJU:0U&J21R7>N*=1T49 4$+3-8"GN1N2"\34.A]"8QG:#N MN."X#Z('::HGR#U\=]WO\T6L][%4P;V9?SM9U^&ZM/?-IAO%7Y7"65,2ZN2C MY!:L+>2?:4N.$],,LLHELH!"Q,$VG,:\= +XPZ"VWYV%P^J] _S_;3'''Z=9 MH]_)9R4=)&#K885:^LK7.P2+[96I$MN?V>MRX&NYN23K W*DH6S576 M ? >GG^0F ]9APQ"&B1F6.U*%PY$,EHF'6GEM^[>/GQHQ6!I@2YAV$Z!7:#Q MKMD()7M7 KE$,GM1BR4+1)XR>$1M@C(Y-[_^;_\!%H-US'2*OD,5U@'JMIZ MX&+(KF@+W#);KQ9,$+.5$%-DCNODE&OM3#8=9C%8FTR7V!Q$K1W ]?Y9"<9P M;;F-H$0@W\,4!UZ0\+@B2;F"+MC6U4^'#;88K..E2T"V45P'"+P2"U[)2+]> MXG^\;27"*U?8NZPW(P*WSY!E[WWI(Q39T=0*V5F#8 M FP'::8GM/WRX^++_SG%)1'UY<=O^!UGFS7JI(HNUJN4BJ/M@ =#'FR20#Y$ M06UM<'+ S?8!RKH*FI%*R@JB8!I6RAD#.,V0A MK0J<&6&.8A#O([ 3R]@0(=L8QR;JZ@F+FQANM9$8/P^ME$QHO:S]?-7@1P84 M[VO@H; H<^)1M!YJ]@ YG>"L/0CN@]N!&ND47.)\:B\1GP2YQ<5C=5>,@( J M@C%28IWG&UCSNP_N)Z>3X'84<.VCD4[!)<_/;I0J(IE,TI$>E(D68JSY="=2 M\<(:CZTKSA\@IQ-/;A1P[:.1GL!U@/O[VT5S4T%37%82C.86E!4%?! :LA.8 M)6Y/$!=//D>1!M=@#3*\TG=W&#/CD; M78$B%3DX1I ?3=L9%,W168;U#'.X5KU] =GUD4H;0#;46PLC"CE!G*25:(E):XM.S<]1[B6F$Z=T=.RUT5;'W>(O4EJ>8'[UYS>< MK_"R]^G&SP]H MOQ#:U:NPYAK%'#UOOPHSJ6%;^;MX;99?^,3X0>"IE!"$MA MCZB15$P!=(B"/$\176S=\/$ .0?-?[N0*!G)>9A](*75F)%>\VN-\1;?JND^ ME_?%4!IF2^9HP9LBB7\9(1AO03A,3FBCH^./(6OOMX_KZK6"Q;6Y;8,K8>R! MQF<,OJ>G+>9S) XWH[ENL>2,5%DIR$(5,O:QSN42'+B+45C$$(+:!5>/O&]< M'VU()+44= =NUZ9$[(RU*\[$.35$DQ)I:R:'W. M^S!%XSI@K8$U@!8ZP-3]C) I44Z0)64EUK)#[L YY&!B="0UIY UOZ7B("0- MEIX;"DEM9-^Q8UX; *:G46^8YY>+^9HBF]-:Z];3G/9]52M7O0FKC7SV*[2\ MN$'+9?!W@># ::\SO,Y2K Y4CAR""PJT+1B]B%R9UE[\3@0>:N$V(ZJOON(T M4UX\XSEZXM/5>L5(P73P*=99 )I^%ZQI'KS<3\ MY/#L*#Q[BRI& R6ZVMM$;JJGD!ELL.BMU\9MUSO9 ))WT3<.&H\,G1T!>[ > MQ\Z!O"MEFO#CMY#PS?R7Q6J]F/\MK%8A?3E9X7I]WO04LRT\U*N"C<*ZY\^2UY*B($X>> MUF/QP(-4020FT+=N$;^?FG&S;0VWV,:"']LNO<=EJIKX3(LB+3&LZ.\7\SD% M^[_0UQ]J5.YD"5+[3"N..%$N) C2,$BYCJ=7-3#?[GJBQ]_5F2.VITH7P\FW MX^F5-:1:S#^N%^GO89[?GU.W^<$0:8^]WM4R[W$XLXT2'YNW?EG,:'6L3H>R MOEVL+Z-7Y86J!]X0%-8I?U9!T%$ )I50>%NL;YT@?YBB%A-1SH3_\4NHHPU/ MUE\6RSH6=L("2U+R!-F96N;*,CA7[W5A17/CC8V#I'7N(6?DB]G;X>*N&25,S0L9[P]U$24MN)7((I;9)^B#!ZT1[0/!%2,]Y M,4-,VWF$K)&O4S\*NIJHI .4?5IN:I]^;)@ZXV^S<"91)!<81C;.2[Q(\%LR:*>:(QY$49Z)4/U5JYY7?,KQ?+UR?KDR6^ M6:U.PCSA0+'E7C0<(^8\7#C'B46-2*B-,V"4I*404$+(,4 2F4NM3/"Q=7/P M,+'H)KES>1/:-F(_S3ERU*)P+T''>E69YAF"$PF2L;(H9ZT-_C&([OORKL/1 M7:!Q+<4VM!8ZV)Y?_!&6^1-]^'3FA8A8I*VC]DH&I5B]7\=*,#*1N\J*IUVE M=8G:50+&@=%Q='VS5FUOP7> FHUK4-/,F8152X#/=+0,\\^GW>*__+C\S/OP M8S,5M')\R39M-+.P.8D[.W^KMS<%61=G2DAQMZ0(W-*JC8(AK5$K7-&M+?@ M?(QK"@^ U:(S'7> \U?DUBU^(&Z,P;M-:<+Y6!6=I W<@2S,U MFPRIW@!2&+,R#>+NWDW.R/GBWA#82G$=8) \H/5RFM9GT> 9$U:1PY.L 99X M <6LJ-=N9%I-B#DDYP9>V-N.^XC(M6*<,SB6Q2A%!2FG++.!5Y:#\*Y^OYQ+-LH$8N_ 3-U81,JFP,F: M@BG&$^2# 9=B!.F4R44)G9J/YN\I"-A?D_= 8@^QCEU^]ND/$M2/TS^O>81O MYK5L:OH=KVS*Q5JEZS0(NRG7TXQ!$ 4A:\$I7M+HPXVQE?>DSG9Y:Q\8V4>U MBV/(N5L O3]9IB^THU_A2T1N2@@)C*NS8GT]DPLHP-2K>2299,FV*V3G;;O'^[* ?U6 3*:&F%*$X\TA^Q) FJ*(Q.6E[T=B,P]B1@ M'(_ZJ/[.T?33@5]TA;F7X=MT'6:G]03W?( M578IM9[@O#.13^:88$_A&YAZB3]@YMP=(Z![QS8FZX M0Z]Q(/!0QFX7?72$I;, ,A2O4KVUMA2*'57T"7PF)\F%*'6]\A[-/TS&;B=- M/IRQVT6L8X?,G_Y8?/JR.*GC?K9,)TFK6>$Q /<1:_DKUI,-"88I32O'*R'M M8][??J_N RW[*'EQ-(F/CZ?*TD?\3G\ASA_E+4KNO2D,&*^7F<2D((IZWT2N M 90FU-SL:G\PB;?UB[M*Y!V I>&D/3Z2'EHG=V0J3?8YR&1!%Z1H/VL&'KT" MS#&(F*)@-Z=V[V68]DP*#S]TX4GOKY$.X#1('0HG0GD]JO/"U:)YC62?BP3. M1-!>*AM]:U0^]VK&^MTVFK7??Q=S[#D=BH9.\3[)73QFR3,X$# M+T&>%I%Z51)HR2A^-YSVGM;9M,.I'KF8MPL_],BZ?\IH?WM2%_>9NJX.2"C. M9^3*0BKURL;,'2U\CQ0,IN28S"ZGH_>1[;Q=G?M>&]=6G>OG U=_7$]"WB_6_X_H#IL7G^480D;12+.FA>"-J M",+ \8S@7$'DW%KN6D]Q&8R9SOV?8==('Q!YSFOE/2ZGBUI;=?:C^CD^R<%P M'9D 5YPCZ8@,,5)@$Z1)FGO-4;2^Q.6X'';>4O5$5]7A8'K.2^U*R%;[59(F ML0@P.B H3 YB\0&R1XOU^A_D@W56#\G8R//*GNG"VALZ3Z[L]6(0TXT\VXNT MGGZ?KG\TKX#=]H7#%L/NQ78?=;$^.%ELMB "%E!<< @L,+!&AE*$]LRT;EU] M+G6Q#C-JAQ(22D\!&XG.8[U//@OIN%2%WYP,_U]UL4?'['!UL;NHOP/'Z/HQ M7\DR*1LB[9,Y@&*\)K%5(0Z,43(QKF[>-OLJ"-V!]*CXG2:Y1\X$QS_P\?R=8'>,\?Q<==X#SN\>5R"@- MSRX"8B(FA(@061*0T49A/-IJTIJ?0_IBZ03O$;T M!0UO?=W$<3GL?$=HC-]6RV=X,/UC++73P^U)<6@]EQI8L&0"R<M^HGB-1_$0+)HZWO/K%S[/> MXO[71GD77NBQ17/:8,[ &R[ M+T)_N@CG^+F>O72^#$EO!:=7A:.LX,)Y#Z*X>AB4(X0L#(B<3#::%^9;I^*. MR-X3+2&OTK6937 M8;K3"")U(TQ=*N&$5A-$\J,QE,?CKN[%XB>*)QYY/)FPX& MQV<==6XOO@DM,!U508@4*H"*R,%+8R';J*V*HL3T!#?=1_E^]NG8X19.AT9@ M)Q3_8Z5R'Y==*,[EDCS0-E#3X*F FH8R(/NN-_7J&[W'!Q>)9B5$"4[6O13@)]%V!S#GSW#"O5.NKY[MA_MDG MI)_!%C\DGI^U(3C++IX0JA^7FI(E)](P!!89J%"OW$LA@,VD>E6,,\>OCSX* MY\\^#?X,3,!@2'[6ZW^'V,A&'RQWBKPE&4%I:<"AT) 9TE^1R61;S\7H@>]G MGW%_!FM_(!0WS=8?O0?Z2MOW\/W/#[SL2+W/V[+;2=]S%I&AEN#K^9;RV8"W MSH.(UB(6'I4TSZOO^>+)#R_^>'/QWWWJ=C[ ZJIM+GNVX.@\Q3+[R^OMW601]G0HA6"DP) M*1Y3) 2#'J*S&6S@*NF8F;?-?:W63(P;A(R=XQH-#L\@I75:]_%BGE_]^0WK MX*5/B_JCV[;"9,F-,QZ,E(FT)!(XX1B0.0NL1EU6#Y(;/@)OXP8R3WCU# *> M9["HK@C@QGGJ>;3W?CE-FV/AME4<9:);NY M3V9O+L<-BY[P0AL84/\X2V[B?1(B!PSF'/O0,4[TS;/R@@Z4A/G&PJ[XV.B.>=^.^E@2#XQ"G^-JU:+1 (.-5DM:65) MRFAY_.%(33GLX.CJ'VA=#@>^Y[ T[SC.>% ^R0CKM#!0D&.=Y&' :4N63/H4 MC0Y9R-S;XMR1QPZ.S_Z!EN>0 'P*"[21JY\=1Y]C@(3W]G=PT&W-I%S!D\8P%LD(H5SX(71]\A MV[ V[DI\P@G4(:#S#/:VQP]P'I26DH&7G +HH$(=6<5);AHA<#12""E9>'IG M@@>O/_-?ZV],H#V#9?DBY\WES6%VJ?)+/?(LK=99@N FTLZ?$6*]1Y';8*5S M:'SL[0CC08:V6E3VOQ;5@##I9,OKYR\5\(YJ3,/N$RZ]B M$J7/6>L"(H7:RIP8A*02%"&B=CZC&V;.[7'9?-H'@PU!WK@_;_; M?9^(^,3''$TT#(QQ=8*@J,.YBP$N',JD,Z8XR)2,X[+YM$\&^UV40R/N&2S* MG7WQ^R47BR\125Y2:/)^D"=P5I.'+J.+S"OMN.ALK;;C_FD?(O:[A$?"9R\K M^_ LU^4YSJ?%.LS>D%"F\]4TG4WNT[*D7!A@8(JLG:W]LT5#%EI[(W2T&#L+ M'[?AZVF?&0Z\&GO"U#-89U=,T0U!2"L%MX8#,\6#"J&0P8D!O(W&>A^LS]V, M>'N,F:=][-?OBFJ#GEZ641M?_;H@^"1K)YBU!HK&6@3D//B@)&#V*@?EC N] M96;NYV;<4X/.%]+X^.EE)0UZO/+B\^?EIGW]ALG1*5NL%^YRS1)YR%F#SX&! MSDYRG4R(K+GCCP']4S/9^,U]JI\_51]ADDQ M3D;O#""B Z55@2BKZ(0F-T%K863S3$@KXI_T5--=,'MKLQI%_1WXB*>4TX=? MD%6<9,.)_J" LRA.[]_PW$I@C GK0U$26Y=>72-@Y$/E<4"P:*61#N"TO^ N MV9[G][,P?QN^XJ^+FH*?,)M85#I X9A!2<\@T((&B>3H66999JV'<@_!Q[C@ M/@!6S5I#&NFX YR_(I]X\0/QBB?X-]P,)7$^,1ED *CE4>Y2;)UI V7#5 MC ^27I9+*_MQ+HG_M9C18V;3]8^-!1%9^Q#);G@3)2B%'EPBD2@;79&&>:&[ MWG3N9NN)EB]VN.TT@,US74F_3K]/,\[SZ4ZL@\U<>Q"<5]-B-/@@"[ 2G;:1 M97/\65^',O5$RPX[7D5[0^8IKZ%M)IC=<1=G9BBCPT VQ1A0K-XEQ5(&RW60 M,?/LFQ_^'9G%)UJ$./+Z.@*\ZK7G430 M1[&#,ME[@BAP-(12Q0TX[Q D"LZL\E:EUI-=>BEVN$B)X_+[-.$]IF&V>21] M]:Y\P+3X/)_^)Q&U6?X;2D^SFHD6LT^%C!"7"A1W&D(=L8<\Y(#6"R6:.V)# M,/*DBR!VP?+]11!CP:(#9^O-G,P=?B2%;_;"W\Y8W)R:,I^0U:O)F9.>=EU1 MP*.2(*)QUOE23/-+71X@IY=BB=' LAA&<_V"\.P,5!EKF)*NGH$2,Y*8"5ES M2,;D$I1%IEI7Z3Q(T+A ;*;V[>"TAPXZ -0'T@D1\.7%//^*WW&V^%9Y.G/- MS@[!(^,Z!:' "MH_E/,>0E (C(7H47CZ<>N$Y!9D=0FN?4"P&%8C75Q*^U>< M4Q0X(YY>Y*_3^;0Z)>OI=[S.%N>(D64.TO@$*HM38R*0,IUB-=37+V15A 9K$0"T*EP2JWVK#0 M2WU,+Q[AF CI8-,_XPSSW8R?+?^)X<&$1-&BU!)!,1T@>%KX3%/TJ%Q"KUIW MQ6Y'V;A;_ZC@N5D3WEZ3'6=:WR+M?JO5-UQNV+W(+X;Y>IJGLY.Z=ZTPG2RG MZRE]\6>:G63,58/TB&\GIS0L"KE7=7Q+? ).S %+7*SQY3<(U2MZ_. MWO7^C.:+1):01>7P_Y=W+;MMW4!TWW\9@*\AAYL"3MH"[J(HTNP-/H,L(@&. M'[OV"2\+,!9T9Q3-]NU9^G-$,PAEAGU[MLZ\>")B?S*X M$AW[$PGB%-M1E=%EJK5[A>TAF\Y\EFT4\AQ%ZIE(#L#,_0>F*@8D#!$$M18; ML=UT&%2"B+5@+CY&5_\?I]SZ8G[TB;77 #"$6O>I<)CUM97B3/-IIR'F5LT4Y=/K CS83;5P(PDDCM(!V]!., M:9T?I@OD),9DLRZZ]&X3O,.,\Q:\O]WL,V/0!^#-B9'"EGIGK0FD(SNJ-9CB M!,^W,0)E';V2)D?5^_+:7K:/LBOPWG..>61X_R_!Q;?U[>KFRBNKD4P!ZTN[ MDT8J\ 6GD\O"&42F[V")^+WA(X:'2W.N+_%G$&#@W85-(>7?X?KF[O-U6'T/ M:2IK?^R$>+FJZ^MO][OO\_<,9CVGUT[ Z4YVTO?W&O*@NI+"S+&H!\%Q"1C% M,6A05;6.C86\4#+K_E5'+]O43^_?]Z0/=T_^,ZULL0J9G4R@);83Y1Q>D;"! M5S9^NSTO;^B[GP>=8^AYY].N?-JOXB\%W #1P'&N35J839:2YQ%4U@@PV2N( MT?$2) Q5BCGJU#\[/]:Z4:3TQ:CR+(]?!+?!&+E)6XF'"2,GJZ50;KT<6[MZ MG]B#&))-6E/LW?+MN15CSG2GXOT"K68,_AGITX*?JT_K=C_/Y2H]Z!/!&B)J M=[J6!,;H5F5C/"BLF&4-FB/E0Y';KB\>APMS0%IW&K'!)HNMU^(Q42HUV#:3 M0M&"!\:*"D1) ,I4E:W&1=\[3SUDTR@*S)F7JGD8#<"YWV[+Y_664YP\?[R] M;F-_LKK /&+"-GR)P<>,PJ J*,TLEBE>^]:AUIVCC3U^E\ M6"\/SM#R!2@L/.1V[5TT>G3:REPE2+ M;&)6K9[>08A25(LN9B\6E!D.F'?N>6H)-KVD,O1$:X"%\HE#K7/OE)Z@E"XB M!Y<^>.39W5J(3G&$::3/+M94BHF4.]CXN^^:\Q))M/AABB:^E^L?6Z5N3@NC MB-\7U\:*@PF>_8DR!Q/:DJI>)==_\_>P76=N;7X.^: '0J.Q[NF(7=[O#TP_ M7^52$R9.9%*2G#\3*2#4!#84S^4?[ M:,TX?_WE7U!+ 0(4 Q0 ( -> :543/0G>\@@ .4R 6 M " 0 !E>&AI8FET,S$Q,C R,C Y,S N:'1M4$L! A0#% @ UX!I M59,&&6D$"0 ##@ !8 ( !)@D &5X:&EB:70S,3(R,#(R M,#DS,"YH=&U02P$"% ,4 " #7@&E5*+:9=N0% I- %@ M @ %>$@ 97AH:6)I=#,R,3(P,C(P.3,P+FAT;5!+ 0(4 Q0 ( -> M:566(*$B.&,! )_E$ 1 " 788 !P :554<*Y =PL %US 1 " M =U[ 0!P :57N!I;-+!4 M ./( 5 " 8.' 0!P"TR,#(R,#DS,%]D968N>&UL4$L! A0#% @ UX!I56Y%T7CDD0 M?DL& !4 ( !K,L! '!R87@M,C R,C Y,S!?;&%B+GAM;%!+ M 0(4 Q0 ( -> :54=N4V>7%0 !?G P 5 " <-= @!P J